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ABSTRACT 
 
Stress impacts upon all organisms and a robust stress response is required for adaptive 
interactions of the organism with the environment. In most higher organisms, an individual’s 
response to stress is mediated by the hypothalamic pituitary adrenal (HPA) axis. Inappropriate 
regulation of this axis can cause debilitating mental health disorders including depression and 
anxiety. These disorders can affect an individual’s ability to interact and respond 
appropriately as different situations arise.  
An important component of this axis is the vasopressin V1b receptor (V1bR), which mediates 
adrenocorticotropin (ACTH) secretion from the anterior pituitary in response to stimulation 
by arginine vasopressin (AVP). AVP also potentiates the ACTH secretion mediated by 
corticotropin-releasing hormone type 1 receptor (CRH-R1) in response to corticotropin-
releasing hormone (CRH) stimulation. Both the V1bR and CRH-R1 are G protein coupled 
receptors (GPCRs). A common feature of GPCR signalling is desensitisation of the response 
following prolonged or repeated exposure to an agonist. Phosphorylation of the receptor is 
one of the mechanisms of desensitisation. This directly, or indirectly, results in rapid and 
reversible uncoupling of the receptor from its heterotrimeric guanine nucleotide binding 
protein (G-protein). Previous research has shown that G protein coupled receptor kinases 
(GRKs) are key phosphorylators involved in the molecular mechanism of GPCR 
desensitisation. One of the mains goals of the research carried out in the Mason laboratory is 
to examine the molecular mechanisms of V1bR desensitisation. The current short term aim is 
to examine the potential role for GRKs in this mechanism.  
It is difficult to study a single receptor type and the molecular mechanisms involved in its 
regulation in a system larger than a cell based assay. As the proposed method of assessing the 
involvement of GRKs in desensitisation of the V1bR is to use RNA interference (RNAi) to 
knock down the expression of the GRKs, primary cell cultures of pituitary corticotrophs are 
an inappropriate choice. This is due to a number of factors, including the difficulty involved 
in transfecting primary cells, and the difficulty involved in interpreting the results from 
primary cell culture experiments as these cultures are composed heterogenous population of 
cells. Therefore, the main aim of this research was to develop a model cell system from an 
immortalised cell line, stably-transfected with the V1bR, in which the involvement of GRKs 
in the molecular mechanism of V1bR desensitisation could be studied. Development of 
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stably-transfected cell lines requires substantial preliminary work and planning in order to 
produce a successful outcome. Once developed, characterisation of the clonal cell lines is 
required.  
The preliminary work involved determining the cell proliferation rate of the parental cell line, 
plasmid sub-cloning and production of a large quantity of plasmid DNA, optimisation of the 
antibiotic selection conditions, and optimisation of the transfection protocol, as well as 
modification of the inositol phosphate (IP) assay protocol. The V1bR activates the 
phospholipase Cβ (PLCβ) second messenger signalling pathway in response to stimulation 
with AVP. This results in the production of IPs and therefore, measurement of IPs in response 
to AVP stimulation of cells labelled with myo-[3H]inositol can be used as an indicator of 
functional V1bR expression.  
In this research a total of nine clonal cell lines resistant to the antibiotic G418 were generated. 
Initial testing of these lines indicated that four probably expressed the V1bR and these were 
selected for characterisation in greater detail. All of these four lines showed significantly 
increased IP production in response to AVP stimulation (P<0.05; t-test). A significant 
decrease in IP production in response to AVP stimulation following an AVP pre-treatment 
was also seen with all four lines (P<0.05; t-test). Current evidence therefore suggests that the 
V1bR in these clonal cell lines signals and desensitises in the normal way. Although further 
characterisation of the clonal cell line is desirable, the data to date indicate that these lines 
should be considered to provide an appropriate model system for examining the molecular 
mechanisms involved in the regulation of the V1bR. It appears that there are some minor 
differences in signalling between the clonal cell lines and therefore this should be a 
consideration when deciding which line is most appropriate to use for investigating a 
particular question.  
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CHAPTER 1:  
 
INTRODUCTION  
 
1.1 REGULATION OF ACTH SECRETION 
1.1.1 THE HPA AXIS 
The HPA axis is an endocrine system which is utilised by higher organisms to ensure the 
maintenance of homeostasis in response to shboth physical and emotional stress events 
(Aguilera, 1994; Buckingham et al., 1997; O'Conner, 2000). Adaptive responses to stress 
events are essential to the survival of the organism and a maladaptive response can decrease 
survival chances and can cause an increased susceptibility to a variety of diseases and 
disorders. Specifically, disregulation of the HPA axis has been shown to be a risk factor in 
many mental health disorders (Pompili et al., 2010), particularly in mood disorders (Bosch et 
al., 2007; Carpenter et al., 2007; Parker et al., 2003; Tyrka et al., 2008; Veenema, 2009).  
The general outline of the HPA axis is depicted in Figure 1.1. As can be seen activation of the 
HPA axis ultimately results in the production of glucocorticoids, which regulate a wide range 
of targets to ensure an adequate stress response and the maintenance of homeostasis 
(Aguilera, 1994; Buckingham et al., 1997; O'Conner, 2000). Glucocorticoid release is 
regulated by the hormone ACTH, which is released from corticotroph cells in the anterior 
pituitary gland. Regulation of ACTH secretion is a tightly controlled multi-factorial process 
(Aguilera, 1994; Antoni, 1993). The hypothalamic neuropeptides, CRH and AVP, are the two 
most potent secretagogues involved in ACTH release. CRH and AVP are secreted into the 
hypophyseal portal circulation from the hypothalamus in a pulsatile fashion. Stimulation of 
ACTH secretion by CRH and AVP occurs when the peptides bind to their specific GPCRs. 
CRH binds to the CRH-R1, and AVP to the V1bR. It is believed that in some species, 
including rats and primates, CRH controls and maintains the basal level of ACTH secretion as 
well as stimulating the production of the ACTH pre-cursor molecule pro-opiomelanortin 
(POMC) (Aguilera, 1994; Gillies et al., 1982; Krieger, 1983), with AVP potentiating ACTH 
secretion, particularly in response to stress events. Release of both CRH and AVP from the 
hypothalamus is increased in response to stress events. This release is differentially regulated 
in response to different types of stress, which allows the stress response to be tailored 
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appropriately to the situation (Aguilera, 1994). As stated above CRH and AVP stimulate the 
release of ACTH, while negative feedback from secreted glucocorticoids inhibits both the 
release of ACTH from the pituitary and CRH and AVP from the hypothalamus (Buckingham 
et al., 1997). ACTH also regulates the secretion of CRH and AVP from the hypothalamus 
through negative feedback.  
 
 
Figure 1.1 The HPA axis. The series of steps in the HPA axis pathway are depicted. Both ACTH and glucocorticocoids are 
sources of negative feedback, which helps to regulate the axis. The figure is adapted from Buckingham et al., (1997). 
Commonly GPCRs, like CRH-R1 and V1bR, are also regulated through negative feedback 
within the cell, which causes the response to become desensitised as a result of repeated or 
prolonged agonist stimulation (Ferguson, 2001; Lohse, 1993). It is believed that the regulation 
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of the receptor content of the V1bR maybe an important step in the control of the ACTH 
responsiveness of pituitary corticotrophs and therefore, the adaptation to stress (Aguilera et 
al., 1994). A key mechanism of GPCR desensitisation is phosphorylation of the receptor, 
which uncouples it from its signalling pathway (Lohse, 1993). This is a rapid and reversible 
mechanism of desensitisation. Other mechanisms of desensitisation include the internalisation 
and down regulation of the receptor, but these occur over longer time scales (Ferguson, 2001). 
The V1bR has been shown to be desensitised at physiologically relevant concentrations and 
durations of AVP stimulation of ovine pituitary cells (Hassan et al., 2003). However, despite 
some investigation into the molecular mechanisms of V1bR desensitisation (Hassan and 
Mason, 2005) it still remains to be fully elucidated.  
1.1.2 THE ROLE OF AVP IN THE REGULATION OF ACTH SECRETION 
AVP is a neuropeptide hormone containing nine amino acids and is very closely related to 
oxytocin (OXT) (Barberis et al., 1998; Vincent and Su, 2008). AVP is synthesised by two 
groups of neurons in the hypothalamus, the parvocellular cells in the paraventricular nucleus 
and magnocellular neurons in the supraoptic and paraventricular nuclei (Antoni, 1993). Axons 
of the parvocellular system project into the external zone of the median eminence, where they 
secrete AVP into pituitary portal secretion. The magnocellular system secretes AVP into the 
peripheral circulation from axon terminals in the neural lobe of the pituitary. Evidence 
suggests that the parvocellular neurons are the primary source of AVP responsible for ACTH 
regulation in response to stress (Aguilera, 1994).  
AVP has been implicated in the release of ACTH from the anterior pituitary since the 1950’s 
(for an example see Martini and Morpurgo, 1955), however, it is only relatively recently that 
the importance of its role in the HPA axis has become clear. Most previous work involving 
ACTH secretion has focused on the role of CRH, as it was known to be a potent secretagogue 
for ACTH secretion and thought to most probably be the main secretagogue in most animals 
(Antoni, 1993). It is now known that AVP potentiates CRH  stimulated ACTH secretion and 
that the stimulation of the pituitary by both peptides results in a synergistic response (Gillies 
et al., 1982). It has been proposed that for a number of species, including primates and rats, 
that the CRH system maintains basal secretion of ACTH and stimulates the production of 
POMC mRNA while AVP stimulation is crucial in the response to stress, particularly chronic 
stress (Aguilera, 1994; Aguilera and Rabadan-Diehl, 2000b; Antoni, 1993). Although, 
research in mice models has indicated that the AVP/V1bR system is involved with both the 
basal and stress responses of the HPA axis (Tanoue et al., 2004). Work in ovine anterior 
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pituitaries has shown that the ACTH response is desensitised following an AVP pre-treatment 
at physiologically relevant concentrations and durations (Hassan et al., 2003). This suggests 
regulation of the ACTH response to AVP stimulation is a physiologically relevant process. 
1.1.3 MECHANISMS OF AVP STIMULATED ACTH RELEASE IN THE ANTERIOR 
PITUITARY  
1.1.3.1 AVP stimulated receptors 
As mentioned in Section 1.1.1, the effects of AVP are mediated through GPCRs. Like all 
GPCRs, the AVP receptors share the common structural features of seven transmembrane 
(TM) α-helices, with an extracellular amino terminus and an intracellular carboxyl terminus 
(Kobilka, 2007). The most variable parts of the GPCR structure are in the amino- and 
carboxyl- termini and the third intracellular loop, between TM5 and TM6. The amino 
terminus of GPCRs is variable in length, to allow for accommodation of a wide variety of 
agonists. For GCPRs activated by peptides, like the AVP receptors, the amino terminus is 
usually between 10-50 amino acids long. The carboxyl terminus and the third intracellular 
loop are known to be involved in coupling with G-proteins. GPCRs are generally very hard to 
crystallise due to their transmembrane portions and their inherent flexibility. However, crystal 
structures have been obtained for rhodopsin and these structures have been used to elucidate 
most of the structural information available for GPCRs (Kobilka, 2007; Palczewski et al., 
2000). Other methods have been used to elucidate structural detail from other GPCRs as well, 
including site directed mutagenesis, cysteine scanning mutagenesis, and engineered metal ion 
binding sites (Kobilka, 2007). However, as rhodopsin is easy to use and readily available it 
has made this the GCPR of choice for investigations into structure. 
The flexibility that makes GPCRs so hard to crystallise is generally considered to be 
functionally important, in that it allows the receptors to specifically alter their conformations 
in response to agonist binding (Ferguson, 2001; Kobilka, 2007). These conformational 
changes mainly occur in the TM segments and cytoplasmic region of the receptor. Most 
commonly the relative positions of TM3, TM5, and TM6 are altered, which results in re-
orientation of the third intracellular loop. The agonist stabilises these changes and therefore 
the partially or fully active conformational states. The agonist binding to the receptor induces 
the conformational changes through activation of specific combinations of molecular 
switches. Once activated the GPCR couples to a specific G-protein. The G-protein transduces 
the signal from the receptor to an intracellular second messenger system. 
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As well as mediating ACTH secretion through the V1bR, AVP also has a number of other 
physiologically relevant effects which it mediates through the other GPCRs that it specifically 
activates. There are a total of four different receptors which AVP can activate, including the 
V1bR. There are two other specific VP receptors, the vasopressin 1a receptor (V1aR), and the 
vasopressin 2 receptor (V2R), as well as the single oxytocin receptor (OTR) (Vincent and Su, 
2008). These receptors show a high level of sequence homology, however, they do bind AVP 
in different ways, but with similar binding affinities (Rodrigo et al., 2007; Thibonnier et al., 
2002; Vincent and Su, 2008). The V1aR, the V1bR, and the OTR, signal via coupling to Gq/11 
and therefore PLCβ, while the V2R signals via coupling to Gs and therefore adenylyl cyclase 
(reviewed in Maybauer et al., 2008). In terms of physiological roles, the V2 receptor is 
present in the kidney and mediates the antidiuretic activity of AVP (reviewed in Maybauer et 
al., 2008). The V1aR is present across the widest range of bodily tissues, with its most 
significant roles in the mediation of vasorestriction and social behaviour (reviewed in 
Maybauer et al., 2008; Shepard et al., 2009). As mentioned above the V1bR mediates the 
release of ACTH from the anterior pituitary, although it is also present in a wide range of 
other tissues, where it mediates a variety of other physiological roles (Lolait et al., 1995; 
Maybauer et al., 2008; Saito et al., 1995; Vaccari et al., 1998).  
Using bovine, human, mouse, and rat AVP receptors and combinations of cell culture and 
membrane preparation techniques along with mouse and rat animal models, selective agonists 
(Derick et al., 2002; Pena et al., 2007) and antagonists (Serradeil-Le Gal et al., 2002) have 
been and are being used to more fully elucidate the differences between the receptors (Guillon 
et al., 2004). Due to the similarities between the receptors, many of the synthetic agonists 
which have been designed to be V2 specific agonists are also partial V1bR agonists, which 
causes problems when they are used medically (Guillon et al., 2006). Therefore, in order to 
design more effective pharmaceuticals the differences between the receptors need to be fully 
characterised so that pharmaceutical specificity can be increased. There are also some species 
specific differences seen with receptor binding affinities and pharmacological properties with 
regards to the synthetic agonists and antagonist (Chini and Manning, 2007; Guillon et al., 
2004; Guillon et al., 2006; Pena et al., 2007; Serradeil-Le Gal et al., 2002; Thibonnier et al., 
2002), which could have implications for extrapolation of signalling details from one species 
to another.  
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1.1.3.2 The V1bR 
The V1bR is a GPCR with 424 amino acids in humans (De Keyzer, 1994; Sugimoto et al., 
1994), and 421 amino acids in rats (Lolait et al., 1995). It was shown to be a distinct receptor 
structurally related to the AVP/OXT superfamily that functionally couples to PLCβ              
(De Keyzer, 1994; Sugimoto et al., 1994). It binds to AVP in a manner distinct from that of 
the other AVP receptors (Thibonnier et al., 2002). The amino acid sequence of the receptor 
contains consensus sequences for both protein kinase C (PKC) and GRKs. 
V1bR mRNA has been identified in a number of rat tissues including the thymus, heart, lung, 
spleen, kidney, uterus, breast, small intestine, liver, pancreas, and in a number of areas in the 
brain (Lolait et al., 1995; Saito et al., 1995; Vaccari et al., 1998). In the brain the V1bR is 
present in greater amounts in the forebrain, hypothalamus, amygdala, and cerebellum and less 
in mid and hindbrain regions (Hernando et al., 2001; Vaccari et al., 1998). The distribution of 
the V1bR in the brain is distinct from both the distributions of the OTR and V1aR, which are 
also present in the brain, indicating functional specialisation of the receptors. This wide 
distribution contributes to the wide variety of physiological responses that have been 
determined for the V1bR, including the release of insulin (Pena et al., 2007), catecholamines 
(Guillon et al., 1998) and glucagon (Yibchok-Anun et al., 1999). The receptor has been 
shown to have a role in regulation of cell proliferation (Thibonnier et al., 1997), water 
balance, and body temperature (Daikoku et al., 2007). There are also indications of 
involvement of the receptor in social interactions and emotional responses such as aggression 
(Caldwell and Young III, 2009; Egashira et al., 2009; Wersinger et al., 2002), social 
motivation (Wersinger et al., 2004) and social recognition (Wersinger et al., 2002). Most of 
this research determining the physiological roles of the V1bR has utilised null mice models. 
However, some rat models have been used as well, along with human and rat perifused tissue. 
1.1.3.2.1 Signalling of the V1bR 
There are a large number of extracellular residues that appear to be involved in the receptor 
binding of AVP (Barberis et al., 1998). Therefore, it has been speculated that the 
hormone/receptor complex is an intricate network of hydrogen bond interactions. The role of 
arginine-8 of AVP is particularly important in binding to the V1bR, where it interacts with the 
negatively charged amino acids in the receptor binding sites (Rodrigo et al., 2007). A 
proposed model of AVP binding to the V1bR can be seen in Figure 1.2. 
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Figure 1.2 AVP binding to the V1bR. A three dimensional image of the proposed binding (Rodrigo et al., 2007).  
 
 
 
Once AVP has bound to the V1bR, normal signal transduction is achieved by coupling of the 
receptor to the G-protein, Gq/11 (Alberts et al., 2002; King and Baertschi, 1990; Maybauer et 
al., 2008; Thibonnier et al., 1997). Gq/11 works by activating PLCβ which hydrolyses 
phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol 1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG). IP3 stimulates release of Ca2+ from intracellular stores, particularly 
from the endoplasmic reticulum (ER), through binding to gated Ca2+ channels. DAG, along 
with the increase in intracellular Ca2+, activates protein kinase C (PKC) which phosphorylates 
target proteins within the cell as well as stimulating entry of Ca2+ from the extracellular space. 
This increase in free intracellular Ca2+ levels stimulates the release of ACTH from the cell. 
Figure 1.3 depicts this general signalling pathway. The Ca2+ release activated by IP3 is 
responsible for the spike phase of the response which is seen initially. The Ca2+ release 
activated by DAG is responsible for the sustained response (reviewed in Mason et al., 2002). 
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Figure 1.3 Intracellular signalling of GPCRs coupled to Gq/11. The agonist binds to the GPCR activating it. Once activated 
it binds to the G-protein Gq/11. This causes the α-subunit of the G-protein to separate from the βγ-subunit. Once separated 
from the βγ-subunit, the α-subunit activates PLCβ. The activated PLCβ then hydrolyses PIP2 to IP3 and DAG. IP3 stimulates 
the release of Ca2+ from intracellular Ca2+ stores. DAG along with this increase in intracellular Ca2+ activate PKC (Alberts et 
al., 2002). 
V1bR signalling is affected by the number of receptors expressed in the membrane and by the 
concentration of AVP available (Orcel et al., 2009; Thibonnier et al., 1997). Low levels of 
receptor expression in Chinese hamster ovary (CHO) cells resulted primarily in the activation 
of PLCβ signalling (as described above), and high levels of receptor expression in these cells  
resulted in activation of both PLCβ and adenylyl cyclase signalling pathways (Thibonnier et 
al., 1997). In HEK293 and COS-7 cells transiently transfected with the V1bR higher 
concentrations of AVP were able to produce signalling through both PLCβ and adenylyl 
cyclase, whereas lower concentrations could only elicit signalling through PLCβ (Orcel et al., 
2009). This occurred in cells with both a normal and a higher than normal level of receptor 
expression. When the cells were stimulated with the selective V1bR agonist 
d[Cha4]vasopressin signalling occurred through both signalling pathways at equivalent 
potencies.  
The V1bR can form homo-dimers as well as hetero-dimers with the CRH-R1 and OTR 
(Young et al., 2007). Current indications are that formation occurs in the ER and is a         
non-regulated process. Dimerisation has been seen among many different GPCR families but 
is only necessary for receptor activation in a few (Kobilka, 2007). Evidence suggests that 
signalling with these V1bR dimers can happen differentially through Gq/11 and Gs (Orcel et 
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al., 2009), potentially making this an important process in the normal signalling of the cells. 
The presence of these dimers has created the potential to design bivalent analogues for 
assessing the receptors and these have therapeutic possibilities (Chini and Manning, 2007). 
Signalling depends upon the ligand as well as the localisation of the receptors within the 
plasma membrane. Localisation within different plasma membrane domains has been shown 
to affect signalling via PLCβ coupled GPCRs (Golebiewska and Scarlata, 2010).  
1.1.3.2.2 The role of the V1bR in ACTH secretion 
As mentioned above the major physiological role for the V1bR is in the anterior pituitary, 
where it mediates ACTH secretion in response to AVP simulation (reviewed in Maybauer et 
al., 2008). Several studies, including both in vitro experiments, with rats, mice, ovine, and 
equine anterior pituitary cells, and in vivo studies with rats, have shown that ACTH 
responsiveness to AVP is decreased following prolonged exposure (reviewed in Mason et al., 
2002). The regulation of ACTH responsiveness to AVP is thought to be important in the HPA 
axis adaptation to stress, particular for maintaining ACTH responsiveness during chronic 
stress (Aguilera, 1994; Aguilera and Rabadan-Diehl, 2000b; Antoni, 1993). Evidence from a 
number of studies involving rats suggests that AVP plays a key role in regulating V1bR 
expression and as a consequence the ability of the pituitary to respond to activation of the 
HPA axis (Aguilera and Rabadan-Diehl, 2000a). Several different chronic stress paradigms 
were examined with rats to investigate the relationship between V1bR receptor levels and 
AVP stimulated ACTH release (Aguilera et al., 1994). The results from these experiments 
showed a direct relationship between ACTH responsiveness and V1bR levels during chronic 
stress. This suggests a role for receptor regulation in adaptations of the HPA axis to chronic 
stress. Work in ovine pituitaries has suggested that the receptor regulation is a physiologically 
relevant process (Hassan et al., 2003). 
Both transcriptional (Rabadan-Diehl et al., 2000; Volpi et al., 2002) and translational 
(Rabadan-Diehl et al., 2007; Rabadan-Diehl et al., 2003) mechanisms have been indicated to 
be involved in the regulation of the rat V1bR expression. However, it appears that it is the 
translational mechanisms that are key for regulation of the total receptor content of cells 
(Aguilera et al., 2003; Volpi et al., 2004). There are two key regulatory elements in the 5’ 
untranslated region which appear to be involved in translational V1bR regulation. These are 
repressor small open reading frames (Nomura et al., 2001; Rabadan-Diehl et al., 2007) and an 
up-regulating internal ribosomal entry site (Rabadan-Diehl et al., 2003). 
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It has recently been suggested that regulation of the V1bR may not directly mediate the 
hypersensitivity of ACTH responses in chronic stress paradigms, and instead maybe 
regulating cell proliferation and remodelling of the pituitary tissue (Aguilera et al., 2008). 
There is evidence in support of this theory, indicating that AVP has a mitogenic effect and 
that this can be mediated by the V1 type receptors (Tahara et al., 1999; Van Wijk et al., 
1995). Whether or not receptor regulation directly affects ACTH secretion, information on the 
molecular mechanisms controlling the regulation of the V1bR should still prove valuable.  
 
1.2 DESENSITISATION OF THE ACTH RESPONSE TO AVP 
When activated by an agonist GPCRs transduce a signal through conformational changes 
which couple the receptor to a signalling pathway (Kobilka, 2007) (see Section 1.1.3.1 for 
details). These conformational changes also enable the process of desensitisation, which is a 
physiologically relevant regulatory mechanism which limits acute and chronic over 
stimulation (Ferguson and Caron, 1998). GPCRs desensitise in response to either repeated or 
prolonged exposure to their agonist. 
In ovine pituitary cells desensitisation of the ACTH response to AVP stimulation (100 nM,    
5 min) has been shown to occur following pre-treatment of the cells for 5 min with 5 nM AVP 
(Hassan et al., 2003). Pre-treated cells showed a significant decrease in ACTH response to 
78.5% of the response seen in control cells that were not pre-treated. An AVP pre-treatment 
of this concentration and duration falls within endogenous ranges in the sheep. This indicates 
that the process of V1bR desensitisation is likely to be a physiologically relevant process and 
therefore it is likely to be a key process in the regulation of ACTH release in vivo.  
1.2.1 MECHANISMS OF DESENSITISATION OF GPCRs  
Desensitisation of GPCRs can occur by a number of mechanisms including, uncoupling of the 
receptor from its signalling pathway through receptor phyosphorylation, internalisation of the 
receptor, and down regulation of the total receptor content (Ferguson, 2001). These 
mechanisms occur over different time scales. Uncoupling of the receptor from its signalling 
pathway results in a rapid and reversible form of desensitisation (Ferguson, 2001; Lohse, 
1993). Phosphorylation is generally a complex and specific process, which allows for 
differential signalling outcomes (Kelly et al., 2008). Phosphorylation of specific GPCRs has 
been shown to be catalysed by one, or a number of, protein kinases, including protein kinase 
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A (PKA), protein kinase B (PKB), protein kinase C (PKC), the G-protein coupled receptor 
kinase (GRK) family, the casein kinase family, and tyrosine kinases (Lohse, 1993; Tobin, 
2008). Which kinase(s) is specifically involved depends upon the receptor and in some cases 
the agonist that is activating the receptor, which indicates that different functional 
conformations of the receptors are phosphorylated by different kinases (Bailey et al., 2009).  
Phosphorylation of receptors by GRKs promotes the binding of β-arrestins, which not only 
leads to uncoupling of the receptor from its cognitive G-protein, but also targets the receptor 
for internalisation (Ferguson, 2001; Kelly et al., 2008). Once internalised the receptors are 
then either, dephosphorylated, re-sensitised, and returned to the plasma membrane, or they are 
degraded and the total cellular complement of the receptor is down regulated. This classical 
model of desensitisation is depicted in Figure 1.4.  
 
 
Figure 1.4 The classical model of GPCR signalling, as regulated by GRKs and β-arrestins. The GCPR is activated by 
the agonist (1) which results in the coupling of the receptor to a specific G-protein, activating it (2) this leads to the 
separation of the α-subunit from the βγ-subunit. The activated receptor is phosphorylated by GRK (3), arrestin binds to this 
phosphorylated receptor, which leads to receptor desensitisation (4), internalisation (5), dephosphorylation (6) and recycling 
back to the plasma membrane (7). GPCRs which have been internalised may also be targeted for down regulation (Kelly et 
al., 2008). 
 
Most of the information currently known about the desensitisation of GPCRs has been 
elucidated using β2-adrenergic receptor (β2AR) (Ferguson, 2001). However, the classical 
desensitisation mechanism outlined is thought to be similar for all GPCRs (Ferguson, 2001; 
Mason et al., 2002; Tobin, 1997), including receptors coupled to the PLCβ signalling pathway 
which have been shown to undergo rapid desensitisation. The magnitude of the 
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desensitisation mediated by phosphorylation is variable between PLCβ coupled receptors 
(Wojcikiewicz et al., 1993).  
A number of factors can affect GPCR signalling and desensitisation including 
compartmentalisation of GPCRs within different membrane domains (Golebiewska and 
Scarlata, 2010; Russo et al., 2009), dimerisation both homo- and hetero-, (Kobilka, 2007), and 
different receptor conformations (Wei et al., 2003). Some GPCRs are still able to signal in 
endosomes after internalisation, however, this signalling can have different functional 
consequences from signalling which occurs at the plasma membrane (Calebiro et al., 2010). 
There is also evidence indicating that there is a phosphorylation-independent pathway for the 
attenuation of GPCR signalling as well as the phosphorylation-dependent pathway (Ferguson, 
2007).  
1.2.1.1 The classical role of GRKs in GPCR desensitisation  
GRKs are a family of serine/threonine protein kinases that specifically bind to and 
phosphorylate agonist occupied GPCRs (Ferguson, 2001; Menard et al., 1997). There are 
seven different GRKs which can be divided into three different groups: 1) GRKs -1 and -7,    
2) GRKs -2 and -3, and 3) GRKs -4, -5, and -6 (Ferguson, 2001; Pitcher et al., 1998; Premont 
et al., 1995; Reiter and Lefkowitz, 2006). GRKs -1, and -7 are found exclusively in the retina, 
and GRK4 expression is mainly confined to the cerebellum, testes and kidneys. All of the 
other GRKs are ubiquitous in mammalian tissues. GRK1 was the first GRK to be identified 
and is specifically associated with rhodopsin. GRKs -2 and -3 were identified through their 
involvement with the β2AR and are therefore also referred to as β2-adrenergic-kinase -1 and -2 
respectively. GRKs1-3 are located in the cytosol under normal conditions, these GRKs are 
then translocated to the plasma membrane upon activation of the receptor. GRKs 4-7 are 
located at the plasma membrane. GRK4 and GRK6 are associated with the membrane via 
palmitoylation on carboxyl-terminal cysteine residues. GRK5 membrane association is 
thought to be mediated by electrostatic interactions of highly basic amino acids in the 
carboxyl-tail of the protein with membrane phospholipids. GRKs phosphorylate GPCRs at 
serine and threonine residues located within the third intracellular loop or the carboxyl-
terminal domain of the receptors. 
There appears to be a level of redundancy among GRKs; when one GRK is knocked down or 
out another can generally compensate for its absence. Knockout of GRK2 is the only GRK 
knock out which is embryonically lethal in mice (Pitcher et al., 1998), indicating that there is 
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some functional specificity. Specifically there are indications that the different groups of 
GRKs have different roles within the signalling process and in some cases compete with each 
other (Reiter and Lefkowitz, 2006). For example GRKs -2 and -3 have been shown with the 
angiotensin II receptor to be more efficient in activating β-arrestin, clathrin dependent 
endocytosis (Kim et al., 2005). Different cell types will also express different levels of the 
various GRKs, providing an ability for different tissues to tailor regulation of the same 
receptor to specific signalling purposes, thereby enabling a variety of physiological roles for 
the same receptor (Tobin, 2008). This may be the case with the V1bR which has been shown 
to have a wide variety of physiological roles. 
1.2.2 MECHANISM OF V1bR DESENSITISATION: CURRENT KNOWLEDGE 
As the V1bR is a GPCR, it is thought that it might follow a similar model of desensitisation to 
that described in Section 1.2.1. However, the specifics of the molecular mechanisms involved 
require investigation. Previous work in this laboratory, carried out using ovine anterior 
pituitary cells has provided data indicating that neither PKC or casein kinase 1 α (CK1α) are 
involved in the desensitisation process (Hassan and Mason, 2005). The data also indicated 
that protein phosphatase 2B (PP2B) is involved in the re-sensitisation process. PP2B has been 
shown with the β2AR to reverse desensitisation mediated by GRK2 (Shih et al., 1999). 
Therefore, it seems that the most likely mediator(s) of V1bR phosphorylation is a GRK(s). 
The V1bR amino acid sequence contains consensus motifs for GRKs (Mason et al., 2002; 
Thibonnier et al., 2002), which confirms the potential ability of these kinases to mediate 
V1bR phosphorylation. The possible involvement of GRKs in the desensitisation process of 
the V1bR is therefore a current focus of research in this laboratory. The role of GRKs in the 
mechanism of V1bR desensitisation is currently being assessed using RNAi, as there are no 
pharmalogical inhibitors of specific GRKs. The difficulties associated with using RNAi 
techniques in primary cell cultures have necessitated the development of a model cell system. 
 
1.3 USE OF A MODEL CELL SYSTEM TO INVESTIGATE THE MECHANISM 
OF V1bR DESENSITISATION 
A wide variety of experimental methods, including both cellular studies and genetically 
altered animal models, have been employed previously to assess the role of specific GRKs in 
the phosphorylation of a wide variety of GPCRs (Pitcher et al., 1998). RNAi is the method of 
choice for loss of function studies, due to its relative efficiency and efficacy compared with 
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other techniques (Editorial, Nature Cell Biology, 2003). This approach has therefore been 
chosen in the Mason laboratory to assess the role of individual GRKs in desensitisation of the 
V1bR. However, the use of RNAi has necessitated a move away from primary cell cultures of 
ovine anterior pituitaries (Hassan, 2001; Hassan et al., 2003) to the development of a model 
cell system using an immortalised cell line (Gatehouse, 2008). The reasons for this are varied 
and include the following. Firstly, primary cell cultures of mature ovine anterior pituitaries 
divide infrequently, if at all, in a cell culture environment, whereas immortalised cell lines 
will divide continuously under the right conditions, making them more practical for long term 
studies (Freshney, 2000; Grimm, 2004; van Beijnum et al., 2008). Secondly, immortalised 
cell cultures are also composed of a phenotypically and genetically uniform population that 
have been derived from a specific tissue, whereas primary anterior pituitary cell cultures are 
composed of a heterogenous population of cells. For example the anterior pituitaries contain 
corticotroph cells which express the V1bR. The OTR is also expressed in the anterior 
pituitary, but within other cell types. The presence of another receptor activated by AVP 
which signals via PLCβ in the anterior pituitary will make any results from biochemical 
assays measuring levels of intracellular molecules after AVP stimulation very difficult to 
interpret. Thirdly, transfection efficiency is limited in primary cells, which means that they 
can be difficult to use with RNAi techniques. 
1.3.1 HEK293 CELLS TRANSIENTLY TRANSFECTED WITH THE V1bR AS A MODEL 
CELL SYSTEM 
Previous work in the Mason laboratory (Gatehouse, 2008) examining desensitisation of the 
V1bR has used human embryonic kidney (HEK)293 cells transiently transfected with the rat 
V1bR (rV1bR) gene (Lolait et al., 1995), as a model cell system. This cell line was first 
described in 1977 (Graham et al., 1977), and is extensively used in research. In fact, as of 
January 2011, the original paper has been cited over 3,000 times according to the ISI Web of 
Knowledge. HEK293 cells were chosen for this research for a number of reasons, including 
the fact that this cell line is an excellent recipient of transfected DNA (Graham, 1992) and is 
widely used in research for this purpose. In an in-depth microarray analysis of HEK293 cells 
(Shaw et al., 2002) (see accompanying database http://www.mbi.ufl.edu/~shaw/293.html) 
there was no indication of expression for any of the AVP receptors or the OXT receptor. 
Experiments in this laboratory (Gatehouse, 2008) and others (Orcel et al., 2009) have shown 
that there is no increase in IP production in response to a saturating concentration of AVP 
(100 nM) without transfection of an AVP receptor. This confirms that no AVP activated 
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receptors are normally expressed in HEK293 cells. Therefore, HEK293 cells are a suitable 
recipient for the rV1bR. A human cell line, like the HEK293 line, is a good choice for RNAi 
work as the sequences of human GRKs are known and siRNA duplexes to target them have 
been published and used to examine the role of GRKs in signalling via the angiotensin II 
receptor (Kim et al., 2005; Wei et al., 2003), the V2 receptor (Ren et al., 2005), and the β2AR 
(Violin et al., 2006). Therefore, these factors make HEK293 cells a good choice as the model 
system for this research. 
When using transient transfections the level of expression of the transfected gene can vary 
with each transfection event. Generation of a V1bR stably-transfected cell line can minimise 
this problem. Over long term experiments the production of stably-transfected cell lines is 
significantly less costly and time consuming than repeated transient transfections. 
1.3.2 THE GENERATION OF A V1bR STABLY-TRANSFECTED MODEL CELL SYSTEM: 
REQUIREMENTS TO ACHIEVE THIS 
The main aim of this research was to develop a model cell system stably expressing the 
rV1bR, in order to avoid the problems associated with transient transfections that were 
described above. Transfection of cells is said to be stable when there is continued expression 
of the gene over time (Grimm, 2004), for example when the plasmid DNA containing the 
gene is integrated into the cell’s genome. 
Generation of clonal stably-transfected cell lines improves consistency between experiments 
including consistent protein expression levels and signalling characteristics. Cell lines   
stably-transfected to express a gene of interest (GOI), provide a homogenous population of 
cells in which the gene and the protein produced can be analysed (Grimm, 2004; Mortensen 
and Kingston, 2009). Analysis of genes and proteins in a cell system closely related to the 
source cell system allows for a greater level of extrapolation. Mammalian cells stably 
expressing a variety of genes are also currently used in production of mammalian 
recombinant proteins for pharmaceuticals because these cells can properly assemble, fold, and 
modify mammalian proteins (Wurm, 2004). In order to generate stably-transfected cell lines, 
several factors need consideration and consequently several preliminary steps are required 
before the cells are transfected and selected for. These include plasmid design (Mairhofer and 
Grabherr, 2008), transfection reagent selection and optimisation for use with a specific cell 
line (Mortensen and Kingston, 2009), and the selection and optimisation of a selection 
16 
 
 
 
marker. Once these stably-transfected cell lines have been generated a suitable method of 
analysis of the expression of the GOI is required. 
An important step in developing a cell system which will express a specific protein stably, is 
to determine which method of plasmid delivery should be used as DNA is a large, highly 
charged molecule and therefore cannot cross the plasma membrane without help (Bonetta, 
2005). There are a wide variety of reagents that can be used for the introduction of DNA into 
mammalian cells, each with its own advantages and disadvantages that need to be evaluated 
(Bonetta, 2005; Grimm, 2004; Mortensen and Kingston, 2009). The differences between the 
methods affect the mechanism used to get the DNA into the cytosol and nucleus as well as 
affecting the way in which the plasmid DNA is integrated and expressed. Therefore, this can 
affect the expression profiles obtained from the stable cell line. Methods of introducing DNA 
to mammalian cells include carrier molecules, electroporation, and viruses. Introduction of 
DNA via carrier molecules is termed transfection, whereas viral introduction is termed 
transduction (Bonetta, 2005). 
Carrier molecule methods of DNA introduction are generally straightforward and efficient to 
use (Bonetta, 2005). There is also a wide variety of different reagents to choose from 
(Bonetta, 2005). The various types of carrier molecules will encapsulate/complex with the 
DNA. This complex is then believed to be incorporated into the cell through endocytosis 
(Ausubel et al., 1994; Felgner et al., 1987; Grimm, 2004). The DNA is then released from the 
endosome, but how this is achieved by the complex is currently not well understood. Plasmid 
design can be used to facilitate importation into the nucleus, however, importation is 
generally most efficiently achieved during cell division when the nuclear membrane ruptures 
(Vaughan et al., 2006). Therefore, these methods tend to work best on dividing cells. Carrier 
molecule methods usually introduce the plasmid DNA to the chromosome as multiple copies 
at a single site (Mortensen and Kingston, 2009). This usually creates a tandem array of similar 
sequences within the host’s genome. The presence of these arrays can lead to intra-
chromosomal rearrangement over time, resulting in a drop in copy number, which will lead to 
a decrease in the levels of expression.   
Electroporation uses an electrical current to create transient holes in the plasma membrane of 
cells (Ausubel et al., 1994; Bonetta, 2005). Once a hole has been created there is no longer a 
barrier to DNA entry, and therefore it can access the cytosol with ease. However, despite the 
wide applicability of this method, it is very harsh on cells and use generally results in high 
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levels of cytotoxicity. In order to use this method expensive equipment is required. This 
method will also work best on dividing cells (Vaughan et al., 2006). Electroporation will most 
commonly introduce one copy of the DNA at one site in the host’s genome (Mortensen and 
Kingston, 2009).  
Introduction of DNA using viruses is the most efficient method of introduction, as the viruses 
have naturally evolved proteins which are highly efficient at facilitating entry to the cell and 
in some cases the nucleus (Bonetta, 2005; Grimm, 2004). However, the protocols can be time 
consuming and their use presents bio-safety issues. Retroviruses contain the protein, 
integrase, which they can use to insert the plasmid DNA into the host cell’s genome, making 
them a very useful tool for developing stable cell lines. The only draw-back to this is that only 
the lentivirus genus of this family of viruses, for example the human immunodeficiency virus, 
can infect non-dividing cells, the rest of the retrovirus family must infect dividing cells. The 
other virus family commonly used for transduction are adenoviruses and although these do 
not have their own proteins for facilitating DNA integration into the genome they can 
introduce DNA to a wide range of cells with high efficiencies.  
Integration of the DNA into the genome is believed to be a random event whether 
introduction to the cell was mediated by chemical or viral methods (reviewed in Murnane et 
al., 1990). DNA has been shown to integrate via both homologous and non-homologous 
recombination pathways (Crabb and Cowman, 1996; Murnane et al., 1990). Viral methods 
use virus protein to incorporate the plasmid DNA into the host’s genome. Whereas with 
chemical methods it is believed that the cellular machinery is used to facilitate integration via 
DNA repair and recombination enzymes (Haber, 1999). 
The random nature of DNA integration can produce difficulties in the generation of stable cell 
lines, as many of these integration events do not result in adequate expression of the GOI 
(Mortensen and Kingston, 2009). To address this issue, it is possible to utilise homologous 
recombination to introduce DNA at specific sites. This is mainly done when creating 
transgenic animals, but it can also be used for stable cell line creation. One such system that 
can be utilised is a lox recombination vector, which is designed to directly select Cre-
mediated site-specific DNA integration at a lox target site previously incorporated into the 
genome (Fukushige and Sauer, 1992). Cre is a recombinase protein that mediates site specific 
integration between loxP sites, on the plasmid and in the genome. Systems like this produce a 
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reproducible level of expression. This is not a suitable approach to obtain stable cell lines if 
the functional impact of differing levels of expression is of interest. 
Carrier molecule and electroporation methods are suitable for both introduction of DNA on a 
single plasmid or on two separate plasmids (co-transfection) (Ausubel et al., 1994; Mortensen 
and Kingston, 2009). Carrier molecule protocols are less complicated than ones for viruses 
and less equipment is required than for electroporation (Bonetta, 2005). This makes carrier 
molecular methods suitable for inexperienced users and a suitable choice for a laboratory 
where only a small number of transfections is required. 
Selection and maintenance of expression using a dominant selection marker provides a simple 
method of isolating stable cells from those with only transient expression (Mortensen and 
Kingston, 2009). There are number of options when choosing a dominant selection marker, 
and one must be chosen that will produce the desired outcome within the timeframe available. 
An appropriate assay must be set up to assess the functioning of the transfected gene (Grimm, 
2004). This is a key step, as before the cell line is used further it must be assessed to ensure 
that gene expression is normal. Characterisation of the expression levels of the gene are also 
crucial and required before further work with the cell line is undertaken. 
1.3.2.1 Plasmid design to improve stable integration of plasmid DNA and protein 
expression 
Several factors in plasmid design can help to increase transfection efficiency (Mairhofer and 
Grabherr, 2008). These include a reduction in the size of the plasmid to improve delivery, 
protection from degradation while in the cytosol, targeting to the nucleus, and minimisation of 
prokaryotic elements within the plasmid. 
Successful transfection is highly dependent upon the cell cycle, with gene expression 50-300 
times higher when cells are transfected just before G2 phase or during mitosis (reviewed in 
Hebert, 2003; Vaughan et al., 2006). This is because the nuclear envelope ruptures and the 
plasmid gains unimpeded access to the nucleus. This method of gaining access to the nucleus 
is utilised most commonly when transfecting dividing cells. However, when transfecting non-
dividing cells the plasmid must be targeted and imported into the nucleus, this process is 
enhanced by a nuclear localisation signal (reviewed in Nakanishi et al., 2001). In general 
nuclear import is believed to be an active signal-mediated process which occurs via the 
nuclear pores. There are a number of transport pathways that can be utilised and these are 
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mediated by a variety of carrier proteins within the cell. For example plasmids containing 
specific sequences from simian virus (SV)40 have been shown to enhance nuclear targeting 
and import (Dean, 1997; Dean et al., 1999; Nakanishi et al., 2001; Vaughan et al., 2006). The 
majority of the plasmid DNA imported with this SV40 sequence, co-localized with the SC-35 
splicing complex antigen which suggests that, in this case at least, that the nuclear import of 
the DNA was dependent on transcriptional processes.  
Once the DNA has reached the nucleus, expression is affected by the site of DNA integration 
into the chromatin (Wurm, 2004). Integration into inactive condensed heterochromatin can 
result in little to no expression of the gene, whereas integration into active euchromatin allows 
for a greater level of expression. Typically in mammalian cells about 10% of the genome is 
packaged into heterochromatin (Alberts et al., 2002). Flanking transgenes with protective cis-
regulatory elements such as insulators, boundary elements, scaffold/matrix attachment 
regions, ubiquitous chromatin opening elements and conserved antirepressor elements can 
help reduce the negative effects of heterochromatin on expression (reviewed in Wurm, 2004).  
1.3.2.2 Selection of an appropriate transfection reagent 
Selection of an appropriate transfection reagent is necessary to ensure that the desired results 
are achieved for expression of the stably-transfected gene (Hunt et al., 2010; Mortensen and 
Kingston, 2009). Carrier molecules have been the method of choice in the Mason laboratory 
for the introduction of DNA into HEK293 cells previously (Gatehouse, 2008). This is because 
they provided a relatively straight forward and low cost method of DNA introduction with 
relatively low cytotoxicity in mammalian cells (Bonetta, 2005). FuGENE 6 (F6) is a carrier 
molecule transfection reagent and was chosen as the transfection reagent for this project due 
to its ease of use and low cytotoxicity, especially with HEK293 cells (Bonetta, 2005; 
Jacobsen et al., 2004). F6 is a non-liposomal formulation of proprietary compounds that has 
been shown to successfully transfect a wide range of cell lines (Bonetta, 2005). In order to 
obtain the best results, several parameters of the transfection protocol need to be optimised for 
use with the chosen cell line (see Section 3.4)  
1.3.2.3 Selecting for stably-transfected HEK293 cells  
When generating a stably-transfected cell line a dominant selection marker is required, as it 
provides the cells which have stably-integrated the plasmid with a selective advantage 
(Mortensen and Kingston, 2009). In this research Geneticin®, also known as G418, was used 
to select for the stably expressing cells. G418 provides a means to select cells if a G418 
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resistance gene has been transfected along with the GOI (Southern and Berg, 1982). 
Aminoglycoside 3’-phosphotransferase (APH(3’)II) from transposon Tn5, designated as neo, 
is the gene which provides mammalian cells with resistance to G418 (Davies and Jimenez, 
1980). G418 was originally isolated from Micromonospora rhodorangea (Wagman et al., 
1974), and is similar in structure to other aminoglycoside antibiotics, such as gentamicin, 
neomycin, and kanamycin, which all act on prokaryote cells (Southern and Berg, 1982). 
Aminoglycoside antibiotics affect prokaryote cells by binding to the aminoacyl-tRNA site (A 
site) on 16S ribosomal RNA, thus decreasing the accuracy of translation in the cells (Vicens 
and Westhof, 2003). G418 works as a selective agent in eukaryote cells by preventing protein 
synthesis through interference with the 80S ribosome (Davies and Jimenez, 1980), 
specifically the 18S subunit (Kaul et al., 2005). G418 will cause the de-stacking of base 1492, 
and this de-stacking in the rRNA site is the critical factor in the action of the antibiotic. In 
order to successfully use a selection agent in the selection of stable clones the minimal 
concentration needed for killing the parental cell line must be determined (see Section 3.3). 
This ensures that the concentration determined will be lethal to all cells that do not integrate 
the neo gene, allowing for those which do stably-integrate the gene into their genomes to be 
selected for (Southern and Berg, 1982). 
1.3.2.4 Characterisation of the developed stable cell lines 
Characterisation of stable cell lines is important to determine the level of expression of the 
GOI and whether the protein produced is functioning normally (Grimm, 2004). Once the cell 
line have been characterised, lines with high and low levels of gene expression can be 
identified. Full characterisation of cell lines is useful when analysing results obtained with a 
stable cell line and also when comparing with other cells expressing the gene.  
Characterisation of GPCRs, can be achieved through measurements of molecules produced 
within the signalling pathway in response to agonist stimulation. The V1bR is coupled to Gq/11 
which activates the PLCβ to hydrolise PIP2 to IP3 and DAG. In turn these molecules stimulate 
an increase in intracellular Ca2+ (see Section 1.1.3.2). Measurement of IP accumulation 
(Gatehouse, 2008; Rabadan-Diehl et al., 2007; Thibonnier et al., 1997; Young et al., 2007) 
and changes in intracellular Ca2+ levels (Gu and Lee, 2010; Nezu et al., 2010; Sato et al., 
2009; Young et al., 2007) are two potential ways of assessing functional signalling with Gq/11 
coupled GPCRs. Receptor binding assays, with [3H]AVP can be utilised to determine the 
actual numbers of V1bRs present at the cell surface and the binding properties (Aguilera et 
al., 1994; Young et al., 2007). 
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Measurement of IP accumulation is a widely used method for assessing signalling in Gq/11 
coupled GPCRs. After the hydrolysis of PIP2 to IP3 and DAG, IP3 is de-phosphorylated in a 
stepwise manner (Berridge et al., 1983), and then joins up with DAG metabolites and 
eventually regenerates PIP2. Li+ inhibits the enzyme inositol monophosphatase preventing the 
de-phosphorylation of inositol 1-phosphate (IP1) to inositol (Berridge et al., 1982). This 
causes the IP3, 1,4-bisphosphate (IP2), and IP1 to accumulate within the cell. The total IPs can 
then be separated from other water soluble cell extracts using anion exchange 
chromatography and increasing concentrations of formate as described previously (Downes 
and Michell, 1981; Richards et al., 1979). By radio-labelling the cells with myo-[3H]inositol 
prior to agonist stimulation and subsequent IP extraction and separation, the eluted samples 
can be counted using a liquid scintillation counter (Berridge et al., 1983). 
This method can be used to assess the function signalling of any GPCRs which signal via 
PLCβ, and has been used previously to assess the V1bR signalling (Gatehouse, 2008; 
Rabadan-Diehl et al., 2007; Thibonnier et al., 1997; Young et al., 2007). Critically the IP 
assay can be used for the assessment of GRK involvement in GPCR desensitisation (Pitcher et 
al., 1998). For example it has been used in the investigation of the role of GRK2 in 
desensitisation of the metabotrophic glutamate 1 A receptor using transiently transfected 
HEK293 cells (Dale et al., 2000). 
 
1.4 AIMS OF THIS RESEARCH 
The aims of this research were the following: 
1) generate and screen HEK293 cell lines stably-transfected with the rV1bR, 
2) characterise at least one of these cell lines, 
3) develop various methodologies required to meet the above objectives. 
The main goal of this research was to develop an rV1bR stably-transfected clonal, model-cell 
system that could be used for investigating regulation of the receptor at the molecular level. 
The successful development of a cell line stably expressing a GOI requires the optimisation of 
various methodologies. Once a model cell system is developed, characterisation of its 
functional profile and the expression level of the protein of interest are required before the 
system can be used for further research. For this model cell system future research will 
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involved investigations into the molecular mechanism involved in the desensitisation of the 
V1bR. 
Due to the developmental nature of this thesis, the results section has been divided up into 
two chapters. Chapter 3 deals with the experimental work and results that were required for 
preparation and generation of the stable cell lines. Chapter 4 deals with the initial 
characterisation of V1bR expression within these cell lines. 
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CHAPTER 2:  
 
STANDARD METHODS  
 
2.1 MATERIALS 
For the sources of materials used in this research please refer to Appendix A. 
 
2.2 SOLUTIONS AND MEDIA 
For the details of all solutions and media used in this research please refer to Appendix B. 
 
2.3 CELL CULTURE  
2.3.1 STANDARD CELL CULTURE CONDITIONS 
In this research HEK293 cells were either cultured untransfected or they were transiently or 
stably transfected with plasmids containing either the enhanced green fluorescent protein 
(EGFP) or the rV1bR. The plasmids used for transfection also contained the neo gene unless 
specified otherwise. Details of both of these plasmids can been found in Section 2.5.1.1. 
Figure 2.1 shows (untransfected) HEK293 cells growing normally. 
 
Figure 2.1 Normal growth of HEK293 cells. Under normal growth conditions HEK293 cells have a 
neuronal morphology, and the monolayer of cells is flat against the tissue cultureware. All images of 
HEK293 cells, unless otherwise stated, were taken on a Leica DM IL microscope using a x20 
objective lens and a x10 eyepiece. This allowed for direct comparison between images.  
24 
 
 
 
The HEK293 cells were cultured in Eagle’s Minimal Essential Medium (MEM) (Invitrogen), 
containing Earle’s salts, L-glutamine, and non-essential amino acids, with sodium bicarbonate 
(BDH Laboratory Supplies) and sodium pyruvate (Invitrogen) added (full MEM details in 
Appendix B). After three weeks, the remaining MEM was supplemented with GlutaMAX™ 
(Invitrogen), due to the breakdown of L-glutamine over that time period. For standard 
culturing, the medium was supplemented with 10% (v/v) foetal bovine serum (FBS) 
(Invitrogen). This supplemented medium will be referred to from here on as MEM+, and any 
departure from this formulation will be indicated. 
For standard culturing HEK293 cells were grown in either 75 cm2 or 25 cm2 flasks in 15 ml or 
5 ml of MEM+ respectively. The size of the flasks used varied depending on the number of 
cells required for specific experiments. Plates with a standard cell cultureware coating were 
used for all experiments unless specified otherwise. The cells were cultured at 37°C inside a 
CO2 water-jacketed incubator (IR Autoflow, Nuaire) in a humid environment of 95% air, 5% 
CO2. 
All procedures and experiments involving the HEK293 cells were carried out in a Biological 
Safety Cabinet-Class II (BH2000, Clyde-Apac), to ensure the maintenance of aseptic 
conditions. Only sterile reagents came into contact with the cells. All plastic ware was 
received sterile from suppliers. All solutions were obtained already sterilised, or those made 
in the laboratory were sterilised by filtration (through 0.22 μm filters or in the case of culture 
medium through 0.45 μm filters) or autoclaving (121°C, 20 min, 20 lb/in2). Glassware was 
sterilised either by autoclaving or dry heat sterilisation (2 h, ≥170°C).   
2.3.2 SUB-CULTURING OF HEK293 CELLS 
The HEK293 cells were regularly sub-cultured (passaged) at 50-80% confluence. It is 
important for the maintenance of the functional viability of HEK293 cells, to ensure that they 
do not reach 100% confluence or greater, as this negatively impacts growth, morphology, and 
function of the cells in later passages. Cells were not passaged when they were below 50% 
confluence as this caused cell growth to be slowed in subsequent passages. 
To passage cells in a 75 cm2 flask, the MEM+ was removed via aspiration and 3 ml of 0.25% 
trypsin with 1 mM ethylenediaminetetraacetic acid (EDTA) (T/E) (Invitrogen) pre-warmed to 
37°C was added to the flask. The flask was tilted to allow the T/E solution to cover the entire 
cell monolayer, and the T/E was then swiftly removed. The cells were incubated at room 
temperature for 8 min, during which time they were observed on an inverted microscope 
25 
 
 
 
(TMS, Nikon). During incubation with T/E, HEK293 cells lose their adherence to the flask 
and dissociate from one another. The morphology of the cells changes from the typical 
neuronal morphology seen with these cells to a round morphology. At the end of 8 min, the 
flask was tapped twice on the bottom and twice on the side. Four to eight ml (for standard 
passaging) or ten ml (for freezing cells, see Section 2.3.4) of MEM+ pre-warmed to 37°C was 
then added to the flask with a 5 ml or 10 ml plastic pipette so that the medium washed down 
over the cells, dislodging them from the surface of the flask. The cell suspension was           
re-pipetted six times, to ensure the break up of any cell clumps, and removed to a 50 ml 
centrifuge (Falcon) tube. The cells were then counted (see Section 2.3.3) and a volume of cell 
suspension containing 0.7 x 106 cells (to passage next in 3 days) or 0.4 x 106 cells (to passage 
next in 4 days) was added to a 75 cm2 flask containing 15 ml of MEM+ pre-warmed to 37°C. 
The cells were cultured for 24 h to allow for adherence. At this point the medium was 
replaced, to ensure the removal of any traces of T/E. The medium was replaced again during 
the cell culture period if it changed colour, indicating a change in pH. Cells were maintained 
for no more than ten passages. Only low passage-number cells were used for cryopreservation 
(see Section 2.3.4). If passaging a 25 cm2 flask, all values were reduced to one third of the 
total values given above. 
2.3.3 CELL COUNTING 
The cells were counted using a haemocytometer to ensure that accurate cell numbers were 
used for both experiments and passaging. This accuracy increased predictability in the 
experimental results and cell growth. The cell counts were also used to determine the viability 
of the cells with trypan blue exclusion (see Appendix B for solution details). Cell viability 
was typically between 95-100%.  
2.3.4 FREEZING AND STORAGE OF CELLS BY CRYOPRESERVATION 
Cryotubes containing HEK293 cells, prepared as described below, were stored in liquid 
nitrogen. Cells were frozen immediately after trypsinisation (see Section 2.3.2). The 50 ml 
tube, containing the cell suspension, was centrifuged at 150 x g for 8 min at room temperature 
(CR 4-12, Jouan). The supernatant was aspirated, and then the bottom of the tube was tapped 
forcefully to loosen the cell pellet. For cells from a 75 cm2 flask split at ~80% confluence, 
four 1 ml aliquots were made for freezing in either Recovery™ Cell Culture Freezing Medium 
(Invitrogen) or freezing medium that was made in the laboratory just prior to freezing (for 
details see Appendix B). To do this 4 ml of chilled Recovery™ Cell Culture Freezing Medium 
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was added to the pellet and used to re-suspend the cells, or 2 ml of MEM without additives 
was added and used to re-suspend the cells followed by 2 ml of freshly made freezing 
medium. If a different sized flask was split, requiring a different number of tubes to be frozen, 
the volumes were adjusted. For example, when freezing the cells from a 25 cm2 flask at ~80% 
confluence, the volumes of media were halved. The freezing mediums were added and the 
cells re-suspended using sterile 5 ml plastic pipettes. The cells were re-pipetted as few times 
as possible to minimise cell damage while still ensuring an even suspension. Aliquots (1 ml) 
of the cell suspension were transferred to labelled Cryo.S tubes (Greiner Bio-one), and placed 
into a Nalgene Cryo 1° Freezing Chamber containing isopropyl alcohol, to ensure gradual 
freezing of the cells. The freezing unit was then transferred to a -80°C freezer. Twenty-four 
hours later the cryo-tubes were moved from the -80°C freezer to liquid nitrogen storage. The 
cells were kept in liquid nitrogen storage until required for use. 
2.3.5 THAWING OF CRYOPRESERVED CELLS 
To thaw the HEK293 cells a tube of cells were removed from liquid nitrogen storage and 
thawed immediately in a 37°C water bath with gentle shaking. The thawed cell suspension 
was transferred using a 5 ml plastic pipette to either a 75 cm2 flask or a 25 cm2 flask 
containing either 19 ml or 4 ml of pre-warmed MEM+ respectively. The flask was then placed 
into the CO2 incubator for culturing. After 24 h of culturing, to allow the cells to adhere to the 
flask, the medium was replaced with 15 ml or 5 ml, respectively, of fresh MEM+ to remove 
the freezing medium and any non-adherent cells from the flask. The medium was also 
replaced on subsequent days if the MEM+ had changed colour. 
 
2.4 MEASUREMENT OF HEK293 CELL PROLIFERATION RATE 
2.4.1 DETERMINATION OF PROLIFERATION RATE 
To determine the proliferation rate of HEK293 cells, the cells were plated at two densities    
(1 x 104 cells/well and 3 x 104 cells/well), into the wells of two 24 well plates (Thermo Fisher 
Scientific), in 1 ml of MEM+. The cells were counted at 24 h intervals over a period of       
10-12 days by lifting the cells in two replicate wells at both densities. An estimate of the 
average confluence of the cells at each plating density was also made at 24 h intervals.  
 To lift the cells for counting, the medium was removed from duplicate wells by aspiration 
and 75-200 μl T/E was added to each well depending on the confluence (see Table 2.1). The 
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plates were incubated for 12 min at 37°C in a CO2 incubator. By incubating the plates in the 
incubator rather than at room temperature, it minimised disturbance to the cells in the wells 
which were not being lifted at that time point. At the end of the incubation a volume of 
MEM+, equal to the volume of T/E used, was added to each well and the cell suspension was 
re-pipetted 7-11 times using a P1000 Gilson pipette set to 80% of the total volume of T/E plus 
MEM+. The re-pipetted cell suspensions were immediately removed to labelled 4 ml 
polystyrene tubes and the 24 well plates returned to the CO2 incubator. The cells were then 
counted as indicated in Section 2.3.3 and the total number of viable cells/well calculated.  
The medium was replaced in the wells when the colour changed from standard, indicating a 
change in pH. The medium was removed and added using a P1000 Gilson pipette. All cell 
counts were carried out at the same time each day, to ensure standard 24 h time intervals over 
the growth period.  
 
 
 
 
 
Table 2.1 Volume of T/E required to dissociate HEK293 
cells at different confluences. Greater volumes of T/E were 
required to disassociate HEK293 cells from the culture ware 
with increasing confluence. All volumes given are for 1 well 
of a 24 well plate. 
 
 
2.4.2 ANALYSIS OF PROLIFERATION DATA 
The daily count data from each plating density were plotted on a semi log graph. An 
individual sigmodial dose-response (variable slope) curve was fitted to each of the data sets. 
The doubling time was determined for both of the initial plating densities during their log 
phase of growth. To do this, the time it took for the cell number to increase from 0.1 x 105 to 
0.2 x 105 was determined. The data were analysed and the graph produced using GraphPad 
Prism 4 (see Section 3.1.2) for the results.  
Confluence Vol. T/E 
0% - 40% 75μl 
40% - 60% 100μl 
60% - 80% 125μl 
80% - 95% 150μl 
95% + 200μl 
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2.5 PREPARATION OF PLASMID DNA FOR TRANSFECTION 
2.5.1 SUB-CLONING OF THE rV1bR GENE INTO A SUITABLE VECTOR (pEGFP-N1) 
FOR STABLE TRANSFECTION 
2.5.1.1 Restriction enzyme digestion of pEGFP-N1 and prV1bR 
The plasmid prV1bR contains the GOI, rV1bR, as well as a gene which provides resistance to 
the antibiotic chloramphenicol. prV1bR is a pALTER®-MAX plasmid (Figure 2.2)           
sub-cloned with rV1bR. pEGFP-N1 (Figure 2.3) contains the egfp gene as well as the neo 
gene, which provides mammalian cells with resistance to G418. The GOI was transferred into 
pEGFP-N1 with the removal of EGFP. This was done to incorporate the GOI on the same 
plasmid as a selection marker for mammalian cells.  
The plasmids prV1bR and pEGFP-N1 were digested with restriction enzymes at positions 
before and after the rV1bR and EGFP genes in order to remove them from their respective 
plasmids. It was preferable, to ensure simple ligation, that the same restriction enzymes were 
used to digest both plasmids. The restriction enzymes chosen were SalI and NotI. This further 
simplified the digestion as both enzymes work in the same buffering system. A restriction 
enzyme digest with a total volume of 20 μl was made up for each plasmid (Table 2.2). Both 
digests were prepared by adding the solutions to separate microfuge tubes from largest 
volume to smallest. The tubes were tapped to mix the solutions, and then centrifuged for        
1-2 s to ensure the total volume was at the bottom of each tube. The tubes were then 
incubated in a water bath at 37°C for 1.5 to 2 h to allow for plasmid digestion. 
 
 
 
 
 
 
                          
Table 2.2 Composition of restriction enzyme digests. The table shows the 
composition of the restriction enzyme digests for both prV1bR and      
pEGFP-N1. Both digests were made up to a total of 20 μl. The restriction 
enzymes and Buffer O are sourced from Fermentas. 
 
 
prV1bR pEGFP-N1 
13 μl sterile H20 13 μl sterile H20 
3 μl prV1bR 
(total ~1 μg) 
3 μl pEGFP-N1 
(total ~1 μg) 
2 μl 10x Buffer O 2 μl 10x Buffer O 
1 μl SalI (10 u/μl) 1 μl SalI (10 u/μl) 
1 μl NotI (10 u/μl) 1 μl NotI (10 u/μl) 
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Figure 2.2 Plasmid map of pALTER®-MAX. GenBank Accession # AF316302. 
 
 
 
 
 
Figure 2.3 Plasmid map of pEGFP-N1. GenBank Accession # U55762. The sequence of the multiple cloning site is 
indicated below the plasmid map. 
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2.5.1.2 Separation of digestion products by gel electrophoresis 
The restriction enzyme digests of prV1bR and pEGFP-N1 were run on a gel so that the 
digested portions of the plasmids could be separated. Once the components were separated, 
the ones required for sub-cloning, rV1bR and the pEGFP-N1 vector without the egfp gene 
(referred to from here on as pN1), could be removed from the gel and ligated to form the new 
plasmid. 
An agarose (0.7%) gel in 0.5x tris borate EDTA (TBE) buffer (see Appendix B) was made. 
The agarose was melted and 20 μl of SYBR® Safe DNA gel stain 10,000x (Invitrogen) 
(1:10,000 dilution) was added. The gel was then poured into the casting tray so that it covered 
about 5 mm of the comb, and left to set. The restriction enzyme digest tubes were removed 
from the water bath and 2 μl of loading dye (supplied with ladder – Fermentas) was added to 
each tube. Each of the digests plus a ladder, Lambda DNA/PstI Marker, 24 (Fermentas)      
(10 μl), were loaded into individual wells. The wells at the edge of the gel and the wells 
between the individual samples were left empty, to ensure the samples remained separate. 
This ensured that the bands could be removed cleanly when excised from the gel. The gel was 
run (using a EPS 1001 power pack from Amersham Pharmacia Biotech Inc.) at 106 V for  
~30 min with 0.5x TBE as the running buffer. The gel was then examined using UV 
illumination (DarkReader™ Transilluminator, Clare Chemical Research) to ensure clear 
separation of the bands and allow individual bands to be excised from the gel. Bands for the 
rV1bR gene (~2.6 kb) and the pN1 vector (~4.0 kb) were excised from the gel using a single 
edged razor blade. Once removed from the gel, the band fragments were place into labelled 
1.7 ml microfuge tubes to be cleaned up prior to ligation. 
2.5.1.3 Clean up and ligation of rV1bR and pN1 excised from gel 
The excised gel fragments were cleaned up to remove agarose, salts, stain, and other 
contaminants using the Zymoclean™ Gel DNA Recovery Kit (Zymo Research Corporation). 
Agarose Dissolving Buffer (300 μl) was added to each tube and the tubes were incubated at 
55°C for 5 min or until all of the gel was dissolved. The melted gel solutions were transferred 
into separate Zymo-Spin™ I Columns inside 2 ml collection tubes. These were centrifuged 
(5424, Eppendorf) at 12,000 x g for 1 min. After centrifugation, 200 μl of Wash Buffer was 
added to each Column, these were then centrifuged again at 12,000 x g for 1 min. This step 
was repeated and the collection tubes were discarded. The Columns were placed into 1.7 ml 
microfuge tubes and 10 μl of sterile water was added directly to the matrix of each Column. 
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These were left to sit for 1 min and then centrifuged at 12,000 x g for 1 min. These steps 
produced ultra-pure DNA, ready for ligation. On average this Kit produces DNA at a 
concentration of 10 ng/μl, therefore this was the assumed concentration of the DNA used for 
ligation. For ligation of the insert and destination vector a 20 μl ligation solution (see Table 
2.3) was made containing a 3:1 ratio of insert:vector (this gives an ~4.5:1 molar ratio). This 
ratio ensured that the destination vector ligated with the insert. The ligation solution was left 
to incubate at room temperature for 1.5 h. 
 
13 μl sterile H2O 
3 μl insert (rV1bR) (total ~30 ng) 
2 μl 10x T4 DNA Ligase Buffer 
1 μl destination vector (pN1) (total ~10 ng) 
1 μl T4 DNA Ligase (5 u/μl) 
 
Table 2.3 Ligation solution for rV1bR and pN1. The Ligation Buffer and T4 DNA 
Ligase were sourced from Fermentas. 
 
2.5.1.4 Transformation of competent E. coli cells with the ligated plasmid in order to 
amplify it 
Competent DH5 alpha E. coli cells were transformed with the ligated plasmid and cultured. 
This was so that plasmid preparations could be made from individual colonies, in order to 
assess the success of the sub-cloning. The cultures of E. coli containing successfully          
sub-cloned plasmids were then used to create glycerol stocks.  
A 100 μl aliquot of frozen, competent DH5 alpha E. coli cells was thawed on ice and split into 
two separate 1.7 ml microfuge tubes each containing 50 μl. Ligation solution (see Table 2.3) 
(5 μl) was added to each tube. To get the E. coli to take up the plasmid DNA the tubes were 
left on ice for ~2 min, heat shocked at 37°C for ~2 min, placed on ice for a further 2 min and 
then 200 μl of LB Broth Miller (Becton Dickson) was added to each tube. The E. coli 
suspension from each tube was plated on two agar plates (see Appendix B): 150 μl onto the 
first plate, and 50 μl onto the second. The use of two agar plates, plated with different 
volumes of bacterial suspension, ensured that individual colonies could be picked. The plates 
contained 30 μg/ml of the selection antibiotic, kanamycin (see Appendix B for stock solution 
details). This ensured that only the E. coli transformed with neo would be able to grow. The 
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plates were incubated overnight at 37°C to allow time for the transformed E. coli to grow into 
colonies. The next morning the plates were examined and colonies noted. 
2.5.1.5 Harvesting and purification of plasmid DNA 
The plasmid DNA synthesised by the E. coli cells needed to be harvested and purified. After 
which, it could be used for assessment of sub-cloning. This assessment was required to ensure 
that the desired plasmid was available for the generation of V1bR-stably expressing HEK293 
cells. 
Ten McCartney bottles, each containing ~10 ml of LB Broth Miller (Becton Dickson) were 
set up and kanamycin stock solution was added to each bottle to give a final concentration of 
30 μg/ml. Individual E. coli colonies were picked from all four plates using a yellow pipette 
tip and placed into separate bottles. These bottles were then incubated overnight with shaking 
(at 250 rpm) at 37°C (ROSI 1000™, Thermolyne). The following morning, ~1.5 ml of culture 
was poured from each bottle into separate 1.7 ml microfuge tubes and centrifuged at      
12,000 x g for 2 min. The supernatant was discarded and another ~1.5 ml of culture from the 
same bottle was poured into the same tube and centrifuged again at 12,000 x g for 2 min. This 
provided a large enough cell pellet for harvesting the plasmid DNA. The AxyPrep™ Plasmid 
Miniprep Kit (Axygen Biosciences) was used to harvest and purify the plasmid DNA. Buffer 
S1 (250 μl) containing RNase A was added to each tube and the pellet was re-suspended by 
re-pipetting. Buffer S2 (250 μl) was then added to each tube and mixed by inversion. This 
buffer lysed the cells. The cell lysates were then neutralised by the addition of 350 μl of 
Buffer S3. The tubes were gently inverted to mix the solutions. It is important not to vortex 
the solutions when mixing them as this can cause shearing of the genomic DNA which can 
result in contamination of the plasmid DNA. The tubes were centrifuged for 5 min at     
12,000 x g to clarify the lysates, and the supernatants were transferred to the assembled 
Columns and Receiver tubes. The Columns and Receiver tubes were centrifuged for 1 min at 
12,000 x g, the contents of the Receiver tubes were discarded and the Columns and Receiver 
tubes were reassembled. W2 Buffer (700 μl) was added to each Column and they were then 
spun for 1 min at 12,000 x g. These wash steps removed contaminants from the plasmid 
DNA. The receiver tubes were discarded after this spin and each Column was then placed into 
a 1.7 ml microfuge tube. Elution Buffer (50 μl) was added to each Column. The Columns 
were incubated at room temperature for 2 min, and then centrifuged for 1 min at 12,000 x g, 
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to elute the plasmid DNA from the Column into the microfuge tube. After this last 
centrifugation the Column was discarded and the tubes with the plasmid DNA were capped. 
2.5.1.6 Screening of plasmid DNA preparations for successfully sub-cloned constructs  
In order to select the appropriate construct to use for the generation of rV1bR-stably 
transfected cell lines all ten of the plasmid DNA preparations were screened. To do this, 
aliquots of the ten plasmid DNA preparations from the separate E. coli colonies were digested 
using SalI and NotI so that the rV1bR and pN1 were separated and therefore the presence of 
both could be screened for.  
A restriction enzyme digest master mix was made (see Table 2.4). A 5 μl aliquot of each 
plasmid DNA preparation was mixed with 15 μl of this master mix in a 1.7 ml microfuge 
tube. The tubes were tapped to mix and spun briefly to ensure that the total volume was 
deposited at the bottom of each tube. The tubes were incubated for 1 h at 37°C in a water 
bath. Loading buffer (2 μl) was added to each tube, and the digested samples were run on an 
agarose (0.7%) gel. The gel was examined under UV illumination to see which preparations 
contained both rV1bR and pN1. The preparation that appeared to have the greatest 
concentration of the desired sub-cloned construct was selected for use in further experiments. 
Glycerol stocks were made from the E. coli culture used to make this preparation. These 
stocks were made by adding equal volumes of glycerol to bacterial culture in a 1.7 ml 
microfuge tube. These tubes were then frozen and stored at -80°C. The successfully           
sub-cloned construct is referred to from here on as pN1-V1bR. An image of this gel was taken 
under UV illumination on the SynGene ChemiGenius2 camera using Gene Snap software 
(Syngene) (see Section 3.2.1.2). 
 
121 μl sterile H20 
22 μl 10x Buffer O 
11 μl SalI (10 u/μl) 
11 μl NotI (10 u/μg) 
 
Table 2.4 Restriction enzyme digest – master mix. The table 
indicates the volumes needed to make enough master mix for 
ten restriction enzyme digests, plus an extra 10%. Total 
volume of the master mix was 165 μl. 
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2.5.2 BULK PREPARATION OF PLASMID DNA  
2.5.2.1 Transformation of competent E. coli cells with pEGFP-N1 
Competent DH5 alpha E. coli cells (Invitrogen) were transformed with the plasmid       
pEFGP-N1. These transformed cells were used to grow bacterial cultures, from which a 
preparation of pEGFP-N1 plasmid DNA could be harvested. 
The pEGFP-N1 DNA used for the transformation was diluted to 4 ng/μl in TE8 (see 
Appendix B). Three 1.7 ml microfuge tubes, each containing 50 μl of competent DH5 alpha 
E. coli cells, were thawed on ice. The first tube was the test tube and was transformed with 
pEGFP-N1, the second was a positive control and was transformed with pUC19 (Invitrogen), 
and the third was a negative control and remained untransformed. For the transformations,  
2.5 μl of pEGFP-N1 plasmid DNA was added to the first tube, 2.5 μl of pUC19 (100 pg/μl) 
was added to the positive control tube, and 2.5 μl of TE8 with no DNA was added to the 
negative control tube. The plasmid DNA and E. coli cells were mixed by hand with gently 
rocking. To promote uptake of the DNA into the cells, the tubes were placed on ice for         
30 min, heat shocked for 20 s at 42°C in a water bath and placed back on ice for a further       
2 min. LB Broth Lennox (Invitrogen) (see Appendix B) was pre-warmed to 37°C and 950 μl 
was added to each transformation tube. The tubes were incubated at 37°C, with shaking (at 
~250 rpm) for 1 h (Minitron Incubator Shaker, Infors HT). The contents of the tubes were 
then plated as described below. 
2.5.2.2 Plating E. coli cells transformed with pEGFP-N1 and glycerol stocks of E. coli 
cells transformed with pN1-V1bR onto selective plates 
To produce colonies to seed the cultures with, the transformed E. coli were first plated onto 
agar plates. Immediately following the transformation procedure described in Section 2.5.2.1, 
the transformed E. coli were plated onto selective plates (see Appendix B) containing 
ampicillin (100 μg/ml) (see Appendix B for stock solution detail) and kanamycin (30 μg/ml) 
for pUC19 and pEGFP-N1 transformed cells respectively. The untransformed E. coli were 
also plated onto plates containing kanamycin. To ensure separate colonies could be identified 
and picked to seed the starter cultures, three different volumes of the suspension of pEGFP-
N1 transformed bacteria (20 μl, 100 μl, and 200 μl), were plated onto separate plates. Aliquots 
of 100 μl of the appropriate bacterial suspensions were plated onto the untransformed 
negative control and the pUC19 positive control plates. The aliquoted volume was spread 
across the plates using a glass spreader. The plates were incubated overnight at 37°C. The 
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next morning these plates were examined for colonies, wrapped with plastic wrap followed by 
aluminium foil and stored upside down at 4°C, until needed to seed the starter culture. 
When plating the glycerol stocks of pN1-V1bR transformed bacteria onto agar plates 
containing kanamycin (30 μg/ml), a scrapping was taken from a frozen glycerol stock with a 
sterile inoculating loop and streaked in a zig zag motion onto the plates. The plates were 
incubated and examined as described above. 
2.5.2.3 Culturing of E. coli cells transformed with pEGFP-N1 or pN1-V1bR 
In order to obtain sufficient plasmid DNA, E. coli colonies transformed with the plasmids 
were picked and bulk cultures were produced. Seeding a bulk culture with a single E. coli 
colony results in a slow growth rate. This is because of the low number of cells. Therefore, a 
single colony is transferred to a smaller starter culture first and cells from this starter culture 
are then used to seed the bulk culture. 
2.5.2.3.1 Starter culture 
Aliquots of LB Broth Lennox (3 ml) containing kanamycin (30 μg/ml) were added to six 
McCartney bottles and pre-warmed to 37°C. Individual colonies of pEGFP-N1 transformed 
bacteria were selected from the culture plates using yellow pipette tips and used to inoculate 
three of these McCartney bottles. The remaining three bottles were inoculated with individual 
colonies of pN1-V1bR transformed bacteria. The inoculated McCartney bottles were 
incubated at 37°C with shaking (at ~300 rpm) for 8 h.   
2.5.2.3.2 Bulk culture 
A 200 μl aliquot of the cloudiest starter culture for pEGFP-N1 was transferred to 100 ml of 
pre-warmed LB Broth Lennox containing kanamycin (30 μg/ml) in a 500 ml conical flask. A 
second 500 ml flask was similarly inoculated with pN1-V1bR. The flasks were incubated 
overnight at 37°C with shaking (at ~300 rpm). If the plasmid DNA could not be harvested 
immediately from the bulk cultures, the bulk cultures were stored at 4°C until harvesting 
could begin. Prior to harvesting the plasmid DNA, a 1 ml aliquot of each bulk culture was 
taken to make glycerol stocks of pEGFP-N1 and pN1-V1bR. 
2.5.2.4 Plasmid purification 
In order to transfect mammalian cells, plasmid DNA needs to be extremely pure. Therefore, it 
is important to use a plasmid purification procedure which ensures that high quality DNA is 
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produced. Here the Invitrogen PureLink™ HiPure Plasmid Purification Kit was used to 
harvest and purify the plasmid DNA, via the steps described below.  
Before the harvesting and purification of the DNA was started, the RNase A was added to the 
Resuspension Buffer (R3), and the Lysis Buffer (L7) was checked to ensure no precipitate 
had formed. If a precipitate had formed it had to be re-suspended before use. The HiPure 
Filter Maxi Column, with the Filtration Cartridge inserted, was placed on a rack. Equilibration 
Buffer (EQ1) (30 ml) was added to the Columns and was allowed to drain by gravity flow. 
The addition of EQ1 ensures that the anion exchange resin in the columns is positively 
charged so that it will be able to bind the negatively charged DNA backbones when the cell 
lysates were added. While the EQ1 was dripping through the Columns, the cell lysates were 
prepared. The overnight bulk cultures were centrifuged (Sorvall® RC-6™ Plus, Thermo 
Scientific) at 4,000 x g for 10 min. The supernatants were discarded and 10 ml of R3 was 
added to each pellet. The cells were re-suspended in this buffer by re-pipetting until the 
suspension was homogeneous. This buffer contains RNase which breaks down any RNA 
released from within the cells once they have been lysed. The cell suspensions were 
transferred to individual 50 ml centrifuge tubes and 10 ml of L7 was added to each tube to 
lyse the cells. The solutions were mixed by gently inverting the tubes five times. This ensured 
an even concentration and distribution of the reagents for cellular breakdown. The resulting 
suspensions were incubated at room temperature for 5 min, to ensure the lysis of all cells. 
Precipitation Buffer (N3) (10 ml) was added to each cell lysate and immediately mixed by 
inversion of the tubes. N3 precipitates impurities in the lysate, clarifying it. It is important to 
mix these solutions gently by inversion as mixing with a vortex can result in shearing of the 
genomic DNA, leading to contamination of the plasmid DNA. Each lysate, including the 
precipitate was transferred to one of the prepared Columns and allowed to drain through by 
gravity flow, until there was less than 1 drop per 10 seconds. To increase the DNA yield the 
Columns were washed with 10 ml of Wash Buffer (W8), which was allowed to drain through 
by gravity flow. The flow through from the initial addition of the precipitated lysates to the 
Columns and the wash were discarded as waste along with the inner Filtration Cartridges. 
Each column was then washed with 50 ml of W8, which was allowed to drain through by 
gravity flow. Washing of the Columns under moderate salt conditions allows the DNA to stay 
bound to the Columns while removing the RNA, proteins, carbohydrates, and other impurities 
from the resin. The flow through from this wash was discarded as waste. Sterile centrifuge 
tubes were placed under the Columns and 15 ml of Elution Buffer was added to each column 
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to produce high salt conditions under which the plasmid DNA was eluted from the resin. The 
Columns were discarded at this point and the eluted plasmid DNA desalted and concentrated 
by alcohol precipitation. To do this, 10.5 ml of isopropanol was added to each eluate in the 
centrifuge tubes and mixed well. The tubes were centrifuged at 15,000 x g for 30 min at 4°C 
in a pre-cooled centrifuge (5810R, Eppendorf). The supernatants were carefully removed and 
discarded and 5 ml of 70% ethanol was added to re-suspend each pellet. The tubes were 
centrifuged at 15,000 x g for 5 min. These re-suspension and centrifugation steps were 
repeated once more. The pellets were then air dried for 10 min, and re-suspended in 500 μl of 
TE Buffer (TE). The resulting plasmid DNA solutions were transferred to microfuge tubes. 
The final concentration of DNA was determined using a spectrophotometer (ND1000, 
Nanodrop). 
2.5.2.5 Screening of harvested pEGFP-N1 and pN1-V1bR plasmid DNA 
To determine whether the plasmids amplified, harvested, and purified in the bulk preparation 
were indeed the desired plasmids, pEGFP-N1 and pN1-V1bR, the purified products were run 
on a DNA gel. The gel separates bands based on size, thus allowing determination of the 
product through size comparison with a DNA ladder containing bands of a known size.  
The plasmids must be cut with a restriction enzyme before they are run on the gel as circular 
DNA migrates through gels at different rates to linear DNA (Sambrook, 1989). XhoI is a one 
cutter restriction enzyme for both plasmids. Therefore, prior to running the gel, restriction 
enzyme digests were made for both pEGFP-N1 and pN1-V1bR in 1.7 ml microfuge tubes (see 
Table 2.5 for volumes of the reagents). The reaction digest was incubated overnight at 37°C. 
 
pEGFP-N1 pN1-V1bR 
1 μl pEGFP-N1 (1 μg/μl) 1 μl pN1-V1bR (1 μg/μl) 
2 μl 10x REact 2 Buffer 2 μl 10x REact 2 Buffer 
2 μl XhoI (10 u/μl) 2 μl XhoI (10 u/μl) 
15 μl Nanopure H2O 15 μl Nanopure H2O 
 
Table 2.5 Restriction enzyme digests of pEGFP-N1 and pN1-V1bR. The table shows the 
composition of the restriction enzyme digests. Both digests were made up to a total volume of 
20 μl. XhoI is from Invitrogen. Details of REact 2 Buffer can be found in Appendix B. 
 
A 50 ml 0.8% agarose gel was made in 0.5x TBE, and 5 μl of SYBR® Safe DNA Gel Stain 
was added. The gel was poured (Easy cast, Owl Scientific) and the ten well comb inserted. A 
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High Mass DNA Ladder (Invitrogen), and uncut and cut plasmid solutions were made up with 
loading buffer (see Appendix B) as shown in Table 2.6 below. The gel was loaded with the 
samples and run at 80 V for ~40 min in 0.5x TBE running buffer. The gel was viewed under 
UV illumination (Multi Wave UV Transilluminator, UltraLum) to determine the position and 
size of the DNA bands. An image of the gel was taken under UV illumination on the SynGene 
ChemiGenius2 camera using Gene Snap software. 
 
 
Lane # DNA Solution Volume of DNA Solution 
Volume of 
ddH2O 
Gel Loading 
Dye 
Lane 1 - - - - 
Lane 2 - - - - 
Lane 3 Ladder 4µl - 1µl 
Lane 4 pN1-V1bR Cut 6µl (RED) 4µl 2µl 
Lane 5 pN1-V1bR Uncut 0.3µl (1μg/μl) 9.7µl 2µl 
Lane 6 pEGFP-N1 Cut 6µl (RED) 4µl 2µl 
Lane 7 pEGFP-N1 Uncut 0.3µl (1μg/μl) 9.7µl 2µl 
Lane 8 Ladder 4µl - 1µl 
Lane 9 - - - - 
Lane 10 - - - - 
 
Table 2.6 Composition of solutions added to the gel. There is a total of 0.3 μg of DNA per lane. Note RED = restriction 
enzyme digest 
 
2.6 OPTIMISATION OF ANTIBIOTIC SELECTION CONDITIONS 
2.6.1 DETERMINATION OF THE G418 CONCENTRATION REQUIRED TO KILL ALL 
UNTRANSFECTED HEK293 CELLS 
A range of eight different G418 concentrations were tested in triplicate over a period of        
21 days using (untransfected) HEK293 cells plated into a 24 well plate. The percentage 
confluence and morphology of the HEK293 cells in the individual wells were assessed at 24 h 
intervals as a way to measure the effect of G418.  
The HEK293 cells were plated into a 24 well plate at 2 x 104 cells/well in 1 ml of MEM+. 
After 24 h, 500 μl of MEM+ containing either 0, 300, 600, 1,200, 1,500, 2,100, 3,000, or      
4,500 μg/ml of G418 (see Appendix B for stock solution details) was added to three replicate 
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wells per concentration. The plate was then gently rocked to mix the solutions in the wells. 
This addition gave final G418 concentrations of 0, 100, 200, 400, 500, 700, 1,000, or        
1,500 μg/ml, respectively. The final plate layout once the antibiotic had been added is shown 
in Table 2.7. 
 
 1 2 3 4 5 6 
A 0 μg/ml 0 μg/ml 0 μg/ml 100 μg/ml 100 μg/ml 100 μg/ml 
B 200 μg/ml 200 μg/ml 200 μg/ml 400 μg/ml 400 μg/ml 400 μg/ml 
C 500 μg/ml 500 μg/ml 500 μg/ml 700 μg/ml 700 μg/ml 700 μg/ml 
D 1000 μg/ml 1000 μg/ml 1000 μg/ml 1500 μg/ml 1500 μg/ml 1500 μg/ml 
 
Table 2.7 Layout of the 24 well plate for the determination of an appropriate antibiotic selection concentration. In the 
table the final concentrations of G418 are indicated. Each concentration was tested in triplicate. A total of eight different 
concentrations were tested. 
 
The medium in the wells was changed every three days after the initial addition of G418. This 
ensured that there was fresh medium for cell growth and that the antibiotic was replenished 
before it had broken down. The old medium was removed via aspiration and 1 ml of fresh 
medium containing the appropriate concentration of G418 was added to each well. The 
confluences of the replicate wells were averaged and graphed.  
It is important to note that adding G418 stock solution to tissue culture medium lowers the 
pH. The antibiotic containing medium was therefore left in a Biological Safety Cabinet-Class 
II for 30-60 min (time depended upon the G418 concentration) to equilibrate to the normal 
pH. It was then placed into a CO2 incubator to bring the temperature up to 37°C, before 
addition to the wells. Another option is to have a buffering system within the culture medium 
or within the G418 stock solution (Ausubel et al., 1994; Mortensen and Kingston, 2009). 
2.6.2 OPTIMAL PLATING DENSITY DETERMINATION 
Once an appropriate concentration of antibiotic was determined, the HEK293 cell plating 
density was optimised. The plating density was optimised to ensure that the HEK293 cells 
reached 80% confluence before major cell death occurred.  
The HEK293 cells were plated at four different densities 2 x 104, 4 x 104, 6 x 104, and            
8 x 104 cells/well in 1 ml of MEM+. The cells were plated onto two 24 well plates. Six wells 
were plated at each density per plate. After 24 h, G418 was added to three replicate wells per 
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plating density per plate. The remaining wells were used as a control and therefore only had 
MEM+ added. A G418 concentration of 500 μg/ml was used for plate one and a G418 
concentration of 700 μg/ml was used for plate two. Initially the G418 was introduced by 
adding 500 μl of 1500 μg/ml G418 in MEM+ to the specified wells on plate one, and 500 μl 
of 2100 μg/ml G418 in MEM+ to the specified wells on plate two. The plates were rocked 
gently to mix the solutions. Table 2.8 shows the plate layout common to both plates. The table 
also indicates which wells were used as test wells and which were used as control wells. 
Every three days after this initial addition of G418, the medium was removed from all the 
wells by aspiration, and then 1 ml of the appropriate solution was added back using a P1000 
Gilson pipette. The plates were cultured for a total of 21 days. The wells were assessed at 24 h 
intervals for percentage confluence and morphology. The confluence values of the replicate 
wells within each treatment group were averaged and graphed. 
 
 
 1 2 3 4 5 6 
A 2 x 10
4 
cells/well T 
2 x 104 
cells/well T 
2 x 104 
cells/well T 
2 x 104 
cells/well C 
2 x 104 
cells/well C 
2 x 104 
cells/well C 
B 4 x 10
4 
cells/well T 
4 x 104 
cells/well T 
4 x 104 
cells/well T 
4 x 104 
cells/well C 
4 x 104 
cells/well C 
4 x 104 
cells/well C 
C 6 x 10
4 
cells/well T 
6 x 104 
cells/well T 
6 x 104 
cells/well T 
6 x 104 
cells/well C 
6 x 104 
cells/well C 
6 x 104 
cells/well C 
D 8 x 10
4 
cells/well T 
8 x 104 
cells/well T 
8 x 104 
cells/well T 
8 x 104 
cells/well C 
8 x 104 
cells/well C 
8 x 104 
cells/well C 
 
Table 2.8 Layout of the 24 well plates for the determination of an optimal plating density. The plate layout in the table 
indicates the plating density for each well. T indicates that the well was a test well and it was therefore treated with antibiotic 
(500 μg/ml for plate one, 700 μg/ml for plate two). C indicates that the well was a control well and it was therefore not 
treated with antibiotic. 
 
It was discovered that during the above experiment the CO2 incubator was operating at a CO2 
concentration below 5%. This potentially affected HEK293 cell growth. Therefore, this 
experiment was partially repeated with the following changes: 
1) HEK293 cells were plated at only two densities (6 x 104 and 8 x 104 cells/well in 1ml 
of MEM+) into one 24 well plate.  
2) The cells in this experiment were cultured for only seven days. 
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The two different concentrations of G418 were then added to three wells at each plating 
density as in the previous experiment. The percentage confluence of the cells in each well and 
the cell morphology were determined, recorded, and analysed as previously described. 
2.6.3 DATA ANALYSIS 
The data were collected from these experiments as confluences and morphologies for 
individual wells. The data from the replicate wells (n=3) were entered into GraphPad Prism 4. 
Prism was used to calculate the means ± SEM and graph the results as a line graph. The line 
graphs produced can be seen in Section 3.3. These graphs were used to determine which 
concentrations of G418 were successful in killing all of the (untransfected) HEK293 cells. 
They were also used to determine the appropriate plating density.  
 
2.7 TRANSFECTION OF HEK293 CELLS USING F6 
The F6 transfection protocol using HEK293 cells was optimised following the manufacturers 
guidelines (Roche Applied Science). The finalised protocol is described below. 
HEK293 cells were plated into a 24 well plate at 60,000 cells/well in 0.5 ml MEM+. The four 
sides of the plate were tapped once each to ensure an even distribution of the cells across well. 
These cells were then cultured for 24 h to allow time for the cells to adhere to the base of the 
well. This culture time also allowed for cell growth. It is important to ensure that the cells are 
between 50-80% confluent when they are transfected, as this is the optimal confluence range 
for transfection and ensures that the cells are in their log phase of growth. 
In order to have the transfection complex ready at a specified time point, preparation was 
started ~1 h in advance. The complex was prepared by mixing F6(μl) with DNA(μg) at a 3:1 
ratio in medium free from serum (MEM-). In a 24 well plate, depending on the DNA 
concentration, ~20 μl of the complex was added to each of the wells, which contained cells 
plus 0.5 ml MEM+. A master mix of complex was prepared to ensure that all wells received 
exactly the same mixture of transfection complex. 
The steps outlined below were used to determine the volumes required of the three solutions 
required to prepare the master mix. To allow for pipetting error the volume made up was 10% 
greater than the minimum amount required for the number of wells to be transfected. 
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1) Number of wells = n 
2) Volume of MEM-/well = 19.4 μl 
3) Volume of F6/well = 0.6 μl 
4) Amount of DNA/well = 0.2 μg 
Therefore if the DNA concentration = x μg/μl, the volume of DNA/well = (0.2 μg / x) μl  
Therefore the volumes of the complex components per well = 19.4 μl MEM- + 0.6 μl F6 + 
(0.2 μg/ x) μl DNA 
Therefore total volume of master mix = (n + (n/10)) (19.4 μl MEM- + 0.6 μl F6 + (0.2 μg/ x) 
μl DNA) 
The transfection complex was made in a laminar flow hood (CF43S, Gelman Sciences), in 
clearly labelled, sterile, 1.7 ml microfuge tubes. The MEM- was aliquoted first. The F6 was 
then removed from the refrigerator ~15 min prior to use to allow it to warm to room 
temperature before the vial was opened. It was mixed by tapping the vial and then vortexing it 
for 1 s to deposit it at the bottom of the vial. Once mixed, the F6 was added directly to the 
MEM in the microfuge tube. It was very important at this step that the F6 did not come into 
contact with the sides of the tube, as contact with plastic adversely affects transfection 
efficiency. The tube was tapped to mix the F6 and MEM and then centrifuged for 1-2 s to 
bring the solution to the bottom of the tube. The solution was incubated for 5 min at room 
temperature, and the plasmid DNA was then added. The tube was tapped to mix the solutions 
then centrifuged for 1-2 s. The resulting solution was incubated at room temperature for        
30 min to allow the complex to form. At 30 min the appropriate volume of the complex 
solution was added to each well, containing cells to be transfected, on the 24 well plate, in a 
drop wise manner, using a P20 Gilson pipette. The pipette tip was changed between the 
individual wells. After the complex had been added to the wells, the plate was swirled gently 
to ensure an even distribution of the complex. The cells were then incubated in a CO2 
incubator for a minimum of 48 h before being used in experiments. This incubation ensured 
sufficient time for gene expression. 
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2.8 STABLE TRANSFECTION 
2.8.1 PLATING AND TRANSFECTION OF HEK293 CELLS WITH pEGFP-N1 AND    
pN1-V1bR PLASMID DNA 
HEK293 cells (untransfected) were plated into the wells of three six-well plates, at      
250,000 cells/well in 2 ml of MEM+. The plates were tapped once on each side to ensure an 
even distribution of the cells. The cells were then incubated for 24 h, at which time they were 
transfected with pEGFP-N1 or pN1-V1bR. The transfection complex was made according to 
the protocol in Section 2.7. The volumes in the transfection formula were adjusted to 
accommodate a six well plate. The adjusted volumes per well were: 
97 μl MEM- + 3 μl F6 + 1 μg DNA 
The cells in well number one were left as an untransfected negative control and the cells in 
well number two were transfected with pEGFP-N1 as a positive control. All of the cells in the 
remaining sixteen wells were transfected with pN1-V1bR.  
2.8.2 SELECTION AND ISOLATION OF CLONAL CELLS STABLY-EXPRESSING   
pEGFP-N1 AND pN1-V1bR USING G418 
In order to establish clonal cell lines stably-expressing the transfected plasmid, clonal lines 
must be selected for and then isolated. After selection and isolated, the lines can then be 
assessed and used for further research. 
After the transfection, the cells were incubated for 48 h, at which time they had reached ~90% 
confluence. At 48 h each of the individual wells were re-plated into 10 cm plates. This         
re-plating was achieved by, removing the medium from the wells of one plate then adding      
1 ml of T/E to each well. The plate was swirled so that the T/E covered all of the cells. The 
T/E was then removed and the plate incubated for 8 min at room temperature. After the 
incubation, 1 ml of MEM+ was added to each of the wells, while the plate was tilted on an 
angle. This dislodged the cells from the base of the well. The resulting cell suspension was  
re-pipetted eleven times with a P1000 Gilson pipette set to 0.8 ml. After re-pipetting, all of 
the suspension from one well was transferred into the corresponding 10 cm plate. The plate 
contained 11 ml of pre-warmed MEM+. The cells in the 10 cm plates were incubated for      
5-6 h to give the cells time to adhere. After this incubation, 4 ml of MEM+ containing      
2000 μg/ml G418 was added to each plate. This produced a final G418 concentration of     
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500 μg/ml. The medium in the plates was replaced every three days. The replacement MEM+ 
contained 500 μg/ml G418. The cells were cultured in these plates for two weeks. 
After two weeks, all of the untransfected control cells were non-viable and the transfected 
cells had reached over 90% confluence. Ten of the 10 cm plates (one with cells transfected 
with pEGFP-N1 and nine with cells transfected with pN1-V1bR) were re-plated into new     
10 cm plates at a plating density of 1.25 x 104 cells/plate. The plate numbers were reduced as 
all seventeen of the plates contained cells that had been successfully transfected. The cells 
were re-plated at a low density to ensure that the colonies picked were clonal. In order to     
re-plate the ten plates in a timely fashion one plate was trypsinised and the cells counted (see 
Section 2.3.3 for cell counting). As all the plates were approximately the same confluence this 
cell count was assumed to be a good estimate of cell numbers for all of the plates. This cell 
count was therefore used to calculate the required dilution for all of the plates. The re-plating 
was achieved by, removing the medium from the plate and adding 4 ml of T/E. The plate was 
swirled to ensure that the T/E had covered all of the cells and the T/E was then swiftly 
removed. The plate was incubated for 8 min at room temperature. Then 6 ml of MEM+ 
without G418 was added to the plate. The resulting cell suspension was re-pipetted eleven 
times using a 5 ml plastic pipette. A diluted aliquot of  each cell suspension was then added to 
the appropriate new 10 cm plate, which contained 15 ml of pre-warmed MEM+ with           
500 μg/ml G418. The morning after the re-plating, all of the plates were examined for any 
signs of unusual cell morphology as an indicator of cell viability, and to ensure that the cells 
had adhered as single cells. The cells were cultured for approximately one week in these 
plates, which allowed time for colony growth. The MEM+ with 500 μg/ml G418 was 
replenished every three days. 
To select individual colonies from the 10 cm plates the medium was removed and the plates 
were washed once with 3 ml of sterile 1x PBS (see Appendix B). The plates were then air 
dried for ~3 min. During this time three colonies (that were about the size of a pin head) were 
selected and their position marked on the base of the plate. After air drying, 15 μl of 1 x PBS 
was added to an individual colony using a P20 Gilson pipette. The colony was scraped with 
the pipette tip to remove it from the base of the plate. The cells were re-pipetted, 4-6 times to 
form a suspension. The cell suspension was then removed to an individual well of a 24 well 
plate, which contained 1 ml of MEM+ with 500 μg/ml G418. Each of the ten 10 cm plates had 
three individual colonies removed. The cells in the 24 well plates were cultured until one 
well, of the three containing cells picked from the same 10 cm plate, had reached over 50% 
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confluence. There were two exceptions to this, in which two wells seeded with colonies from 
the same 10 cm plate were continued further. This was done because the cells from these     
10 cm plates had morphologies closest to that of the parental (untransfected) HEK293 cell 
line. During culture of the cells in the 24 well plates the MEM+ with 500 μg/ml G418 was 
changed every three days. 
Once one of the three wells had reached over 50% confluence the cells from that well were    
re-plated back into a 10 cm plate at 1.25 x 104 cells/plate. The process of colony selection was 
then repeated as described above. Colony selection was repeated to ensure the cell lines 
established were clonal. To re-plate from a well in a 24 cm plate back into a 10 cm plate, the 
medium was removed from the well and 0.2 ml of T/E was added. The plate was swirled to 
cover all of the cells with the T/E. The T/E was then swiftly removed and the plate incubated 
at 37°C in a CO2 incubator for 5 min. This incubation is a departure from the normal protocol 
of trypsinisation (Section 2.3.2). The T/E incubation step was changed to minimise adverse 
effects on the remaining cells in the 24 well plate, which were not re-plated at the same time. 
Following the 5 min incubation, 0.4 ml of MEM+ with 500 μg/ml of G418 was added to the 
well. The cell suspension was re-pipetted, with a P1000 Gilson pipette set to 0.32 ml, eleven 
times. The cells were counted (see Section 2.3.3), then diluted and added to the new 10 cm 
plate. 
2.8.3 PRODUCTION OF STABLY TRANSFECTED CLONAL CELL LINE STOCKS 
Once the cells had been through the colony selection and isolation process a second time the 
cells were transferred to a 25 cm2 flask for the production of clonal cell line stocks. To do this, 
the first well of the three to reach over 50% confluence was removed from the 24 well plate as 
described above except, all of the cells that were not used for counting were transferred to a 
25 cm2 flask. Once the cells were removed to the 25 cm2 flask they were named and identified 
as an individual stably-transfected clonal cell line. Once the clonal cell lines had reached over 
50% confluence in the 25 cm2 flasks, they were sub-cultured into separate 75 cm2 flasks (see 
Section 2.3.2). Once the 75 cm2 flask reach ~80% confluence the cells were frozen for storage                   
(see Section 2.3.4). The frozen cell stocks were then used to assess the stably-transfected 
clonal cell lines. 
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2.9 IP ASSAY 
2.9.1 PLATING AND TRANSFECTION 
HEK293 cells, either untransfected or stably-transfected were plated into wells of Primaria™ 
24-well Multiwell™ plates (Becton Dickson). The cells were plated at 60,000 cells/well in 
either 0.5 ml (untransfected) or 1 ml (stably-transfected) MEM+. For each condition to be 
tested in the assay, three replicate wells were plated. The cells were then incubated for           
24 h. Wells containing untransfected HEK293 cells were transiently transfected at 24 h (see 
Section 2.7). Wells containing stably-transfected cells were only assessed for percentage 
confluence and cell morphology at 24 h. Approximately 22 h after the transient transfection 
another 0.5 ml of MEM+ was added to these wells. This addition ensured that there were 
sufficient nutrients for cell growth. Nothing was added to the wells containing the stably-
transfected HEK293 cells at this time point. After this point the untransfected and stably-
transfected cells were treated in the same manner. 
2.9.2 LABELLING WITH myo-[3H]inositol 
The cells were radio-labelled 52 h after plating. To do this, the medium was removed from the 
wells and they were washed once with 0.8 ml Dulbecco’s Modified Eagle Medium (DMEM) 
without inositol (MP Biomedical). The wells were then radio-labelled with 0.5 ml of labelling 
medium (see Appendix B). The cells were incubated in this medium for 20 h. This ensured 
that the myo-[3H]inositol (Perkin Elmer Inc.) was incorporated into PIP2 via inositol 
metabolism by the cells. 
2.9.3 TREATMENT OF CELLS WITH AVP 
After the cells were labelled with myo-[3H]inositol, they were assessed for IP production in 
response to AVP stimulation as an indicator of functional expression of the V1bR. Two 
protocols were used for this 
1) measurement of the total IP production in response to stimulation with AVP (100 nM, 
15 min), 
2) measurement of IP production in response to stimulation with AVP (100 nM, 15 min) 
with or without an AVP (5 nM, 5 min) pre-treatment, as an indicator of receptor 
desensitisation to AVP. 
These protocols differed in their wash and AVP-stimulation regimes. The protocols for the 
separation of inositol phosphate metabolites and the counting of samples were the same.  
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2.9.3.1 Wash and AVP stimulation of HEK293 cells transfected with pN1-V1bR 
HEK293 cells have low levels of adherence and therefore have a tendency to lift from the 
base of the well in cell-based assays, as these assays consist of a number of washes within 
quick succession. Due to this tendency to lift, cultureware coatings promoting cell adhesion 
and careful technique were required to remove and add the washes. 
2.9.3.1.1 Determination of responsiveness to a 100 nM, 15 min stimulation with AVP 
The plate was removed from the incubator after labelling of the cells and all of the wells were 
washed once with 0.5 ml of pre-warmed “basal solution” (see Appendix B). Half of the wells 
were designated as “basal” wells, and these received another 0.5 ml of the “basal solution”   
(0 nM AVP). The remaining wells were stimulated with AVP, and these received 0.5 ml of 
pre-warmed “stimulation solution” (100 nM AVP) (see Appendix B). The plate was then 
incubated at 37°C for 15 min, in a CO2 incubator.   
2.9.3.1.2 Determination of AVP responsiveness and magnitude of desensitisation following an 
AVP pre-treatment 
The plate was removed from the incubator after labelling and all of the wells were washed 
once with 0.5 ml of the “control solution” (see Appendix B). The cells in half of the wells 
were pre-treated with AVP and these received 0.5 ml of pre-warmed “pre-treatment solution” 
(5 nM AVP) (see Appendix B). The other half of the wells were not pre-treated with AVP and 
these received 0.5 ml of pre-warmed “control solution” (0 nM AVP). The plate was then 
incubated in a CO2 incubator at 37°C for 5 min. After 5 min, the plate was removed from the 
incubator and all of the wells washed twice with 0.5 ml of “basal solution”. The cells in half 
of the control wells and half of the pre-treated wells were not stimulated with AVP and these 
received 0.5 ml of the “basal solution” (0 nM AVP). The cells in the remaining wells were 
stimulated with AVP and these received 0.5 ml of the “stimulation solution” (100 nM AVP). 
The plate was then incubated at 37°C for 15 min, in a CO2 incubator. 
2.9.4 SEPARATION OF INOSITOL PHOSPHATE METABOLITES BY ANION EXCHANGE 
CHROMATOGRAPHY 
Polyprep Chromatography Columns (Biorad Laboratories) were set up in a rack over a waste 
collection tray, and 2 ml of resin (Biorad AG1-X8), mixed with Nanopure H2O, at a 1 g:1 ml 
ratio, was added to each. Once the excess water had dripped through a resin bed of 
approximately 1.6 ml remained. 
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After the 15 min test incubation described above, the plate was immediately removed from 
the incubator and placed on ice where 0.5 ml of ice cold “stop” solution (see Appendix B) 
was added to each well. The plate was left on ice and 1 min later 0.5 ml of “neutralisation” 
solution (see Appendix B) was added to each well. The cells in each well were then lysed and 
transferred to their respective columns. To do this, the base of each well was scraped with a 
P1000 Gilson pipette tip to dislodge the cells. The cell suspension was then vigorously              
re-pipetted seven times to lyse the cells and transferred to the corresponding column. All 
solutions that were added to the columns were added slowly and evenly with the tip against 
the side of the column just above the solution level, to minimise resin disturbance. The pipette 
tip was changed between each well, to avoid cross-contamination.  
Solutions that were added to the columns were allowed to drip through before the next 
solution was added. After the contents of all of the wells had been added to the columns, the 
columns were washed with 10 ml of Nanopure H2O to elute free inositol. The columns were 
then rinsed with 8 ml of elution buffer II (see Appendix B) in order to elute 
glycerophosphoinositides. After elution buffer II had finished dripping through all of the 
columns, the ends of the columns were blotted with paper towels to remove any remaining 
drops. Labelled collection vials were then placed underneath the columns. To elute the 
inositol phosphates, 3 ml of elution buffer VI (see Appendix B) was added to the columns and 
the eluates were collected into the vials. Once elution buffer VI had dripped through, the ends 
of the columns were blotted and the collection vials were removed. If the columns were to be 
used again on the same day, this is the point at which they were regenerated. To regenerate 
the columns they were first rinsed with 10 ml of regeneration solution (see Appendix B), 
which removed any remaining inositol phosphate metabolites. The columns were then washed 
three times with 10 ml of Nanopure H2O. This re-equilibrated the columns so that they were 
ready for the next batch of samples.   
2.9.5 COUNTING OF THE SAMPLES   
The levels of [3H]-IPs in the eluates produced from the IP assay were measured by liquid 
scintillation counting. One ml of each eluate was transferred to a scintillation vial, to which 
10 ml of the scintillation cocktail (OPTIPHASE ‘HISAFE’ 3, Perkin Elmer Inc.) was added. 
The scintillation vials were then capped and shaken well to mix the two solutions. This 
produced a solution with a cloudy appearance. To allow this to clear before counting, the vials 
were left for ~20 min in the dark. Once clear, each scintillation vial was transferred to the 
liquid scintillation counter (Wallac 1410, Perkin Elmer). The sides of the vials were not 
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touched to avoid the potential for counting errors produced by smears. The samples were 
counted for 20 min each using the “CPM count” function. This counts per minute (CPM) 
function is used when all of the samples are expected to have similar counting efficiencies. 
The counter will determine the CPM by fitting a reference spectrum to the spectrum of the 
unknown sample. The software will then calculates the CPM value that will produce the 
spectrum based on stored information. The readout produced by the counter contains the 
values for the following parameters for each sample: CPM (corrected counts per minute), 
SQPI (spectral quench parameter for 3H), and CPM1 (uncorrected CPM). The SQPI (sample 
quenching) was typically between 105-113 for all samples. The counter produced the 
corrected CPM value by performing background and chemiluminescence corrections to the 
raw counts. The corrected CPM values of replicate sample were averaged and the SEM 
calculated by hand.  
2.9.6 ANALYSIS OF THE ASSAY RESULTS 
The IP response of cells to agonist stimulation in this research was expressed as the CPM or 
the stimulated response as a percentage of the control response, as has been done previously 
(Freedman et al., 1997; Gaudreau et al., 2002). The CPM values of replicate wells in 
individual experiments were averaged and the SEM calculated to produce a mean CPM value 
for a specific treatment within an experiment. The CPM mean values from replicate 
experiments were entered into GraphPad Prism 4, which was used to calculate the overall 
mean ± SEM, and the results were plotted in a bar graph. The stimulated response data was 
calculated by expressing the stimulated response with or without a pre-treatment as a 
percentage of the control response with or without a pre-treatment. The calculated values of 
percentage stimulation with or with out an AVP pre-treatment were then entered into Prism, 
which was used to calculate the overall mean ± SEM, and the results were then plotted in a 
bar graph. The significance of differences in the IP responses to AVP stimulation was 
determined through t-tests conducted using Prism software. A result of P<0.05 was 
considered to be significant. The actual levels of significance are as indicated in the text. All 
data were reported as mean ± SEM. 
All graphs of IP assay results were created using GraphPad Prism 4. The Prism data analysis 
outputs were used to created tables using Microsoft Excel 2007.  
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2.10 WASTE DISPOSAL 
Waste contaminated with either the HEK293 cells or E. coli DH5 alpha cells is bio-hazardous 
and was disposed of as follows. 
2.10.1 DISPOSAL OF HEK293 CELL WASTE 
Liquid waste containing HEK293 cells was treated with 1% Virkon overnight, prior to being 
flushed down the sink with running water. Any plasticware used for HEK293 cell work was 
autoclaved prior to disposal with the normal rubbish. Any glassware that came in contact with 
HEK293 cells was treated with 1% Virkon overnight. The Virkon was then flushed down the 
sink with running water, and the glassware was washed as normal. 
2.10.2 DISPOSAL OF E. COLI DH5 ALPHA WASTE 
Liquid contaminated with the DH5 alpha E. coli was collected in a waste container and 
autoclave before being flushed down the sink with running water. The only exception to this 
was any waste that also contained alcohol. This was collected separately and treated with 1% 
Virkon overnight before being flushed down the sink with running water. Any plastic ware 
that came into contact with the DH5 alpha E. coli was autoclaved before being disposed of 
with the normal rubbish.  Any glassware to come in contact with DH5 alpha E. coli was 
treated with 1% Virkon overnight. The Virkon was then flushed down the sink with running 
water, and the glassware was washed as normal 
2.10.3 RADIOACTIVE WASTE DISPOSAL 
Waste from the IP assays was mixed waste containing both bio-hazardous HEK293 cells and 
radioisotope (3H). The waste was first treated with 1% Virkon overnight and then flushed 
down the sink with running water for a minimum of 30 min. All of the plasticware that came 
into contact with HEK293 cells was first treated overnight with 1% Virkon. The plasticware 
and rubbish was then collected together and disposed of in rubbish bags according to National 
Radiation Laboratory requirements. During the IP assay, no glassware came into contact with 
the isotope. 
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CHAPTER 3: 
  
PREPARATION FOR AND GENERATION OF V1BR-STABLY 
TRANSFECTED HEK293 CELL LINES 
 
3.1 MEASUREMENT OF HEK293 CELL PROLIFERATION RATE  
3.1.1 INTRODUCTION 
Cell line growth follows a characteristic progression (Freshney, 2000). It begins with the lag 
phase, where little to no cell growth is seen. Then there is the exponential growth phase, 
which is also known as the log phase. During this phase there is rapid linear cell growth. 
Finally there is the stationary phase, which is also known as the plateau phase. During this 
phase again there is little to no cell growth. The results of cell experiments can be affected by 
their growth phase. Therefore, when transfecting cells with F6 (see Section 2.7) the 
manufacturer (Roche Applied Science) recommends for good quality, consistent transfection 
results that the cells are transfected during their log phase of growth, preferably when the cells 
are between 50-80% confluent. The antibiotic G418, used in this research to select stably 
transfected cells, also works best against log phase cells (Southern and Berg, 1982).   
Plasmid DNA complexed with carrier molecule transfection reagents is believed to enter the 
cell by utilising the endocytosis pathway (Grimm, 2004). However, the DNA must still reach 
the nucleus, especially for the production of stable transfectants. This happens most 
efficiently when the cells are dividing as the nuclear envelope ruptures and the DNA gains 
access to the host genome (reviewed in Hebert, 2003; Vaughan et al., 2006). G418 works best 
against rapidly dividing cells as it interferes with ribosomal function and therefore translation 
(Southern and Berg, 1982), which occurs at the highest rate when cells are rapidly dividing. 
Cell cultures are utilised as model systems as they are generally homogenous populations of 
cells (Freshney, 2000). However, it must be taken into account that the cells are generally 
most uniform when they are in the log phase of growth as opposed to the plateau phase. 
Therefore, ideally all experiments should be conducted while the cells are in log phase. To 
achieve this goal careful planning is required. 
As the growth phases of the cells can have a significant impact on experimental outcomes it is 
important to have information on the growth characteristics of a particular cell line. This 
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growth information allows informed decisions to be made during the planning stages of 
experiments and this planning promotes successful experimental outcomes. To obtain growth 
characteristic information on HEK293 cells, a growth curve was constructed for this 
(untransfected) cell line. This growth curve was then used to determine the phases of growth 
for HEK293 cells. The protocol developed for the measurement of cell proliferation rate (see 
Section 2.4) was optimised from that described by Freshney (2000), and used to obtain the 
growth curves shown below. 
3.1.2 RESULTS  
The growth curves for the two different plating densities are shown in Figure 3.1. These 
curves were obtained in collaboration with Katherine van Bysterveldt, a fellow MSc student. 
The growth curves developed for cells plated at both of the densities showed a classic sigmoid 
shape. There was a lag phase of 2 days, which was then followed by a linear growth of 4-6 
days. These curves have the same linear slope, and the cell numbers appear to be doubling 
approximately every 24 h. The supplier of the HEK293 cells, ATCC, lists HEK293 cells as 
having a doubling time of 34 h. The doubling time measured here was about one third less 
than this. After the linear growth phase both curves level off indicating a plateau phase. 
0 2 4 6 8 10 12
103
104
105
106
107
1x104
3x104
Days from plating
C
el
ls
/w
el
l
 
 
Figure 3.1 Growth curves of HEK293 cells. Cells were either plated at 1x104 or 3x104 cells/well in a 24 well plate. Growth 
was then measured over 10-12 days. The curves have sigmoid appearances, which indicate the three phases of growth, lag, 
log, and plateau. Both curves have the same linear slope, and appear to double in number approximately every 24 h during 
this phase. This was determined by the time taken to increase cell numbers from 1 x 105 to 2 x 105. The data is expressed as 
mean ± SEM first 10 days (n=2), last 2 days (n=1). 
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Each day in addition to counting the cells, the average percentage confluence was determined 
for all wells plated at the same density. This allowed the phases of cell growth to be correlated 
with percentage confluences (Table 3.1). From the table it can be seen that between 20-90% 
confluence cells are within their log phase of growth and hence suitable for use in 
experiments. This information enabled future assessment of the cells using an inverted 
microscope to provide information not only on the confluence of the cells but also on their 
growth phase. It is an ideal range as cells between 50-80% confluent are seen to be in the log 
phase of growth, which is optimal for transfection. It also confirms that HEK293 cells should 
be sub-cultured when they are between 50-80% confluent, in order to maintain a uniform cell 
culture. 
 
Growth 
Phase 
Approx. % 
Confluence 
Lag < 20% 
Log 20-90% 
Plateau > 90% 
 
Table 3.1 The percentage confluences 
correlating to the different growth 
phases of HEK293 cells. 
 
3.2 PREPARATION OF PLASMID DNA FOR TRANSFECTION 
3.2.1 SUB-CLONING OF THE rV1bR GENE INTO A SUITABLE VECTOR (pEGFP-N1) 
FOR STABLE TRANSFECTION 
3.2.1.1 Introduction 
Vector design is an important step to ensuring the successful delivery of plasmid DNA into 
cells, especially when using non-viral techniques (Mairhofer and Grabherr, 2008). In order to 
get the best possible results when stably transfecting mammalian cells, it is preferable to have 
the GOI on the same plasmid as the selection marker. An alternative possibility is to            
co-transfect the cells with two different plasmids. However, by transfecting with only one 
plasmid there is increased confidence that if the selection marker is expressed the GOI will be 
also. This means that fewer stable clones will require screening in order to find the ones 
which are expressing the GOI.  
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Previously in this laboratory, pALTER®-MAX (Figure 2.2) and prV1bR plasmids, obtained 
by Dr. Drusilla Mason as a gift from Dr. Greti Aguilera (National Institutes of Health (NIH), 
Bethesda, USA) were used to transiently transfect HEK293 cells (Gatehouse, 2008). The full 
rV1bR clone (~2.6 kb) (Lolait et al., 1995) was inserted into pALTER®-MAX (5.5 kb) to 
produced prV1bR (~8.1 kb). pALTER®-Max was originally from Promega and the prV1bR 
plasmid was made by Bioserve – Biotechnologies (MD, USA). However, the prV1bR plasmid 
alone is unsuitable for stable transfections as it does not contain a gene for mammalian 
selection. The pEGFP-N1 vector (Figure 2.3), obtained as a gift from Dr. Gabriele Dachs 
(University of Otago, Christchurch), contains the neo gene for mammalian selection. pEGFP-
N1 (4.7 kb) was originally obtained from Clontech.   
It was decided to sub-clone the GOI, rV1bR, into the pEGFP-N1 plasmid rather than use a    
co-transfection method to create the stable cell lines. The sub-cloned plasmid was created 
using the protocol described in Section 2.5.1. It was decided to remove EGFP (~0.7 kb) in this 
process for two reasons: 
1) to keep the plasmid size as small as possible to increase transfection efficiency, and 
2) to reduce the potential for the production of artefacts in V1bR signalling by attaching 
EGFP to the end of rV1bR. 
The fact that the neo gene provides for selection in both prokaryotic and eukaryotic cells 
(Southern and Berg, 1982) makes it particularly useful, as it halves the number of selection 
markers required. This helps to keep the plasmid size as small as possible, and hence 
improves transfection efficiency (Mairhofer and Grabherr, 2008). 
3.2.1.2 Results 
The success of the sub-cloning of the rV1bR gene into the pEGFP-N1 with the removal of the 
EGFP gene is illustrated in the image (Figure 3.2) of the gel that was run at the end of the 
sub-cloning protocol (see Section 2.5.1.6). The four lanes directly to the right of the ladder, 
containing the restriction enzyme digested plasmids from mini preparations #1 - #4 had clear 
separation of the bands. The bands were of the appropriate size to be the destination vector 
(pN1 ~4.0 kb) and the rV1bR gene (~2.6 kb). Due to the more intense light signal from mini 
preparation #1, two bands are not obvious in the image, but were clearly separate when the 
gel was viewed directly. This data indicates that these four plasmid DNA preparations contain 
the desired plasmid construct. The mini preparations #5 through 10 did not show clear 
separation of the bands, and thus it is unclear whether these preparations do contain the 
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desired construct or just the destination vector. It is possible that two bands could not be seen 
due to DNA overloading. It is also possible that some of the E. coli colonies that grew were 
only transformed with the destination vector as this contained the selection marker. 
 
 
Figure 3.2 Image of the gel on which the digested sub-cloned plasmid DNA preparations were run. The four 
preparations run immediately to the right of the ladder show separation of the bands indicating the presence of both the 
destination vector pN1 (~ 4.0 kb) and the GOI rV1bR (~2.6 kb). The lane immediately to the right of the ladder does not 
show clear band separation in the image but did when the gel was viewed directly. The other six preparations did not show 
clear separation. This may have been due to excess DNA in the lanes.  
 
Preparation #1 was selected for use in further research as it appears to have the highest 
plasmid DNA concentration of the four preparations. In Table 3.2 results from 
spectrophotometry analysis of this preparation can be seen. The overnight culture, which 
preparation #1 was made from, was used to create glycerol stocks so that larger preparations 
of plasmid DNA could be made in the future. All other preparations and cultures were 
discarded. This new construct, designated pN1-V1bR is ~6.6kb in size. The size of the 
plasmid has increased as the egfp gene (~0.7 kb) that was removed is much smaller in size 
than the rV1bR (~2.6 kb).  
 
 Concentration 260/280 260/230 
pN1-V1bR 309.4 ng/μl 1.90 2.12 
 
Table 3.2 Spectrophotometer results for plasmid preparation #1. A 260/280 ratio 
of above 1.8 is considered pure for DNA. The 260/230 ratios are a secondary measure 
of purity, these are usually higher than the 260/280 ratio, typically between 1.8 – 2.2. 
These data show that the construct purity was acceptable and the preparation was 
suitable for mammalian transfections. 
 
56 
 
 
 
3.2.2 BULK PREPARATION OF PLASMID DNA  
3.2.2.1 Introduction 
For the transfection optimisation (using pEGFP-N1), the IP assay modification (using pN1-
V1bR), and the stable transfection (using pN1-V1bR), large amounts of highly purified 
plasmid DNA was required. pEGFP-N1 rather then pN1-V1bR was used for the optimisation 
of the transfection protocol for HEK293 cells with F6, because the presence of a fluorescent 
gene in the vector simplified the assessment of transfection efficiency. In order to have 
enough plasmid DNA stock for all these experiments large plasmid DNA preparations were 
required of both plasmids. To make plasmid DNA preparations, competent bacterial cells are 
transformed with the plasmids and cultured under antibiotic selection conditions. The plasmid 
DNA can then be harvested from the bacterial cell cultures and purified to the high quality 
required for mammalian cell transfection.  
It is important that the plasmid DNA used to transfect mammalian cells is highly purified, as 
contaminants such cellular DNA, RNA, and protein, and endotoxins produced by bacteria can 
affect the transfection efficiency. The extracted DNA can be assessed for cellular 
contaminates using spectrophotometry. The presence of endotoxins are more difficult to 
detect, but can be reduced by using a protocol specifically designed to exclude endotoxins. 
Effects of endotoxins are apparent when levels are greater than 2000 endotoxin units (EU)/ μg 
DNA, with cell proliferation and viability affected above 10,000 EU/ug DNA (Butash et al., 
2000). Sufficient reduction in endotoxin levels can usually be achieved through purifying the 
DNA using anion exchange resin, although endotoxin free conditions may be needed for 
certain in vivo studies (Butash et al., 2000). To achieve good results from mammalian 
transfections, plasmid DNA with the greatest possible purity is preferred. High quality DNA 
was ensured by using the Invitrogen PureLink™ HiPure Plasmid Purification Kit to harvest 
and purify the plasmid DNA as described in Section 2.5.2. 
Once a plasmid DNA preparation has been made it is important to show that it is of the 
correct plasmid and if there is any contamination. To do this a DNA gel was run and the 
bands examined. As the two plasmids purified here are different sizes, the gel also enabled 
determination of whether cross contamination had occurred. Circular DNA migrates through a 
gel at a different rate to linear DNA (Sambrook, 1989). This difference depends on a number 
of properties of the gel. To compare circular plasmid DNA with the linear DNA ladder to 
determine its size, the plasmid must linearised with a restriction enzyme. It is important that 
this restriction enzyme will only cut the plasmid once, as this ensures that the plasmid runs as 
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a single linear DNA fragment and that the band produced will be representative of the actual 
plasmid size. To determine whether the same restriction enzyme could be used for both 
plasmids the list of restriction enzymes sites for pEGFP-N1 was examined for an enzyme that 
would cut at only one site. This site needed to be in the part of the vector that was present in 
both plasmids. There is only one XhoI site in pEGFP-N1, and this is in the appropriate portion 
of the plasmid. XhoI has been used previously in this laboratory as a one-cutter for prV1bR 
(Gatehouse, 2008), and it was determined at that time that there are no sites for XhoI in the 
rV1bR sequence. The XhoI site in prV1bR plasmid is outside the region that was transferred 
when the rV1bR was sub-cloned into pN1. XhoI was therefore selected as an appropriate 
restriction enzyme for cutting the two plasmids prior to running them on a gel.  
3.2.2.2 Results 
The maxi plasmid DNA preparations produced 500 μl of DNA for each plasmid. Both of 
these products were assessed using the spectrophotometer. Table 3.3 shows the concentration 
and purity of the prepared plasmids. This table shows that large quantities of both plasmids 
were produced, with a high level of purity. Before running the gel described in Section 
2.5.2.5, the plasmids were digested with the restriction enzyme XhoI. The restriction enzyme 
digest of each was run alongside the uncut plasmids as well as a DNA ladder. An image of the 
resulting gel taken under UV illumination can be seen in Figure 3.3. This shows both 
plasmids were successfully prepared, as they are present in the appropriate size regions of the 
gel. This result combined with the data from the spectrophotometer shows that the plasmids 
produced are what were expected and have been purified to a standard suitable for use in 
mammalian transfections. This means that the experiments that required the large amounts of 
high pure plasmid DNA could proceed. 
 
 pN1-V1bR pEGFP-N1
260/280 1.89 1.90
260/230 2.28 2.27
Concentration 1643.8 ng/μl 1819.2 ng/μl
 
Table 3.3 Plasmid DNA preparation purities and concentrations. A 260/280 
ratio of above 1.8 is considered pure for DNA. The 260/230 ratios are a secondary 
measure of purity, these are usually higher than the 260/280 ratio, typically 
between 1.8 – 2.2. The spectrophotometer results above show that the plasmid 
preparations were successfully purified. 
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Figure 3.3 Image of the gel run to confirm plasmid identity. Lanes 3 and 8 
show the ladder, lane 4 shows pN1-V1bR cut with XhoI, lane 5 shows pN1-V1bR 
uncut, lane 6 shows pEGFP-N1 cut with XhoI, and lane 7 shows pEGFP-N1 
uncut. The ladder band sizes are indicated on the side. This shows that the cut 
pN1-V1bR is of a slightly greater weight than 6 kb, corresponding to its size of 
~6.6 kb. The cut pEGFP-N1 is approximately mid-way between 4 kb and 6 kb 
corresponding to its size of 4.7 kb. 
 
3.3 OPTIMISATION OF ANTIBIOTIC SELECTION CONDITIONS 
3.3.1 INTRODUCTION 
Approximately one in 104 transfected cells will stably integrate the plasmid DNA (Ausubel et 
al., 1994; Haber, 1999; Mortensen and Kingston, 2009). Therefore, a selection marker is 
required in order isolate these cells from the ones in which transfection was unsuccessful or 
was only of a transient nature. Prior to use of the selection marker in selecting stably 
transfected cells, appropriate selection conditions must be determined through testing the 
marker against the (untransfected) parental cell line. In this case selection conditions were 
determined using (untransfected) HEK293 cells. 
The construct used, for selection of stably expressing clonal cell lines, contains the selection 
gene neo (see Section 3.2). Therefore, appropriate selection conditions needed to be 
determined for G418 (Invitrogen) with parental (untransfected) HEK293 cells. The 
concentration of G418 required to kill a specific cell lines varies and therefore a wide range of 
concentrations were tested (Mortensen and Kingston, 2009; Southern and Berg, 1982). As 
different lots of the antibiotic can have different potencies, each lot used in this research was 
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tested as well. However, lot testing was done over a much smaller range of G418 
concentrations, and one pre-determined plating density.  
Determination of the selection conditions consisted of two parts:  
1) determination of the concentration of G418 sufficient to kill all parental 
(untransfected) HEK293 cells, and  
2) determination of an optimal plating density for the selection process, using this G418 
concentration.   
To chose the range of G418 concentrations to use for determining an appropriate selection 
concentration, a number of sources were consulted including Southern and Berg (1982), 
Ausubel (1994), Violin (2008), Mortensen and Kingston (2009), and the Ambion pSilencer 
neo Expression Vector instructions. The plating densities chosen were a range of those 
regularly used in this laboratory when plating HEK293 cells.  
There are two key time points in determining the appropriate antibiotic selection conditions: 
1) massive cell death within 7-9 days, and 
2) complete cell death within 2-3 weeks. 
Ideally the cells should reach ~80% confluence before they start to die. This can be adjusted 
through optimisation of the plating density. A maintenance concentration of the selection 
marker is also required to ensure the cells maintain expression when passaged normally after 
the original selection process. This concentration is commonly half that required for the 
original selection of the stable transfectants. 
The protocols used to optimise the antibiotic selection conditions (see Section 2.6) were 
adapted from the Ambion pSilencer neo Expression Vector instructions, Invitrogen 
pcDNA3.1(+) pcDNA3.2(-) instructions, and from the protocols reported by Ausubel (1994). 
3.3.2 RESULTS 
3.3.2.1 Selection and maintenance concentrations of G418 
Eight different concentrations of G418 were tested in the range of 0 μg/ml to 1,500 μg/ml. 
The results were graphed and can be seen in Figure 3.4. This figure shows that a G418 
concentration of 100 μg/ml had minimal effect on the growth of HEK293 cells, only reducing 
confluence by 10-15% when compared with the control concentration of 0 μg/ml. 
Concentrations of G418 between 200 μg/ml and 1,500 μg/ml were able to reduce cell 
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numbers to varying degrees, as indicated by a drop in confluence. These concentrations killed 
some of the cells as indicated by a change in cell morphology from a normal neuronal 
morphology (Figure 3.5a) to small round structures with a grainy appearance (Figure 3.5b). 
The viability of cells with the latter morphology was assessed through trypan blue exclusion. 
All cells with this changed morphology took up the stain showing they were no longer viable. 
Concentrations of G418 of 500 μg/ml and above were all successful in killing all of the 
HEK293 cells within 2-3 weeks.  
In this experiment the HEK293 cells did not reach ~80 % confluence before they started to 
die, suggesting that the plating density needed to be optimised. Two concentrations of G418 
(500 μg/ml and 700 μg/ml) were chosen to for this optimisation experiment. These 
concentrations were chosen as they were the lowest and second to lowest concentrations that 
caused a large amount of death after 7-9 days and killed all of the cells within 3 weeks. Using 
two concentrations rather then one meant a greater range of options could be assessed. 
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Figure 3.4 Determination of an appropriate antibiotic selection concentration. Graph of percentage confluence of 
untransfected HEK293 cells treated with varying concentrations of G418. All cells in the experiment were plated at                
2 x 104 cells/well in a 24 well plate. The data shown are mean ± SEM (n=3) 
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Figure 3.5 Images of HEK293 cells treated with 0 μg/ml and 1,500 μg/ml G418. Both images were taken on day 4 of the 
experiment. a) Shows HEK293 cells treated with 0 μg/ml G418. The cells still look like normal HEK293 cells, neuronal in 
morphology and growing in a monolayer. b) Shows HEK293 cells treated with 1,500 μg/ml G418. The cells have become 
circular in morphology, with a grainy appearance and the cellular monolayer can be seen to be breaking up. 
 
3.3.2.2 Optimal plating density for antibiotic selection 
Four different plating densities were assessed, with the two G418 concentrations selected 
above: 2 x 104, 4 x 104, 6 x 104, and 8 x 104 cell/well in a 24 well plate. The results of this 
experiment can be seen in Figures 3.6 (plate one - 500 μg/ml) and Figure 3.7 (plate two -   
700 μg/ml). These figures show that all of the G418 treated cells were effectively killed 
within 2-3 weeks. This occurred slightly faster at the G418 concentration of 700 μg/ml. Only 
two of the initial plating densities, 6 x 104 and 8 x 104 cell/well, reached close to 80% 
confluence before the cells began to die.   
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Figure 3.6 Determination of the optimal plating density with 500 μg/ml G418. 0 μg/ml and 500 μg/ml G418 were tested 
with different initial plating densities of HEK293 cells in a 24 well plate. The test wells received the G418. The data are  
expressed as percentage confluences, mean ± SEM (n=3). 
a b 
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Figure 3.7 Determination of the optimal plating density with 700 μg/ml G418. 0 μg/ml and 700 μg/ml G418 were used 
with different initial plating densities of HEK293 cells in a 24 well plate. The test wells received the G418. The data are 
expressed as percentage confluences, mean ± SEM (n=3). 
 
 
 
 
After this experiment it was discovered that the CO2 incubator had not been maintaining the 
interior environment at 5% CO2, 95% air. This may have negatively impacted the growth of 
the HEK293 cells, because the correct CO2 level is required to maintain the normal pH of the 
culture medium. Therefore, the first seven days of the experiment were repeated with both 
G418 concentrations. However, only the two higher initial plating densities (6 x 104 and         
8 x 104 cells/well) were used. The results from this second experiment can be seen in      
Figure 3.8. This shows that the cells at both of the initial plating densities reached ~80% 
confluence before beginning to die, at both of the G418 concentrations. 
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Figure 3.8 Second determination of optimal plating density. 0 μg/ml, 500 μg/ml, and 700 μg/ml G418 were used at the 
initial plating densities of 6 x 104 and 8 x 104 cells/well in a 24 well plate. Test wells were treated with G418. Data obtained 
with cells treated with 500 μg/ml are shown in orange and dark green, and those obtained with 700 μg/ml are shown in light 
green and grey. The experiment was conducted over 7 days. Data are expressed as percentage confluences, mean ± SEM 
(n=3). 
 
The information from these experiments allowed the determination of the minimum 
concentration of G418 required to kill the untransfected parental cell line. This was 500 μg/ml 
G418. Therefore, the maintenance concentration was set at 250 μg/ml G418. These 
experiments showed that plating densities equivalent to 6 x 104 cells/well and above in a      
24 well plate or equivalent were appropriate. 
 
3.4 OPTIMISATION OF F6 TRANSFECTION PROTOCOL 
3.4.1 INTRODUCTION 
There are many methods which can be used to transfect mammalian cells with plasmid DNA 
including carrier molecules, viruses, and electroporation (Bonetta, 2005; Mortensen and 
Kingston, 2009). An advantage of carrier molecules over other methods is that these protocols 
are generally simple and do not require expensive equipment (Bonetta, 2005). It is  important 
when generating stable cell lines to ensure high levels of transfection, as the more DNA that 
is introduced to a cell the better the chance of it being stably integrated (Mortensen and 
Kingston, 2009). Maintaining a high level of functional viability is also an important concern. 
Many lipid based transfection reagents including non-liposomal reagents provide ease of use 
and low level of cytotoxicity (Bonetta, 2005), along with high levels of transfection. Previous 
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work in this laboratory used HEK293 cells that were transiently transfected using 
Lipofectamine™ 2000 (Invitrogen) (Gatehouse, 2008). A disadvantage with using this 
transfection reagent is that it must be used with cells at a high confluence to minimise 
cytotoxicity (see manufacturers product insert). This is a disadvantage when trying to ensure 
log phase cells for subsequent experiments. It was noted that some research groups were 
using F6 to transfect HEK293 cells to produce stable lines and Lipofectamine™ 2000 to 
transfect other cell lines, such as U2-OS cells (Violin et al., 2006) and mouse embryonic 
kidney cells (Violin et al., 2008). Correspondence with the authors confirmed that they had 
found F6 resulted in lower levels of HEK293 cell cytotoxicity than Lipofectamine™ 2000. F6 
has been shown to produce high levels of transfection and low levels of cytotoxicity across a 
wide range of cell lines (Jacobsen et al., 2004). Therefore, the decision was made to switch 
transfection reagents in order to minimise cytotoxicity during transfection and maximise the 
likelihood of success in generating clonal stable cell lines.  
Transfection results can be improved for a specific cell line by optimising a number of the 
parameters. The efficiency of a transfection reagent depends mostly upon the cell line used 
(Sambrook, 1989), rather than the plasmid it is transfected with. Therefore, when optimising 
F6 for use with HEK293 cells, a variety of plasmids can be used. Optimising the protocol 
utilising transient transfections will generally produce a protocol with conditions suitable for 
producing stable transfectants (Mortensen and Kingston, 2009). Therefore, transient 
transfections were used for optimisation. 
Three parameters were evaluated during optimisation of the transfection protocol. These were 
selected based on information from the manufacturer (Roche Applied Sciences), and from 
Bonetta (2005) and Jacobsen et al. (2004) who examined transfection reagents and F6 
optimisation respectively. The parameters evaluated were: 
1) the ratio of F6 (μl) to DNA (μg),  
2) the time required for complex formation, and 
3) the time required for the cells to express the transfected gene 
In order to determine the optimal ratio and times for the above parameters, an efficient 
method of analysis was required. Therefore, the HEK293 cells were transiently transfected 
with pEGFP-N1. Expression of the egfp gene produces a fluorescent protein, EGFP 
(excitation maximum = 488 nm, emission maximum = 507 nm), which can be evaluated using 
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confocal microscopy (TCS SP5, Leica). As the cells are assessed by viewing them, the same 
cells can be used to assess different time points. In contrast, optimisation using pN1-V1bR 
and a functional assay to assess V1bR expression, would be time consuming and the cells in a 
particular well could only be assessed at one time point. The final version of the transfection 
protocol can be seen in Section 2.7. Only the three parameters described above were altered; 
every other step was carried out as described in the final protocol. The experiment was 
repeated three times with some modifications (see below). 
3.4.2 RESULTS 
The data from the experiments assessing the three transfection parameters were collated into a 
single graph for ease of comparison (Figure 3.12). Confocal microscopy images of the 
transiently transfected cells (for an example see Figure 3.13), were used to calculate the 
percentage of cells fluorescing at each time point. Percentage fluorescence was used as a 
measure of the percentage of cells transfected as it was assumed that only the cells expressing 
EGFP had been transfected. To produce the data for the 24 h time point, five images were 
taken for each well in conserved positions of the well: top, upper middle, middle, lower 
middle and base. The percentage fluorescence was calculated for each of the five images. 
These percentages were used to produce an average percentage fluorescence for each well, 
which represented a specific combination of conditions. The equivalent wells in each of three 
replicate experiments were then averaged and the SEM calculated. At 48 and 72 h only one 
image was taken for each well. This was conserved at the upper middle position as it was 
generally the most representative of the images for a well. Two of the replicate experiments 
were taken to the 48 h time point. The wells in the two replicates treated with the same 
conditions were averaged and the SEM calculated. Only one of the replicate experiments was 
taken out to72 h. Therefore, the percentage fluorescence for this time point is based on only 
one count and therefore no SEM could be calculated.  
3.4.2.1 Ratio of F6 (μl) to DNA (μg) 
The first parameter examined was the ratio of F6 (μl) to DNA (μg). Three different F6:DNA 
ratios were assessed, 3:1, 3:2, and 6:1. All three were trialled first in an initial pilot 
experiment (data not shown). In this experiment, a sharp drop off in the transfection 
efficiency was seen for cells that were transfected at the 3:2 ratio, when compared to cells 
transfected with either of the other ratios. Therefore, the 3:2 ratio was excluded from further 
optimisation experiments in order to simplify them.  
66 
 
 
 
Figure 3.9 shows the percentage fluorescence 24 h post transfection. This figure shows that 
the F6:DNA ratio of 3:1 has consistently higher levels of transfection efficiency than the 6:1 
ratio, when the two other parameters were held constant. This consistency made the decision 
to use the 3:1 ratio for transfection clear. 
 
 
Figure 3.9 Percentage fluorescence when treated with different F6:DNA ratios and complex formation times. The data 
were determined from images taken 24 h after transfection. It can be seen the F6:DNA ratio of 3:1 produces a greater level of 
fluorescence at all complex formation times assessed. Data are mean ± SEM (n=3).  
 
 
3.4.2.2 Time required for complex formation between F6 and DNA 
The second parameter examined was the length of time for complex formation. Four different 
complex formation times were examined, 15, 30, 45, and 60 min. The complex must have a 
minimum of 15 min to form. Reducing this time will reduce the transfection efficiency 
(Jacobsen et al., 2004). However, it has been shown that the transfection efficiency can be 
increased with HEK293 cells when the complex formation time is increased. An initial pilot 
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experiment was run that included complex formation times of 15, 30, and 45 min (data not 
shown). The transfection efficiency was low with a complex formation time of 15 min when 
compared with efficiencies with either of the other complex formation times. Therefore, it 
was decided to exclude this complex formation time from the final optimisation experiments 
and instead include the longer complex formation time of 60 min (Figure 3.10). A complex 
formation time of 30 min has a greater level of transfection efficiency then any of the other 
complex formation times assessed. Therefore, 30 min was chosen as the complex formation 
time for transfection experiments. 
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Figure 3.10 Complex formation time. The percentage fluorescence was determined from images taken at 24 h post 
transfection, with a F6:DNA ratio of 3:1. It can be seen that the complex formation time of 30 min produces the highest 
percentage fluorescence. Data are mean ± SEM. 
 
 
3.4.2.3 Time required for expression of the transfected gene 
The third parameter examined was the incubation time required for the HEK293 cells to take 
up the complex and express the gene. Three different incubation times were examined, 24 h, 
48 h, and 72 h. As seen in Figure 3.11, percentage fluorescence increased between                
24 and 48 h, but little difference was seen between 48 and 72 h. This indicates to a large 
increase in the number of transfected cell up to 48 h. Therefore, an incubation time of 48 h 
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was chosen as a suitable time for gene expression by the cells. An optimal EGFP expression 
time of 48 h has also been seen in other experiments using this plasmid (Hunt et al., 2010). 
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Figure 3.11 Percentage fluorescence over time. It can be seen that there is an large increase in percentage fluorescence 
between 24 and 48 h. However, between 48 and 72 h it plateaus. The data for each time point are the mean fluorescence of all 
the F6:DNA ratios and complex formation times assessed at that time point. The data are expressed as the mean ± SEM 
(n=6). 
 
 
Figure 3.12 Optimisation of HEK293 cell transfection with F6. The data were collated from three replicate experiments, 
allowing for the best combination of conditions to be chosen: F6:DNA ratio (3:1), duration of complex formation (30 min) 
and time since transfection (48 h). The data are expressed as percentage fluorescence, mean ± SEM, 24 h (n=3), 48 h (n=2), 
72 h (n=1). 
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Figure 3.13 Confocal microscopy images of HEK293 cells expressing pEGFP-N1. a) The bright field image, and b) the 
fluorescent image are of cells 48 h post transfection with an F6:DNA ratio of 6:1 and a complex formation time of 45 min. 
These images are examples of those taken with the confocal microscope in order to determine the percentage fluorescence. 
Both images were taken at the same magnification and show the same field of view to allow for direct comparison 
 
 
3.4.3 IMPACT OF THE TRANSFECTION PROTOCOL ON THE IP ASSAY PROTOCOL 
The optimised transfected conditions affected the incubation times used for the IP assay. 
Previous use of the assay in this laboratory assessed expression of the rV1bR at 24 h post 
transfection (Gatehouse, 2008). Based on these transfection optimisation results, the optimal 
time to evaluate the rV1bR function was likely to be 48 h post transfection. This change in 
protocol increased the IP assay duration by one day. To maintain protocol consistency and 
therefore a consistent growth period, the increased time was conserved for both transiently 
and stably transfected cells. 
 
3.5 GENERATION OF A MODEL CELL SYSTEM STABLY-TRANSFECTED 
WITH pN1-V1bR 
3.5.1 INTRODUCTION 
Stably-transfected model cell systems are a commonly utilised tool in the examination of gene 
expression and function (Mortensen and Kingston, 2009). Mammalian model cell system are 
also often utilised in the production of recombinant proteins to be used as pharmaceuticals 
(Wurm, 2004). This is because, unlike prokaryotic and plants cell systems, mammalian cells 
can perform the correct post-translational modifications on proteins for use in humans and 
other animals (Sambrook, 1989; Wurm, 2004). 
a b 
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In order to develop a stably-transfected model cell system, optimal for a specific research 
purpose, a significant amount of preliminary work and planning is required (Mortensen and 
Kingston, 2009). This ensures that the model cell system produced meets the requirements for 
the subsequent experiments, and therefore that reliable and meaningful data are produced. The 
preliminary steps completed in this research for the production of the model cell system are 
described in the previous sections of the Chapter. This section deals with the transfection and 
G418 selection of stably-transfected clonal cell lines. There were a few parameters within the 
stable transfection protocol (see Section 2.8), which were optimised to ensure a streamlined 
and successful completion. The protocol used to generate the stably-transfected cell lines was 
developed from information provided by Southern and Berg (1982), Roche Applied Science 
(see instructions for G418 use), Ausubel (1994) Mortensen and Kingston (2009), and 
discussions with Dr. Gabriele Dachs (University of Otago, Christchurch).  
3.5.2 ASSESSMENT OF PROTOCOL 
Cells were either left untransfected, or they were transfected with pEGFP-N1 or pN1-V1bR. 
The untransfected cells were used as a negative control for transfection. This was assessed 
when the G418 was added to the cells and all of the untransfected control cells died as they 
were not resistant to the antibiotic. The cells transfected with pEGFP-N1 were used as a 
positive control for transfection, because EGFP expression could be assessed by fluorescence 
confocal microscopy at any time point during generation of the clonal cell lines.  
Two days after transfection the cells in each well of the six well plates were transferred to a 
10 cm plate, given time to adhere, and then the G418 was added for the first time, to select for 
stable transfectants. Presumably because of the high DNA transfection rate of F6, there were 
too many stably-transfected cells transferred to each plate to allow identification of individual 
colonies after the death of the non-stably transfected cells. Therefore, the stably-transfected 
cells were re-plated at a much lower density into second 10 cm plate for colony selection. 
This extra step could be removed by reducing the density of transfected cells plated into the 
first of these two 10 cm plates, negating the need for replating after G418 addition. Based on 
confluence data, transferring approximately half of the cells in each well of the six well plates 
to each of the 10 cm plates should be a sufficient reduction. However, this appears to be lower 
than the optimised plating density (see Section 3.3.2.2) and requires confirmation before the 
protocol is adapted.    
Two different methods of picking individual colonies from the 10 cm plates were tested;  
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1) The colony was removed, without removal of the medium, using a short glass Pasteur 
pipette with a flame-smoothened edge or a P200 Gilson pipette. Colonies were 
selected and picked while examining the plate under an inverted microscope, set up in 
a Biological Safety Cabinet-Class II. The colonies were scraped and the loosened cells 
sucked up with the pipette and then transferred to a well in a 24 well plate. 
2) The details of the other method are as outlined in the protocol (see Section 2.8.2). 
Briefly, the medium was removed from the plate and the plate was washed with        
1x PBS. The colonies of cells were then allowed to air dry. The chosen colonies were 
marked, and then removed by adding 15 μl 1x PBS directly to the colony, scraping it 
then removing the cell suspension. 
The second method proved to be more reproducible than the first. With the first method the 
cells dispersed more easily in the medium and therefore the whole colony was not always 
transferred across to the 24 well plate. The glass pipette the tip tended to slide across the base 
of the plate with greater ease and, in doing so, sometimes more than one colony was scrapped 
off the plate surface. The second method put the cells under greater stress, as they were 
exposed to the air for 3-6 min. However, using this method was more straightforward, as 
colonies could be seen and picked without the microscope. This made it possible to ensure 
that only one colony was picked and that all the cells were transferred. Better results were 
therefore achieved when using this method. 
Three colonies were picked off every 10 cm plate and transferred to individual wells of a 24 
well plate. This was necessary as some of the transferred colonies did not grow in the 24 well 
plate. Other issues with some of the colonies included: very slow growth rates and changed 
morphologies. The cells from colonies picked from two of the 10 cm plates grew very well 
compared to others. This was a benefit as having more than one colony available allowed a 
greater number of colonies with normal morphologies and growth rates to be chosen.  
After the second selection process the cells from the seed colonies were then established as 
individual clonal cell lines as indicated in Section 2.8.3. Once established as individual lines, 
they were named, for example clonal cell line 1C5-210210. The first number, in this case 1, 
indicates the number of the 24 well plate that the colony was transferred to in the second 
round of colony selection. The letter and the second number, in this case C5, indicate the well 
which the colony was transferred to. The suffix number, 210210, indicates the date when the 
cells were transfected, February 21st 2010. The suffix is therefore the same for all of the 
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clonal cell lines. Ten individual clonal cell lines were established. These were then screened 
and assessed as is described in Chapter 4. 
 
3.6 MODIFICATION AND OPTIMISATION OF IP ASSAY PROTOCOL 
3.6.1 INTRODUCTION 
An assay of the levels of intracellular IPs produced in response to AVP stimulation of cells 
was used as an indicator of functional rV1bR expression (see Chapter 4). Specifically it was 
used to determine the AVP responsiveness of clonal cell lines and the desensitisation of this 
response following a pre-treatment. This assay is a cell based assay and as such requires a 
number of wash steps, particularly in determining the desensitisation of the response (see 
Section 2.9). HEK293 cells exhibit poor adherence when subjected to a number of washes 
within a short time frame. A number of factors within the assay were assessed in order to 
optimise HEK293 cell adherence including: 
1) culture-ware coatings, 
2) protein source added to the media, 
3) wash media, and   
4) technique of media replacement 
The effects of changes made to these parameters were visually assessed by evaluating the 
percentage confluence and cell morphology before and after the washes. The changes that 
enhanced cell adherence were then incorporated into the final protocol which can be seen in 
Section 2.9. 
3.6.2 RESULTS 
3.6.2.1 Assessment of different cell culture-ware coatings 
Due to the number of washes in the IP assays, cell culture-ware coated to promote cell 
adhesion must be used with HEK293 cells. Several plate coatings used to promote cell 
adhesion were assessed, these included poly-D-lysine (PDL), Amine, Carboxyl and Primaria 
(Becton Dickson). 
The different plate coating types were assessed in a number of trial experiments using both 
untransfected and transiently transfected HEK293 cells. The transfected cells were slightly 
more fragile than the untransfected cells and as such were observed to lift off the cultureware 
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more readily then the (untransfected) HEK293 cells. This was taken into account when 
assessing the results from these experiments. In these trial experiments some changes in 
morphology were seen after wash steps. This was usually an indicator of reduced adherence. 
When conducting these trial experiments the HEK293 cells never exceeded 100% confluence. 
This ensured that the results were not negatively impacted by cell growth phase. Table 3.4 
summarises the results from transiently transfected cells assessed on the different plate 
coating types. 
 
Plate type Final Morphology
Final 
Confluence 
Percentage 
Stimulation 
PDL Changed ~20% 159% 
Amine Changed ~20% 262% 
Carboxyl Normal ~70% 122% 
Primaria Normal ~70% 197% 
 
Table 3.4 Summary of the results from different plates coatings with transiently 
transfected cells. The final morphologies and confluences were determined after all of the 
washes described in Section 2.9.3.1.2. The percentage stimulation was determined after the 
washes described in Section 2.9.3.1.1. 
 
When HEK293 cells were grown on PDL and Amine coated plates they exhibited a change in 
morphology from normal, after the pre-label wash and the addition of the labelling medium. 
This change in morphology was generally associated with a lower level of adherence, which 
resulted in variable numbers of cells remaining in the wells after all the washes. This 
variability produced unreliable results from these plates. The change in morphology started at 
the edge of the wells where gaps would form in the cell monolayer. The cells then started to 
group together in mounds. While this was occurring the gaps became more pronounced and 
the cells at the edges of the gaps in particular became rounded rather than flattened. 
Sometimes during media changes these mounds lifted from the plate surface and formed balls 
of cells which collected in the media at the centre of the wells. On the Amine coated plates the 
extent of the morphological changes were exacerbated by higher concentrations of FBS, and 
as a consequence cells were plated onto these plates in 5% FBS, rather than 10%. Examples 
of the changed morphology can be seen in Figure 3.14. The reproducibility of the values 
obtained for AVP stimulated IP production in cells plated on Amine coated plates was only 
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acceptable when the protocol did not involve the extra washes required when desensitisation 
was being measured.  
HEK293 cells that were plated onto Carboxyl coated plates had a different morphology from 
normal initially. This changed to a normal morphology usually the day after plating. HEK293 
cell adherence on this type of plate coating was of an acceptable level. However, the cell 
growth rate on these plates was slower than that seen on the other types of plate coating. The 
AVP responsiveness of the cells plated on this sort of coated plate was unacceptably low. 
Untransfeceted and transfected HEK293 cells exhibited high levels of adherence along with 
an unchanged morphology on Primaria coated plates. This level of adherence provided 
consistent and reliable numbers of cells to work with. This reliability allowed for significant 
differences to be seen between treatments. The responsiveness of the cells to AVP on this 
type of plate was of a workable level and was reproducible. The reproducibility of results on 
these coated plates made them a good choice for the IP assay experiments. 
 
 
 
Figure 3.14 Change in morphology seen with HEK293 cells. This image was taken 
of cells grown on a PDL coated plate. Gaps have formed with rounded edges. The 
cells can be seen to be mounding up around the edges of the gaps. This is most 
pronounced on the right hand side of the image. 
 
3.6.2.2 Optimisation of selected IP assay solutions 
Preliminary experiments using 1x PBS for the wash medium prior to labelling, lowered the 
levels of cell adherence. Therefore, it was decided to change the wash medium to inositol free 
DMEM. This allowed the cells to be washed clean of inositol prior to labelling while 
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maintaining a gentler wash medium. A greater level of cell adherence was seen after this 
change in wash medium. Therefore this change was permanently incorporated into the 
protocol.  
The cells were plated for the IP assay in 10% FBS. However, to improve reproducibility in 
the functional assays any serum should be removed from the medium prior to the assay. It 
was therefore decided to change the protein source in the labelling medium from FBS to 
bovine serum albumin (BSA). As BSA was already the standard protein source for the AVP 
stimulation and pre-treatment steps, it was therefore a suitable choice to test. This change to 
the labelling medium reduced the morphology changes seen, as well as increasing the level of 
cell adherence. 
3.6.2.3 Optimisation of media removal and addition to maintain cell adherence and 
normal morphology  
To ensure that the wells spent as little time as possible without medium during the changes, 
no more than twelve wells were handled at one time. If the experiment required more than 
twelve wells, more than one plate was plated. These plates were staggered 3 h apart. This was 
done because the lifting of the cell monolayer occurred to a greater extent the longer the cells 
were without medium. To further address this issue the medium was changed in six wells at a 
time. For example the media was removed off the first six wells and the wash added. The 
media was then removed from the next six wells and the wash added. The wash and the new 
solution were removed and added in the same stepwise manner. The media and solutions were 
all removed from the wells via aspiration. The new media and solutions were added to the 
well using a P1000 Gilson pipette with the tip against the side of the well. These solutions 
were always added in one smooth motion, as a “stop-start” motion lead to a decrease in cell 
adherence. 
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CHAPTER 4:  
 
SCREENING AND ASSESSMENT OF V1BR-STABLY 
TRANSFECTED HEK293 CELL LINES 
 
4.1 INTRODUCTION 
The V1bR plays an important role in the regulation of the HPA axis, which controls an 
individual’s response to stress (see Chapter 1 for details). Understanding how the V1bR is 
regulated is an important step to understanding adaptation to stress (Aguilera, 1994). Previous 
work using ovine anterior pituitary cells has shown that the V1bR desensitises in response to 
repeated AVP stimulation, and that this desensitisation occurs at concentrations and durations 
of AVP exposure which fall within endogenous ranges (Hassan et al., 2003). A pre-treatment 
with 5 nM AVP for 5 min significantly reduced the ACTH response to AVP to 78.5% of the 
control response. This indicated that V1bR desensitisation is likely to be a mechanism of 
receptor regulation in vivo. Since receptor desensitisation appears to be involved in receptor 
regulation in vivo, a research focus in the Mason laboratory involves deducing the molecular 
mechanisms of desensitisation of the V1bR.  
In the classical model of GPCR signalling, desensitisation is produced from a combination of 
mechanisms including uncoupling of the receptor from its signalling pathway as a result 
phosphorylation, receptor internalisation, and down regulation of the receptor (Ferguson, 
2001; Lohse, 1993) (see Chapter 1 for details). These mechanisms occur over different time 
scales. Phosphorylation of the receptor results in rapid (within seconds) and reversible 
desensitisation (Ferguson, 2001). The magnitude of desensitisation mediated by 
phosphorylation with PLCβ coupled receptors is variable (Wojcikiewicz et al., 1993). 
Maximum desensitisation is achieved through a combination of all of the mechanisms. 
Previous work in the Mason laboratory has ruled out PKC and CK1α as potential 
phosphorylators in V1bR desensitisation (Hassan and Mason, 2005). This research did 
indicate that PP2B was involved in resensitisation of the receptor, which has previously been 
shown to be involved with the resensitisation of the β2AR when it is desensitised by GRK2 
(Shih et al., 1999). The GRK family are common GPCR phosphorylators (Pitcher et al., 
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1998), and therefore, GRKs are currently thought to be the most likely candidates for V1bR 
phosphorylation. 
RNAi is the method of choice for loss of function studies. This is because RNAi, the siRNA 
form in particular, is excellent at degrading target mRNA and therefore ‘knocking down’ the 
mRNA and protein expression of specific genes (Editorial, Nature Cell Biology, 2003). The 
use of siRNA techniques means primary cell cultures are an inappropriate choice as they are 
difficult to transfect and their heterogenous nature makes interpretation of biochemical assays 
very difficult (Freshney, 2000; Grimm, 2004; van Beijnum et al., 2008). Therefore, the 
decision to use siRNA necessitated a change from use of primary cell cultures to a model cell 
system using an immortalised cell line, which provided an easily transfectable homogenous 
cell population. The development of a model cell system stably-transfected with the V1bR 
was therefore the goal of this project. HEK293 cells are a good option for the development of 
a model system as, in addition to being easy to transfect, the sequences of human GRKs are 
known, and specific siRNAs have been developed to target them (Ren et al., 2005). These 
siRNAs have been used previously in HEK293 cells to knockdown and examine the role of 
specific GRKs in phosphorylation of the V2R.  
The preparation for and the development of the model cell system was described in Chapter 3. 
This Chapter focuses on the partial characterisation of the generated clonal cell lines. Once 
characterisation is completed, these cell lines will provide a homogenous pool of cells suitable 
for detailed investigation of the molecular mechanisms of V1bR signalling and its regulation. 
 
4.2 INITIAL SCREENING OF CLONAL CELL LINES TO IDENTIFY THOSE 
RESPONDING TO AVP 
4.2.1 INTRODUCTION 
Due to the random nature of DNA integration (Mortensen and Kingston, 2009), different 
clonal cell lines can have different levels of gene expression. It is also possible that even 
though the resistance gene is expressed, the GOI is not. This meant that after selection, all ten 
of the established clonal cell lines required individual assessment to determine whether they 
expressed functional V1bRs. This assessment of the cell lines utilised the IP assay.  
The IP assay can be used to assess signalling and desensitisation for any PLCβ coupled GPCR 
in an intact cell system. The desensitisation of the IP response can also be assessed following 
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an agonist pre-treatment. This assay has been used previously with HEK293 cells to assess 
signalling with a number of GPCRs including; the human endothelin receptors A and B 
(Freedman et al., 1997), the type 1A angiotensin II receptor (Oppermann et al., 1996), and 
metabotropic glutamate 1A receptor (Dale et al., 2000). The IP assay has also been previously 
used to examine V1bR signalling and desensitisation (Gatehouse, 2008; Rabadan-Diehl et al., 
2007; Thibonnier et al., 1997; Young et al., 2007).  
The measurement of IP production in response to AVP stimulation allows for a number of 
factors involved with V1bR signalling to be examined including: 
1) the responsiveness of the cell lines to AVP stimulation,   
2) the magnitude of response desensitisation following a pre-treatment with AVP,  and 
3) any changes in stimulated IP production over a number of passages. 
Characterisation of these signalling parameters is necessary, in order to provide a baseline for 
subsequent work with this model cell system.  
The IP production of the clonal cell lines in response to AVP stimulation was used as an 
indicator of rV1bR expression. Initially all of the lines were screened for increased IP 
production in response to AVP (100 nM, 15 min) using the IP assay (see Section 2.9). This 
screen allowed for identification of individual clonal cell lines that respond to AVP. The AVP 
responsiveness and the desensitisation of this response following an AVP (5 nM, 5 min) pre-
treatment of the identified cell lines were then examined in greater detail (see Section 4.3). 
4.2.2 RESULTS 
Ten clonal cell lines were selected using G418 and established as individual lines. These were 
then screened for expression of either EGFP or rV1bR. The one clonal cell line that was 
transfected with pEGFP-N1 was assessed for EGFP expression using fluorescence confocal 
microscopy. The nine clonal cell lines that were transfected with pN1-V1bR were screened 
for functional expression of the rV1bR by assessing intracellular IP production in response to                 
AVP (100 nM) stimulation for 15 min (see section 2.9.3.1.1 for details). Briefly, this involved 
washing the cells that had been incubated for 20 h with myo-[3H]inositol once with the “basal 
solution” and then incubating the cells with either “basal solution” (0 nM AVP) or 
“stimulation solution” (100 nM AVP) for 15 min. This allowed AVP stimulated IP production 
to be compared to the basal level of IP production. 
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The day after transfection, the cells transfected with pEGFP-N1 were assessed using 
fluorescent confocal microscopy. A large number of the cells were shown to be expressing 
EGFP (data not shown). See Section 3.4 for an example of images of fluorescing cells. 
However, when the stable clonal cell line established from cells transfected with pEGFP-N1 
was assessed, it did not express EGFP. No assessment of expression was made between these 
two time points. 
Nine clonal cell lines were generated from the cells transfected with pN1-V1bR. These cell 
lines were all initially screened once with the IP assay with all treatments in triplicate, in 
order to assess their responsiveness to AVP. Four of the nine clonal cell lines assessed 
responded to AVP stimulation with an increase in IP production of ~50% or more (Table 4.1). 
This indicated that the rV1bR was probably expressed in these four clonal cell lines. Of the 
four lines, 2A5-210210 and 1C5-210210 (referred to from here on as 2A5 and 1C5, 
respectively), appear to have a greater responsiveness to AVP, than 1C1-210210 and 2C2-
210210 (referred to from here on as 1C1 and 2C2, respectively). Of the five remaining lines,        
2A1-210210 cells were too fragile to survive a single freeze-thaw cycle. Therefore, AVP 
responsiveness could not be assessed in this line. The other four lines, 1A5-210210,          
2B2-210210, 2B4-210210, and 1B1-210210, had insufficient levels of AVP responsiveness 
for them to be considered for further characterisation. 
 
Clonal cell 
lines 
IP response (% 
response of     
0 nM AVP) 
2A5-210210 253% 
1C1-210210 168% 
1A5-210210 100% 
2B2-210210 122% 
2C2-210210 148% 
2A1-210210 - 
2B4-210210 108% 
1C5-210210 286% 
1B1-210210 110% 
 
Table 4.1 Screening of the established clonal cell lines. The AVP stimulated 
IP response is expressed as a percentage of the basal response. 
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The four cell lines that showed an increase in IP production in response to AVP stimulation 
were further characterised. This included assessments of both the response to AVP and the 
desensitisation of this response following a 5 min AVP (5 nM) pre-treatment. 
 
4.3 PARTIAL CHARACTERISATION OF V1bR-STABLY TRANSFECTED 
HEK293 CELL LINES  
4.3.1 INTRODUCTION 
The four clonal cell lines, shown by their responsiveness to AVP to express the V1bR, were 
partially characterised in greater detail. Within the time frame of this thesis, the main focus 
for characterisation of these lines was on determining the presence of a functional receptor. In 
this case, this meant determining if the external signal (AVP stimulation) was successfully 
received and transduced across the plasma membrane. Successful reception and transduction 
were measured as an increase in IP production. The cell lines were also assessed to see if they 
were capable of undergoing desensitisation following an AVP pre-treatment. This was of 
particular importance, since this is a normal aspect of V1bR function and is currently under 
investigation in this laboratory. Both of these parameters were examined using the IP assay 
(see Section 2.9). 
A different wash and AVP treatment protocol was used for these experiments than that which 
was used for screening purposes. This change allowed for both the IP response to a 15 min 
100 nM AVP treatment to be determined along with the change in the IP response following a 
pre-treatment for 5 min with 5 nM AVP (see Section 2.9.3.1.2 for full details). Briefly, after 
the 20 h myo-[3H]inositol incubation the cells were washed once with “control solution”, and 
then incubated with either “control solution” (0 nM AVP) or “pre-treatment solution” (5 nM 
AVP) for 5 min. After this pre-treatment the cells were washed twice with “basal solution” 
and then incubated with either “basal solution” (0 nM AVP) or “stimulation solution”       
(100 nM AVP) for 15 min. 
4.3.2 RESULTS 
4.3.2.1 IP response of the clonal cell lines to AVP stimulation 
All four of the clonal cell lines, selected from the screening process exhibited large (>300% at 
the first passage) increases in the levels of IP production in response to stimulation with AVP 
(Table 4.2). This indicates that all of these cell lines express the rV1bR. IP levels were 
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significantly increased by AVP stimulation in both first and tenth passage cells (Figure 4.1). 
The stimulated IP responses for all of the four cell lines from passage one and passage ten (as 
indicated in Table 4.2) were compared. Clonal cell line 1C5 exhibited a larger IP response to 
AVP stimulation at both passage one (P<0.01; One way ANOVA with Bonferroni’s test) and 
passage ten (P<0.01; One way ANOVA with Bonferroni’s test) than the other three cell lines. 
The IP responses were ~500% and ~320% of the basal response at the first and tenth passage 
respectively. AVP stimulated IP production decreased significantly between the first and tenth 
passages (Table 4.3). This decrease was approximately one third for all of the clonal cell lines 
between passages one and ten.  
 
          
Figure 4.1 IP responses of cells treated with 0 nM (“basal”) or 100nM (“stimulated”) AVP. All of the cells lines 
exhibited a significant increase in IP production in response to AVP stimulation at both the first passage (a) and tenth passage 
(b). This increase in IP production indicates that the cell lines are expressing the rV1bR. The data are expressed as mean ± 
SEM (n=3). Asterisks indicate a statistically significant difference between the basal and stimulated responses for each cell 
line (t-test; *P<0.05; **P<0.01). 
a 
b 
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   1C1 1C5 2A5 2C2 
First Basal CPM 472.2 ± 29.9 320.9 ± 8.9 353.1 ± 50.2 277.2 ± 16.9 
passage    Stimulated 
CPM 1327.0 ± 147.4 1597.0 ± 137.1 1215.7 ± 139.5 876.0 ± 63.4 
  
Stimulated IP 
response (Ausubel et 499.9 ± 51.9% 347.1 ± 12.7% 315.6 ± 4.3% 
  P value 0.0089 0.0062 0.0054 0.0030 
Tenth Basal CPM 575.0 ± 73.5 308.9 ± 17.1 465.8 ± 15.0 486.1 ± 63.0 
passage Stimulated 
CPM 1163.3 ± 114.6 1222.0 ± 111.9 991.4 ± 58.8 1041.6 ± 172.2 
  
Stimulated IP 
response 203.9 ± 9.3% 320.0 ± 20.1% 212.6 ± 6.8% 212.3 ± 7.6% 
  P value 0.0039 0.0068 0.0037 0.0184 
 
Table 4.2 IP responses of cells treated with 0 nM (“basal”) and 100 nM (“stimulated”) AVP. The results from both 
passage one and ten cells are presented for all four cell lines. All of the clonal cell lines exhibit a significant increase in IP 
production in response to AVP stimulation. This indicates that all of the cell lines are expressing the rV1bR. The “basal” and 
“stimulated” IP response data are expressed as CPM. The stimulated IP response is the stimulated CPM as a percentage of 
the basal CPM. Data are mean ± SEM (n=3). One way paired t-tests were performed to determine the significance of the 
difference between the basal and stimulated CPM. A P value of <0.05 was considered significant. 
 
 
  1C1 1C5 2A5 2C2 
First passage 
stimulated IP 
response 
302.0 ± 17.8% 499.9 ± 51.9% 347.1 ± 12.7% 315.6 ± 4.3% 
Tenth passage 
stimulated IP 
response 
203.9 ± 9.3% 320.0 ± 20.1% 212.6 ± 6.8% 212.3 ± 7.6% 
Change in 
stimulated 
response 
67.8 ± 4.9% 64.8 ± 5.0% 61.5 ± 4.1% 67.3 ± 2.2% 
P value 0.0082 0.0318 0.0007 0.0003 
 
Table 4.3 Comparison of the AVP stimulated IP production between passage one and ten for the four cell lines. There 
is a significant decrease for all cell lines in AVP stimulated IP production between passage one and ten cells. Data are 
expressed as percentage changes in IP responses, mean ± SEM (n=3). Two way un-paired t-tests were performed to 
determine the significance of the difference between the stimulated response with first and tenth passage cell. A P value of 
<0.05 was considered significant. 
 
4.3.2.2 Desensitisation of the cells to AVP stimulation 
All of the clonal cells lines exhibited a significant decrease in IP production in response to 
AVP stimulation following an AVP pre-treatment (Table 4.4). This decrease in IP production 
shows desensitisation of the cells response to AVP stimulation following an AVP pre-
treatment, which indicates desensitisation of the V1bR. Only lines 1C5 and 2A5 exhibited a 
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significant decrease in AVP responsiveness with both first and tenth passage cells (Figure 
4.2). The pre-treated response of clonal cell line 1C5 was 60.1 ± 4.7% and 69.1 ± 3.8% that of 
the control response for first and tenth passage cells respectively. The pre-treated response of 
2A5 was 65.2 ± 4.6% and 77.1 ± 4.9% of the control response for first and tenth passage cells 
respectively. With clonal cell lines 1C1 and 2C2, the decrease in AVP responsiveness was 
only significance with tenth passage cells. The pre-treated responses at the tenth passage were 
79.6 ± 4.5% and   84.9 ± 2.9% of the controls, respectively. 
No significant differences in the magnitude of desensitisation between first and tenth passage 
cell were seen with any of the clonal cell lines (Table 4.5).  
 
 
 
    1C1 1C5 2A5 2C2 
First Control IP response 302.0 ± 17.8% 499.9 ± 51.9% 347.1 ± 12.7% 315.6 ± 4.3% 
passage    Pre-treated IP response 242.7 ± 45.9% 296.1 ± 17.3% 225.0 ± 9.0%  273.6 ± 25.1% 
  Change in IP response 79.1 ± 10.8% 60.1 ± 4.7% 65.2% ± 4.6% 86.7 ± 7.9% 
  P value 0.0866 0.0221 0.0134 0.1193 
Tenth Control IP response 203.9 ± 9.3% 319.9 ± 20.2% 212.6 ± 6.8% 212.3 ± 7.8% 
passage Pre-treated IP response 161.4 ± 3.4% 220.8 ± 15.3% 164.2 ± 13.6% 180.7 ± 12.2% 
  Change in IP response 79.6 ± 4.5% 69.1 ± 3.8% 77.1 ± 4.9% 84.9 ± 2.9% 
  P value 0.0321 0.0107 0.0204 0.0150 
 
Table 4.4 IP responses of cells stimulated with AVP, with or without an AVP pre-treatment. Only clonal cells lines 1C5 
and 2A5 showed a significant reduction in IP response to AVP stimulation following an AVP pre-treatment with both first 
and tenth passage cells. Lines 1C1 and 2C2 only exhibited a significant reduction with passage ten cells. The data are 
expressed as percentage changes in the IP response compared to a control, mean ± SEM (n=3). One way paired t-tests were 
performed to determine the significance of the difference between the control and pre-treated IP response, a P value of <0.05 
was considered significant. 
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Figure 4.2 IP responses of cells stimulated with AVP, with or without an AVP pre-treatment. a). At the first passage,  
only cell lines 1C5 and 2A5 show a significant reduction in the IP response to AVP (100 nM, 15 min) stimulation following 
an AVP  (5 nM, 5 min) pre-treatment. b). At the tenth passage, all of the clonal cell lines showed a significant reduction in IP 
response to AVP stimulation following an AVP pre-treatment. The results are expressed as the AVP stimulated IP response 
as a percentage of the basal response. Data are expressed as mean ± SEM (n=3). Asterisks indicate a statistically significant 
difference between IP production in cells that were pre-treated with AVP and those that were not (t-test; *P<0.05). 
 
 
a 
b 
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  1C1 1C5 2A5 2C2 
First passage 
desensitisation 79.1 ± 10.8% 60.1 ± 4.7% 65.2% ± 4.6% 86.7 ± 7.9% 
Tenth passage 
desensitisation 79.6 ± 4.5% 69.1 ± 3.8% 77.1 ± 4.9% 84.9 ± 2.9% 
P value 0.9726 0.2038 0.1496 0.8420 
 
Table 4.5 Comparison of the magnitude of desensitisation between first and tenth passage cells. None of the clonal cell 
lines show a significant difference between the magnitude of desensitisation seen with the first and tenth passage cells. Data 
are expressed as the magnitude of desensitisation. The desensitisation was calculated as the AVP pre-treated response as a 
percentage of the control pre-treated response, mean ± SEM (n=3). Two way un-paired t-tests were performed to determine 
the significance of the difference between the magnitude of desensitisation seen at the first and tenth passages. P values of 
<0.05 were considered significant.  
 
4.3.2.3 General growth characteristics of the clonal cell lines 
Some general differences between the four clonal cell lines were observed while culturing the 
cells for the IP assays. Line 2A5 grew at a consistently faster rate than the other three. When 
the line was passaged the new flask was seeded at 6,000 cells per cm2, in order to reach       
50-80% confluence after 4 days of culturing. This seeding density was comparable with the 
seeding density of the parental HEK293 cells. These were seeded in flasks at 5,200 cells      
per cm2 in order to reach 50-80% confluence after 4 days. The lines 1C5 and 1C1 grew at a 
slightly slower rate than 2A5, and were seeded in flasks at 9,200 cells per cm2 in order to 
reach 50-80% confluence after 4 days. The growth rate was approximately the same between 
the two lines. Line 2C2 grew at the slowest rate of all four lines and required the flasks to be 
seeded at 12,000 cells per cm2 in order to reach 50-80% confluence after 4 days. This is 
double the plating density required for line 2A5. In general, the clonal cell lines seemed to 
have a lower level of adherence than the parental HEK293 cells, as they tended to lift in 
greater numbers during the washes in the IP assay.  
The other major observable difference with the cell lines was that 1C5 cells were slightly 
larger (Figure 4.3) than the other three lines, which appear to be of a similar size to the 
parental HEK293 cells (see Figure 2.1). This difference in size was most notable when the 
cells were being counted, as the individual 1C5 cells would appear much larger on the 
haemocytometer grid than the cells from the other clonal cell lines. As a consequence the cell 
counts for 1C5 were consistently lower than expected from the estimation of confluence. 
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Figure 4.3 Image showing clonal cell line 1C5 morphology. Cells of the clonal cell line 
1C5 appear slightly larger than those from the other three clonal cell lines. These other three 
clonal cell lines were similar in size to the parental HEK293 cell line, which can be seen in 
Figure 2.1.  
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CHAPTER 5:  
 
DISCUSSION  
 
5.1 SUMMARY 
The main goal of this project was to develop a stably-transfected model cell system that could 
be used to investigate the molecular mechanisms of V1bR desensitisation. In addition to 
generation of V1bR-stably transfected cell lines, this research involved both preparatory work 
and a partial characterisation of four pN1-V1bR expressing lines. 
Preparation and planning ensured that a model cell system appropriate for examining the 
molecular mechanisms of V1bR desensitisation was developed. Several parameters were 
examined and optimised to ensure the successful completion of this project, in particular: 
1) the choice of parental cell line, 
2) cell growth phases and the effect of this upon experimental results, 
3) plasmid design and purification, 
4) the choice and optimisation of a selection marker, and 
5) the choice and optimisation of a transfection reagent. 
Many facets of these parameters are inter-related and therefore had to be optimised to work 
cohesively within the framework of this project to ensure its successful outcome (see Chapter 
3 for full details). Briefly, HEK293 cells were chosen as a parental cell line, as this cell line 
can be transfected easily and is appropriate for future work with siRNA. Determining the cell 
growth rates and phases enabled more precise experimental planning for the later experiments 
in this research. This greater precision in experimental planning helped to ensure the 
successful completion of experiments and maintained the health of the cultured cells. Plasmid 
sub-cloning was utilised so that the GOI and the selection marker were included on the same 
plasmid. Sub-cloning also simplified the transfection protocol as a co-transfection was not 
required. This also provided greater confidence, during selection, that if the cells were 
resistant to G418 that they would also express the GOI, V1bR or EGFP. Purification of the 
plasmids was an important step as successful transfection of mammalian cells requires highly 
pure DNA. As can be seen from the results in Chapter 4, the plasmid DNA produced was of a 
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sufficiently high quality to successfully transfect mammalian cell lines. The choice of 
mammalian antibiotic used for selection was made as a consequence of the selection marker 
available, neo. This gene provides not only eukaryotic cells with resistance to G418, but it 
also provides prokaryotic cells with resistance to neomycin and kanamycin (Southern and 
Berg, 1982). This means that neo can be used for selection in plasmid production in E. coli as 
well as selection of stably-expressing mammalian cell lines. Optimisation of G418 selection 
conditions determined 500 μg/ml as an appropriate selection concentration, and 250 μg/ml as 
an appropriate maintenance concentration. This was in the mid range of the concentrations 
tested. G418 was easy to use and successfully killed all untransfected cells, as was determined 
by the 100% death rate of the untransfected negative control for the stable transfection (see 
Section 3.5). F6 was chosen as the transfection reagent for this project, as it has a 
straightforward transfection protocol, works on cells with a lower percentage confluence than 
many other similar reagents, and produces only low levels of cytotoxicity (Jacobsen et al., 
2004). The F6:DNA (μl:μg) ratio, the complex formation time and the time required for 
expression of the gene were optimised, as per the manufacture’s instructions. The optimised 
F6 transfection protocol was successfully used in the generation of the clonal cell lines (see 
Sections 3.4 and 3.5). 
Once these parameters were optimised, a model cell system stably-expressing the pN1-V1bR 
could be developed. A total of ten clonal cell lines (transfected with either pEGFP-N1 or  
pN1-V1bR) were selected using G418 and established as individual clonal cell lines. Nine of 
these lines were established from cells transfected with pN1-V1bR and one from cells 
transfected with pEGFP-N1. Cells transfected with pEGFP-N1 were used as a positive control 
to ensure that transfection had been successful, prior to G418 selection. Details of the key 
points in the development of these stably transfected cell lines can be seen in Section 3.5. 
Due to the time constraints imposed by MSc. degree requirements only AVP responsiveness 
was used to characterise the established clonal cell lines. This characterisation was chosen for 
evaluation because it is the key indicator of functional expression of the receptor. The clonal 
cell line established from cells transfected with pEGFP-N1 was assessed using fluorescence 
confocal microscopy, so that EGFP expression could be determined. 
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5.2 PARTIAL CHARACTERISATION OF THE GENERATED CLONAL CELL 
LINES 
The day after transfection, a day before G418 selection began, the cells transfected with 
pEGFP-N1 were assessed using fluorescent confocal microscopy. A high number of these 
cells exhibited EGFP expression, which indicated successful transfection of the plasmid (data 
not shown). However, the clonal cell line established from these through G418 selection did 
not express EGFP. This is most likely because the generation of stable cell lines (unlike 
transient expression) requires integration of plasmid DNA and this happens in a random 
fashion (Mortensen and Kingston, 2009). Random integration may have resulted in some 
genes in the plasmid being expressed while others are not. Possible reasons for this include, 
position effects, where integration into hetero- versus eu- chromatin will effect the expression 
level (Wurm, 2004). The cell linearises the DNA before it is integrated, and the point at which 
the plasmid is cut can affect expression of a particular gene, as the plasmid may be cut in the 
middle of a gene. Transgenes can be silenced after integration, which may mean initially 
expression is exhibited, but this is lost over time. As only one clonal line was established for 
EGFP expression, most likely random chance resulted in that particular clonal cell line not 
stably expressing the GOI, even thought most cells were seen to be expressing EGFP prior to 
G418 selection. 
To address this issue, homologous recombination can be used to introduce DNA at specific 
sites (Mortensen and Kingston, 2009). These systems are generally used in the development 
of transgenic animals, but the same principles can be applied to cell lines. One such system 
that can be utilised is a lox recombination vector which is designed to directly select Cre-
mediated site-specific DNA integration at a lox target previously incorporated into the 
genome (Fukushige and Sauer, 1992). Cre is a recombinase protein that mediates site specific 
recombination between loxP sites. Using a system such as this, the point at which the DNA is 
inserted into the host genome is reproducible. All clonal cell lines generated will be subjected 
to the same position effects and will exhibit the same level of expression. This approach was 
not used for this project. As a consequence, integration of the plasmid DNA into the genome 
was unique in each line. This means that some of the lines may not express the GOI, even if 
they have exhibited expression of the selection marker. This is because selection is based on 
expression of neo only.  
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Nine clonal cells lines transfected with pN1-V1bR were selected using G418 and established 
as individual cell lines. These lines were designated as 1A5-210210, 1B1-210210,            
1C1-210210, 1C5-210210, 2A1-210210, 2A5-210210, 2B2-210210, 2B4-210210, and     
2C2-210210. Clonal cell line 2A1-210210 was too fragile to withstand a single freeze-thaw 
cycle. Therefore, only the eight remaining lines were screened for changes in IP production in 
response to AVP stimulation, which was used as an indicator of rV1bR expression.  From 
these screening experiments four of the eight clonal cell lines, 1C1, 1C5, 2A5, and 2C2, 
appeared to respond to AVP stimulation. The magnitude of AVP responsiveness and the 
desensitisation of this response were then characterised in these four clonal cell lines in 
greater detail.  
All four of these chosen clonal cell lines showed a significant increase in the magnitude of 
response to AVP stimulation (100 nM, 15 min) with both first and tenth passage cells (see 
Figure 4.1). This response was at least double the basal response with both first and tenth 
passage cells. With cell line 1C5 there was a 5-fold increase in production with first passage 
cells. The increased IP production in response to AVP stimulation in 1C5 was significantly 
larger than the other lines. The AVP response dropped somewhat between the first and tenth 
passages for all four lines. The decrease was approximately equivalent between the cells lines 
with the responses of the passage ten cells being about two thirds of the responses of the 
passage one cells. Due to the range of changes that can occur in cell lines over time, no future 
experiments are likely to use cells beyond passage ten. Therefore, this data characterises the 
total decrease in the AVP responsiveness that could be expected over the course of future 
experiments. 
The decrease seen in the responsiveness of the cells is most likely a consequence of the way 
in which the DNA has integrated into the genome as a result of the transfection method used 
(Mortensen and Kingston, 2009). Carrier molecule methods of transfection can introduce 
multiple copies of the plasmid DNA at the same site. These arrays of similar sequences can 
lead to intra-chromosomal rearrangement, which can lead to a decrease the number of copies 
of the plasmid and therefore of the gene over time. This drop in copy number will lead to a 
drop in the level of expression. Other methods of transfection incorporate the plasmid DNA in 
different ways. For example electroporation usually introduces one copy of the DNA at a 
single site. However, there are other disadvantages associated with the other methods of 
transfection which make them a less desirable choice than carrier molecules (see Section 
1.3.1). As carrier molecules were chosen as the transfection method a significant drop in the 
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level of gene expression over time is not unexpected. Importantly the results indicate that the 
V1bR was still measurable and reproducibly expressed, as the response to AVP stimulation is 
still significant. Therefore, regardless of the drop in the magnitude of the response, the stable 
cell lines can still be used to examine the molecular mechanisms of V1bR signalling up to 
passage ten. 
Following a 5 min pre-treatment with 5 nM AVP, all four of the chosen clonal cell lines 
exhibited a significant decrease in IP production in response to a 15 min stimulation with   
100 nM AVP. From the first passage experiments, lines 1C5 and 2A5 showed a significant 
drop in IP production in response to AVP stimulation following an AVP pre-treatment. This 
IP response was between 60-65% of the control response. The other two lines, 1C1 and 2C2, 
did not show significant desensitisation at the first passage. The tenth passage experiments 
showed significant levels of desensitisation of IP production in response to AVP stimulation 
following a pre-treatment in all four of the cell lines. The magnitude of the responses ranged 
between 69-85% of the control responses, with only cell line 1C5 showing responses that 
were <70% of the control responses. The magnitude of desensitisation was not significantly 
different between the first and tenth passage cells for any of the lines. This was true even for 
1C1, and 2C2. It is possible for lines 1C1 and 2C2 that a greater number of replicate 
experiments may be required to see a significant level of desensitisation at the first passage. 
This is because the magnitudes of desensitisation appeared similar at both passages, but there 
was a higher standard error for the results from the first passage.  
It is desirable when choosing a cell line for investigating the molecular mechanisms of V1bR 
desensitisation that the line has similar signalling properties to the original tissue as this will 
increase confidence when exptrapolating details. Perifused ovine anterior pituitary cells 
previously examined in this laboratory exhibited an ACTH response to AVP stimulation   
78.5 ± 1.5% of the control following an AVP (5 nM, 5min) pre-treatment (Hassan et al., 
2003). A number of factors do need to be considered when comparing these results directly to 
those from the clonal cell lines. The receptors examined in the experiments were from 
different species, ovine V1bR in the perifusion studies (Hassan et al., 2003) and the rat V1bR 
(Lolait et al., 1995) used in this research. Different molecules were used to quantify 
signalling, ACTH secretion (Hassan et al., 2003) and IP production (this research). As there 
are a number of signalling steps between IP production and ACTH secretion any one of these 
may have affected the measurements. Different protocols were also used to obtain the data, 
and may have affected the results obtained. However, given the difference, all of the clonal 
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cells lines produced results that were remarkably similar to those seen with the perifused 
ovine anterior pituitaries. The lines all showed partial desensitisation within 5-15 min 
following a low (5 nM) AVP pre-treatment. Since the clonal cell lines exhibit slightly 
different properties, the line most suited to examining a particular question will be able to be 
utilised. This will provide greater flexibility in experimental design. 
A number of other in vitro studies involving rat, mouse, ovine, and equine systems and in vivo 
studies with rats have also shown desensitisation of the V1bR in response to prolonged AVP 
stimulation (reviewed in Mason et al., 2002). These studies have in general measured either 
ACTH as the output of the signalling pathway, or AVP binding properties. As well as 
measuring different outputs, these experiments were generally conducted over longer time 
scales, for example AVP pre-treatments of hours not minutes. This means that the 
desensitisation seen in many of these experiments may involve internalisation and down-
regulation rather than, or in addition to, receptor G-protein uncoupling, which generally 
occurs within seconds (Ferguson, 2001). So the studies focusing on receptor desensitisation 
that are most relevant for comparison with the results obtained using the V1bR-stably 
transfected HEK293 cells are those in which perifusion ovine anterior pituitary cells were 
used (Hassan et al., 2003; Hassan and Mason, 2005) to look at regulation via rapid 
uncoupling. 
The results presented here describing AVP responsiveness and desensitisation, indicate that 
all the clonal cell lines should be further characterised. However, 1C5 and 2A5 appear to have 
the greatest potential as model cell systems for examining the molecular mechanisms of 
desensitisation for a number of reasons. Clonal cell line 1C5 has a significantly greater 
stimulated IP response than the three other lines (P<0.01; One way ANOVA with 
Bonferroni’s test). The actual numbers of receptors must be determined before assigning this 
difference to differences in receptor expression. This is because it is possible that the 
difference in stimulated IP response may be due to differences in any of a number of steps in 
the PLCβ mediated signalling pathway (Alberts et al., 2002). Therefore, absolute numbers of 
expressed receptors need to be determined through binding assays and Scatchard plot 
analysis. It would be interesting to investigate signalling mechanisms in cell lines with 
different expression levels of the V1bR as different signalling pathways have been shown 
previously to be activated in cells expressing the receptor at different levels (Thibonnier et al., 
1997). From the results of the first passage experiments, both 1C5 and 2A5 showed a 
consistent level of AVP desensitisation to <70% of the control response. This consistent and 
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considerable magnitude of desensitisation will be important when trying to determine if the 
knock down of specific GRKs has any affect on the magnitude of desensitisation and hence 
determine which kinase is responsible for uncoupling. A considerable and consistent 
magnitude of desensitisation will be important as knocking down GRKs may only produce 
small changes in desensitisation. These changes are more likely to be noticeable if the 
standard desensitisation is consistent and of a considerable magnitude. The clonal cell line 
2A5 exhibited the growth rate closest to that of the parental (untransfected) HEK293 cell line. 
This indicates that integration of the plasmid DNA into this cell line has been the least 
disruptive to normal cellular function.  
 
5.3 V1bR-STABLY TRANSFECTED HEK293 CELL LINES AS A MODEL 
CELL SYSTEM 
5.3.1 POTENTIAL USES 
After full characterisation of the clonal cell lines, they will be valuable as model systems to 
dissect the V1bR signalling pathway and its regulation at the molecular level. In the Mason 
laboratory they will be used initially to examine the mechanisms involved with V1bR 
desensitisation. 
The desensitisation process of GPCRs involves a combination of mechanisms including 
phosphorylation of the receptor which uncouples the receptor from its signalling pathway, 
internalisation of the receptor, and down regulation of the receptor (Ferguson, 2001; Lohse, 
1993). These mechanisms occur over different temporal scales, phosphorylation of the 
receptor occurs rapidly (within seconds) and in a reversible manner. The results of pervious 
research have ruled out a number of possible phosphorylators including PKC and CK1α, and 
have demonstrated the involvement of PP2B in the resensitisation process (Hassan and 
Mason, 2005). PP2B had earlier been shown to be involved with the resensitisation of the 
β2AR, when it was desensitised by GRK2 phosphorylation (Shih et al., 1999). GRKs are also 
known to be a common phosphorylator of GPCRs (Pitcher et al., 1998), and therefore, GRKs 
are currently thought to be the most likely candidates for phosphorylation of the V1bR. Only 
four of the seven GRKs (GRKs -2, -3, -5, and -6) have the appropriate distribution to make 
them possible candidates (Ferguson, 2001; Pitcher et al., 1998). The potential involvement of 
all four should be examined as there appears to be some level of redundancy (Pitcher et al., 
1998). However, there is also the possibility that the different groups of GRKs (GRKs -2 and  
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-3, and GRKs -5, and -6) have different functional signalling consequences (reviewed in 
Reiter and Lefkowitz, 2006) as has been seen with other GPCRs, including the angiotensin II 
receptor (Kim et al., 2005), and the V2R (Ren et al., 2005). This potential for functional 
differences in specific GRK signalling should be examined so that a full picture of GRK 
involvement in the molecular mechanism of V1bR desensitisation can be obtained.  
This model cell system could also be utilised to investigate of other aspects of V1bR 
signalling, including internalisation and down regulation, re-sensitisation and transport back 
to the plasma membrane. Internalisation and recycling of the receptor could be monitored by 
fluorescence microscopy (reviewed in Daly and McGrath, 2003). Fluorescent monitoring is 
particularly useful as the same cells can be assessed over a variety of time points. To do this a 
fluorescent V1bR agonist that will internalise with the receptor would be required for this to 
be considered a feasible option. Down-regulation could be determined through receptor 
binding assays, with cells assayed for receptor numbers before and after a prolonged exposure 
to AVP. As down-regulation of receptor content can take hours to occur (Ferguson, 2001), the 
length of AVP stimulation would have to be much longer than that used to assess signalling 
and desensitisation in this research (see Section 2.9). 
The effects of AVP concentration on signalling and desensitisation could also be investigated. 
The concentration of AVP has already been shown to effect V1bR signalling in transiently 
transfected HEK293 cells (Orcel et al., 2009). There, higher concentrations of AVP resulted 
in signalling via cAMP as well as IP second messenger systems. Investigations into if and 
how utilisation of different pathways affects desensitisation, specifically phosphorylation, 
could be completed. Desensitisation of the receptor and the molecular mechanisms involved 
could be assessed using different AVP stimulation protocols and measuring the accumulation 
of IPs (as per this research) or cAMP as described by Orcel et al., (2009). 
Therefore, the model cell system developed in this project has a wide variety of potential 
uses. This makes it a valuable tool in the investigation of V1bR signalling and desensitisation. 
It is hoped that these investigations will then be able to provide insights into normal V1bR 
signalling and desensitisation within pituitary corticotroph cells.   
5.3.2 LIMITATIONS 
Although there are a variety of potential of uses for this model cell system, there are 
limitations which must be carefully evaluated. Good experimental design and planning, which 
takes these limitations into account, is crucial in ensuring valid results are obtained. These 
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results will then be able to be used as a basis for developing a model of the signalling and 
desensitisation mechanisms within pituitary corticotroph cells 
It has been shown that intracellular molecules involved in signalling processes can often be 
affected by cellular context, including expression of GRKs and β-arrestins (Ferguson, 2001). 
These differences can affect the signalling and desensitisation mechanisms utilised by the 
GPCR under investigation, as it has been shown that GPCR phosphorylation is a complex 
process and it is possible to phosphorylate one receptor with a number of different kinases 
(Tobin, 2008). While this provides the potential to tailor signalling of the same receptor in 
different cells within an organism to cater for differing physiological roles, it may mean that 
the mechanism seen in these clonal cell lines is different from that in seen pituitary 
corticotroph cells, as the cellular context is different. Therefore, although this model cell 
system will provide valuable information on the likely mechanism of desensitisation, any 
mechanistic details should be confirmed with work in pituitary corticotroph cells. 
Investigations using corticotroph cells are associated with a number of inherent difficulties 
including limited numbers of divisions, greater difficulty to transfect, and a heterogenous 
population of cells (Freshney, 2000; Grimm, 2004; van Beijnum et al., 2008). Deducing a 
large amount of molecular mechanistic detail in the easier to use immortalised cell lines, will 
mean that focussed experiments that take these difficulties into account can be planned for the 
primary cell cultures in order to confirm these details. 
The AVP receptors have been shown to have some species specific differences in interactions 
with different synthetic agonists and antagonists (Chini and Manning, 2007; Guillon et al., 
2004; Guillon et al., 2006; Pena et al., 2007; Serradeil-Le Gal et al., 2002). Most of the 
synthetic agonists and antagonists were developed using receptors from the rat. When these 
synthetic peptides were then tested on human AVP receptors they were shown to have 
different binding affinities and pharmacological properties. However, the binding affinities of 
AVP appear to be conserved. As there are indications of some species specific differences in 
the receptors, this should be a consideration when extrapolating the molecular mechanisms of 
receptor desensitisation from one species to another. This consideration will be particularly 
important if differences in signalling and desensitisation are examined using synthetic 
agonists or antagonists. 
The clonal cell lines developed in this project have yet to be fully characterised. This 
characterisation will provide more detailed information of receptor expression within the 
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model cell system. Comparison of the expression profiles in the clonal cell lines and pituitary 
corticotrophs should help identify the particular clonal cell line most appropriate for 
addressing a specific question. Investigations utilising these cell lines should allow more 
accurate deduction of signalling mechanisms.  
 
5.4 FUTURE WORK 
As discussed above, the clonal cell lines will need to be characterised to a greater extent 
before they are used to determine the molecular mechanism of desensitisation of the V1bR. In 
order to more fully characterise these clonal cell lines a number of experiments are required 
including: 
1) receptor binding assays using [3H]AVP to determine the number of receptors present 
at the plasma membrane of each cell line, 
2) measurement of intracellular Ca2+ changes in response to stimulation with AVP, and 
3) growth curves for all four of the clonal cell lines 
Receptor binding assays will provide information on the total numbers of receptors present at 
the plasma membrane of the clonal cell lines. This will allow determination of whether the 
clonal cell lines are expressing the receptor at different levels. [3H]AVP has been used 
previously for receptor binding studies with the rV1bR in both anterior pituitary tissues 
(Aguilera et al., 1994) as well as immortalised cell cultures (Orcel et al., 2009; Young et al., 
2007). Specifically Orcel et al., (2009) used receptor binding assays to determine the level of  
receptors present at the plasma membrane in transfected HEK293 cells. Therefore, this 
approach is likely to be most compatible with the developed model cell system as it also used 
HEK293 cells. 
Examining the levels of intracellular Ca2+ will allow further analysis of whether signalling is 
occurring normally within the clonal cell lines. Fluorescence microscopy has been utilised 
recently to examine changes in intracellular Ca2+ levels with the GPCR protease activated 
receptor 2 (Gu and Lee, 2010) and IP3 stimulated intracellular Ca2+ levels in response to 
mechanical stimulation (Nezu et al., 2010) as well as with the rV1bR (Young et al., 2007). 
Young et al., (2007), examined the changes in intracellular Ca2+ levels of the wild type rV1bR 
as well as various tagged forms of the receptor in response to 10 nM AVP in CHO cells. This 
research used the rat V1bR, transiently transfected into CHO cells. The results from that 
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research should be able to provide a comparison for changes in intracellular Ca2+ levels in the 
clonal cell lines developed in this research. 
As differences in the growth rates of the clonal cell lines were observed during passaging, it 
would be useful to generate growth curves for each of the lines. This would provide specific 
details on the growth phases for each clonal cell line. It would also provide an indication of 
the disruption caused to the individual lines through plasmid DNA integration into the 
genome. The growth curves could be compared with those developed for the parental 
(untransfected) HEK293 cell line. This would provide information on how disruptive the 
transfection event had been to the cell growth rate and therefore the cell cycle and general 
overall health of the cell. This experiment would not provide any further information on cell 
signalling. 
Along with the AVP responsiveness and desensitisation data, these future experiments will 
provide a more complete picture of signalling in the clonal cell lines. This will provide a base 
line for work analysing the molecular mechanisms of desensitisation. 
The characterised clonal cell lines will then be used in our laboratory to determine the 
molecular mechanism of rV1bR desensitisation. Initially this will involve using siRNA to 
knock down GRKs -2, -3, -5, and -6. The success of the various knock downs can be 
determined using Western blots and quantitative reverse transcriptase PCR measurements of 
GRK protein and mRNA respectively. The protocols for these have already been developed in 
this laboratory for GRK5 by Gatehouse (2008) and as yet unpublished MSc work by 
Katherine van Bysterveldt. The effect of these knock downs on desensitisation will be 
examined using the IP assay and therefore, the effect that knock down of individual GRKs has 
on IP production in response to AVP stimulation. This work will most likely require 
alterations to the IP assay protocol used in this research. It is most likely that AVP 
responsiveness will be measured over a time course, in both control cells and in those where 
expression of a specific GRK has been knocked down. If the knocked down GRK was 
involved in the desensitisation process, IP accumulation would be expected to increase to a 
higher level over the time course as all of the receptors would continue to transduce the 
external signal. In contrast in the control cells the rate of IP accumulation would drop over 
N.CITE 
provide information concerning the molecular mechanisms involved in V1bR desensitisation.    
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APPENDIX A: 
   
MATERIALS 
 
A.1 REAGENTS 
AG1-X8 anion-exchange resin   BioRad Laboratories 
Agarose      Gibco, Invitrogen Corporation 
Amine coated 24 well plates    Becton Dickinson Biosciences 
Ammonium formate     Sigma-Aldrich Company 
Ampicillin      Sigma-Aldrich Company 
Arginine Vasopressin Powder   Sigma-Aldrich Company 
AxyPrep™ Plasmid Miniprep Kit   Axygen Biosciences 
Bacteriological Agar     Germantown 
Biodegradable Counting Scintillant   Amersham Biosciences 
Bovine Serum Albumin    Gibco, Invitrogen Corporation 
Bromophenol Blue     BDH Laboratory Supplies 
Buffer O (10x)     Fermentas Life Sciences 
Carboxyl coated 24 well plates   Becton Dickinson Biosciences 
Concentrated Hydrochloric Acid   BDH Laboratory Supplies 
Competent DH5 alpha E. coli cells   Invitrogen Corporation 
Dimethyl Sulfoxide     Sigma-Aldrich Company 
Dulbecco’s modified Eagles medium (-inositol) MP Biomedical 
Ethanol (100%)     BDH Laboratory Supplies 
Foetal Bovine Serum     Gibco, Invitrogen Corporation 
Formic Acid      Sigma-Aldrich Company 
FuGENE 6      Roche Applied Science 
G418 Powder      Gibco, Invitrogen Corporation 
Glycerol      BDH Laboratory Supplies 
GlutaMAX™       Gibco, Invitrogen Corporation 
High DNA Mass Ladder    Gibco, Invitrogen Corporation 
Human Embryonic Kidney 293 cell line  ATCC 
Hydrochloric acid     BDH Laboratory Supplies 
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Isopropanol      BDH Laboratory Supplies 
Kanamycin Sulfate     Acros Organics 
L-ascorbic acid     Sigma-Aldrich Company 
L-glutamine       Gibco, Invitrogen Corporation 
LB Broth Miller (Luria Bertani)   Becton Dickson Biosciences 
LB Broth Base (Lennox Broth Base)   Invitrogen Corporation 
Lambda DNA/PstI Marker, 24   Fermentas Life Sciences 
Lithium Chloride     Sigma-Aldrich Company 
Magnesium Chloride      BDH Laboratory Supplies 
Minimal Essential Medium (MEM)   Gibco, Invitrogen Corporation 
myo-[3H]inositol     Amersham Biosciences 
MYO-INOSITOl,[3H]     Perkin Elmer Inc. 
NotI Restriction Enzyme    Fermentas Life Sciences 
OPTIPHASE ‘HISAFE’ 3 scintillantion cocktail Perkin Elmer Inc. 
Penicillin/Streptomycin    Gibco, Invitrogen Corporation 
Poly-D-Lysine coated 24 well plates   Becton Dickinson Biosciences 
Polyprep Chromatography Columns   BioRad Laboratories 
Primaria coated 24 well plates   Becton Dickinson Biosciences 
pUC19 plasmid DNA     Invitrogen Corporation 
PureLink™ HiPure Plasmid Filter Purification Kits Invitrogen Corporation 
Recovery™ Cell Culture Freezing Medium  Invitrogen Corporation 
SalI Restriction Enzyme    Fermentas Life Sciences 
Sodium bicarbonate     BDH Laboratory Supplies 
Sodium chloride     BDH Laboratory Supplies 
Sodium formate     Sigma-Aldrich Company 
Sodium pyruvate     Gibco, Invitrogen Corporation 
Sodium tetra borate      Sigma-Aldrich Company 
Standard cell culture 24 well plates   Thermo Fischer Scientific 
Subcloning Effciency™ DH5α™ Competent Cells Invitrogen Corporation 
SYBR® Safe DNA Gel Stain  10,000X  Invitrogen Corporation 
T4 DNA Ligase     Fermentas Life Sciences 
T4 DNA Ligase Buffer    Fermentas Life Science 
Tris-HCl TRIZMA Base    Sigma-Aldrich Company 
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Trypan Blue      BDH Laboratory Supplies 
Trypsin/EDTA (T/E)     Gibco, Invitrogen Corporation 
XhoI restriction enzyme    Gibco, Invitrogen Corporation 
Zymoclean™ Gel DNA Recovery Kit  ZymoResearch Corporation 
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APPENDIX B: 
   
SOLUTIONS AND MEDIA 
 
B.1 CELL CULTURE 
B.1.1 MINIMAL ESSENTIAL MEDIUM (MEM) 
One packet of commercially prepared powder for 1 L MEM was dissolved in Nanopure H2O. 
Sodium bicarbonate (NaHCO3) (1.5 g) and 10 ml of sodium pyruvate (final concentration   
110 mg/l) were added. The solution was then made up to 1 L with Nanopure H2O and the pH 
adjusted to 7.1. The solution was filter sterilised with a 0.45 μm membrane filter, and the 
medium was checked for sterility. The medium was stored at 4°C for no more than three 
months. For culturing HEK293 cells the medium was supplemented with 10% FBS (v/v). For 
selecting stable clones it was also supplemented with 500 μg/ml G418. For the maintenance 
of stable clones it was supplemented with 250 μg/ml G418. After three weeks of storage the 
medium was supplemented with GlutaMAX™ (final concentration 2 mM). When required the 
medium was also supplemented with penicillin (final concentration 100 U/ml)/streptomycin 
(final concentration 100 μg/ml). 
B.1.2 PHOSPHATE BUFFERED SALINE (PBS) 
To make a 5x stock solution the reagents below were dissolved in Nanopure H2O and the 
solution was made up to 200 ml. The pH was adjusted to ~7.1. To make a 1x working solution 
the same weight of chemicals was made up to 1 L with Nanopure H2O. The pH was then 
adjusted to 7.4. The solutions were stored room temperature, and discarded if any precipitate 
or growth appeared.  
 
KH2PO4    0.2 g 
KCL     0.2 g 
NaCl     8.0 g 
Na2HPO4    1.15 g (or 2.2 g Na2HPO4.7H2O) 
 
B.1.3 TRYPAN BLUE STOCK SOLUTION 
A 2% trypan blue stock solution was made by dissolving 0.02 g of trypan blue (BDH) in      
10 ml of Nanopure H2O. This solution was filtered into a clear glass vial through a 0.22 μm 
filter. The filtered solution was stored at 4°C and discarded if a precipitation or growth 
appeared.  
 
 
B.1.4 TRYPAN BLUE WORKING SOLUTION 
Trypan blue working solution was made by adding 4 parts of trypan blue stock solution to 1 
part 5x PBS in a 4 ml polystyrene tube. The working solution was made up fresh as required 
for cell counts. 
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B.1.5 FREEZING MEDIUM 
To freeze the HEK293 cells for cryogenic storage two different freezing mediums were used 
over the course of this research. The first was a commercially prepared medium from 
Invitrogen, Recovery™ Cell Culture Freezing Medium. The second was prepared entirely the 
laboratory. 
 
To prepare cells at ~80% confluence from a 75 cm2 flask for freezing as four 1 ml aliquots, 
the following solutions were initially mixed.  
 
MEM-     1.2 ml 
DMSO     0.4 ml  
FBS     0.4 ml 
 
These above solutions were mixed in a glass container because concentrated DMSO can 
permeate plastic. The cell pellet was re-suspended in 2 ml of MEM-. The above 2 ml solution 
was then slowly added to the cell suspension and gently mixed. The final concentration of 
DMSO was 10%, and the final concentration of FBS was 10%. The cells were then aliquoted 
into 1 ml cryotubes for freezing. The volumes the freezing medium were halved in order to 
freeze two tubes of cells at ~80% confluence as 1 ml aliquots from a 25 cm2 flask. 
 
B.2 PREPARATION OF PLASMID DNA FOR TRANSFECTION 
B.2.1 TBE AGAROSE (0.7%) GEL 
The agarose was dissolved into 200 ml of 0.5x TBE buffer. This mixture was heated in order 
to dissolve the agarose. Once the agarose was dissolved SYBR® Safe was added. The gel was 
allowed to cool slightly before adding it to the box. Enough of the gel mixture was poured 
into the box to ensure that approximately 5 mm of the comb was covered. The gel was 
allowed to set and was run using 0.5x TBE as a running buffer. 
 
Agarose    1.4 g 
SYBR® Safe    20 μl 
 
B.2.2 TBE BUFFER 0.5x 
The reagents listed below were dissolved in 1 L of Nanopure H2O to make a 5x stock 
solution. The pH of the resulting solution was adjusted to 8.0 and then stored at 4°C. The 5x 
stock solution was diluted 1:9 in Nanopure ddH2O to produce the 0.5x working solution. 
 
Tris-Base    54 g 
Boric Acid    27.5 g 
0.5 M EDTA    20 ml 
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B.2.3 LB BROTH 
B.2.3.1 Culture Broth 
LB broth powder with different compositions was sourced from two different manufacturers, 
Becton Dickson Biosciences and Invitrogen Corporation. The instructions on how both of 
these were made are described below. 
B.2.3.1.1 LB Broth Miller  
To prepare LB Broth Miller (Luria Bertani) sourced from Becton Dickson Biosciences, 25 g 
of powder were dissolved in 1 L of Nanopure H2O. The resulting broth solution was sterilised 
by autoclaving. The broth solution has the following final composition: 
 
Tryptone    10 g/L 
Yeast Extract    5 g/L 
NaCl     10 g/L 
 
When required, antibiotics were added to the broth after sterilisation. 
 
B.2.3.1.2 LB Broth Base (Lennox Broth Base)  
To prepare LB broth (Lennox Broth Base) sourced from Invitrogen, 20 g of powder were 
dissolved in 1 L of Nanopure H2O. The resulting broth solution was sterilised by autoclaving. 
The broth solution has the following final composition: 
 
SELECT Peptone 140   10 g/L 
SELECT Yeast Extract  5 g/L 
NaCl     10 g/L 
 
When required, antibiotics were added to the broth after sterilisation. 
 
B.2.3.2 Agar Plates 
Bacteriological agar (Germantown) (15 g) was added to 1 L of broth prior to autoclaving. 
Plates were poured after the solution was sterilised. To do this the agar/broth was heated in 
the microwave to dissolve the agar. The solution was cooled to ~50°C before pouring the 
plates (~25 ml per plate). If antibiotics were required they were added just prior to pouring. 
The plates were left to set for 25 min with the lids on. Once set, the plates were turned upside 
down with the bases propped open on the lids, which were facing upwards, to allow the 
vapour to escape for ~10 min. The lids were then turned face down and the plates, with the 
upside down bases propped open on the lids, were then left to dry for ~4-5 hours. Once dry, 
the plates were wrapped in plastic wrap, then with aluminium foil and stored upside down at 
4°C. The plates were kept for no more than 1-2 weeks before use. 
 
B.2.4 KANAMYCIN STOCK SOLUTION 
Kanamycin was received in a commercially prepared powdered form. The required amount 
was weighed and made up to 40 mg/ml with the appropriate volume of Nanopure H2O. The 
solution was filter-sterilised through a 0.22 μm filter. The sterile solution was aliquoted and 
stored at -20°C. Working solutions of kanamycin were created by diluting appropriately in 
culture broth. 
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B.2.5 TE8 
The reagents listed below were dissolved in 100 ml of Nanopure H2O. This gave the final 
concentrations of Tris-HCl 10 mM and EDTA 1 mM. The solution’s pH was adjusted to 8.0 
and then sterilised by autoclaving. The sterile solution was stored at room temperature. 
 
Tris-HCl (TRIZMA Base) (pH 8.0) 0.121 g 
EDTA     0.037 g 
 
B.2.6 REact 2 BUFFER 10x 
The reagents listed below were dissolved in 25 ml of Nanopure H2O. The initial pH had to be 
lowered slightly before the chemicals would dissolve. Once the reagents were dissolved the 
solution’s pH was adjusted to 8.0. It was aliquoted into 1.7 ml microfuge tubes in 1 ml lots 
and store at -20°C until needed. 
 
Tris-HCl (TRIZMA Base), pH 8.0 1.51 g 
MgCl     0.51 g  
NaCl     0.73 g 
 
B.2.7 AMPICILLIN STOCK SOLUTION 
Ampicillin was received in a commercially prepared powered form. The required amount was 
weighed and made up to 50 mg/ml with the appropriate volume of Nanopure H2O. The 
solution was filter-sterilised through a 0.22 μm filter. The sterile solution was aliquoted and 
stored at 4°C. The working solutions of ampillicin were created by diluting appropriately in 
culture broth. 
 
B.2.8 0.8% AGAROSE GEL 
Agarose was added to 50 ml of 0.5x TBE buffer. SYBR® Safe was added and the solution 
was heated in the microwave until all the agarose had dissolved. The solution was allowed to 
cool to about ~50°C before pouring. The gel took ~30 min to set. The running buffer for the 
gel was 0.5x TBE. 
 
Agarose     0.4 g 
TBE      0.5x 
SYBR® Safe DNA Gel Stain  10,000x 1:10,000 dilution 
 
 
B.2.9 GEL LOADING DYE 6x 
The reagents listed below were added to Nanopure H2O to give the final concentrations listed. 
A total volume of 12 ml was made and the solution was aliquoted and stored at 4°C. 
 
Bromophenol Blue   0.25% 
Xylene Cyanol   0.25% 
Glycerol    30% 
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B.3 OPTIMISATION OF ANTIBIOTIC SELECTION CONDITIONS 
B.3.1 G418 STOCK SOLUTION 
G418 was received in commercially prepared powder form. The required amount was 
weighed and made up to 50 mg/ml with the appropriate volume of Nanopure H2O. The 
solution was filter-sterilised through a 0.22 μm filter. The sterile solution was aliquoted and 
stored at 4°C. The solution can be stored at this temperature for up to two years. Working 
solutions of G418 were created by diluting appropriately in MEM+. 
 
B.4 INOSITOL PHOSPHATE (IP) ASSAY 
B.4.1 LABELLING SOLUTION 
The BSA and GlutaMAX™ were mixed with an appropriate volume of DMEM without 
inositol to give the concentrations below. The solution was then filter sterilised through a  
0.22 μm filter, and placed in the CO2 incubator at 37°C to equilibrate. Just prior to labelling 
the wells the myo-[3H]inositol was added to the solution to give the below concentration. 
 
BSA     0.1% 
GlutaMAX™    1% 
myo-[3H]inositol   2.5 μl/ml 
 
B.4.2 LITHIUM CHLORIDE (LiCl) 1 M 
LiCl was dissolved into Nanopure H2O to make a 1 M stock solution. This stock solution was 
filtered sterilised into a sterile glass vial through a 0.22 μm filter, and stored at 4°C. 
 
B.4.3 AVP STOCK SOLUTION 
AVP was received in a commercially prepared powder form ([Arg8]-vasopressin, acetate salt). 
The required amount was weighed and made up to 20 μM with the appropriate volume of 
MEM containing 0.3% BSA and 0.005% L-ascorbic acid. The stock solution was aliquoted 
and stored at -80°C. The stock solution was diluted in MEM- to give the desired 
concentrations for IP assays. 
 
B.4.4 DETERMINATION OF AVP RESPONSIVENESS OF TRANSFECTED CELLS  
B.4.4.1 Basal solution 
The reagents listed below were mixed in MEM- to obtain the concentrations below. The 
solution was equilibrated to 37°C, by placing it in a CO2 incubator. 
 
BSA     0.1% 
LiCl 1 M stock solution  10 mM 
 
B.4.4.2 Stimulation solution 
AVP stock solution (20 μM) was diluted to 100 nM with basal solution. The AVP was added 
to the solution just prior to use, or if added earlier in the day it was stored in the refrigerator 
until   30 min prior to use, when it was equilibrated to 37°C in a CO2 incubator. 
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B.4.5 DETERMINATION OF AVP RESPONSIVENESS AND MAGNITUDE OF 
DESENSITISATION OF TRANSFECTED CELLS 
B.4.5.1 Control solution 
The BSA was mixed into an appropriate amount of MEM- to give the below concentration of 
BSA. The solution was equilibrated to 37°C, by placing it in a CO2 incubator. 
 
BSA     0.1% 
 
B.4.5.2 AVP pre-treatment solution 
AVP stock solution (20 μM) was diluted to 100 nM with control solution. This 100 nM AVP 
solution was diluted to 5 nM with control solution to give the pre-treatment solution. The 
AVP was added to the solution just prior to use, or if added earlier in the day it was stored in 
the refrigerator until ~30 min prior to use, when it was equilibrated to 37°C in a CO2 
incubator. 
 
B.4.6 “STOP” SOLUTION 
The chemicals were dissolved in an appropriate volume of Nanopure H2O, to give the 
concentrations below. The solution was stored at 4°C. 
 
KOH     1 M 
Sodium Borate   18 mM 
EDTA     3.8 mM 
Sodium hydroxide   7.6 mM 
 
B.4.7 “NEUTRALISATION” SOLUTION 
Hydrochloric acid (37%) was mixed with Nanopure H2O to give a 7.5% HCl solution. Five 
ml of this solution was combined with 5 ml of the “stop” solution and 5 ml of MEM. The pH 
of the mixture was measured and adjusted to 7.0 by addition of a known volume of Nanopure 
H2O. The “neutralisation” solution was then adjusted by adding the appropriate volume of 
Nanopure H2O so that when the three solutions were combined in equal volumes the resulting 
solution would have a neutral pH. The neutralisation solution was stored at 4°C. 
 
B.4.8 ELUTION BUFFER II 
The solution was made up fresh on the final day of the IP Assay. The reagents were dissolved 
in an appropriate volume of Nanopure H2O to give the concentrations below. 
 
Sodium borate    5 mM 
Sodium formate   60 mM 
 
B.4.9 ELUTION BUFFER VI 
The solution was made up fresh on the final day of the IP Assay. The reagents were dissolved 
in an appropriate volume of Nanopure H2O to give the concentrations below. 
 
Formic Acid     100 mM 
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Ammonium Formate   2 M 
 
B.4.10 REGENERATION SOLUTION 
The solution was made up fresh on the final day of the IP Assay. The reagents were dissolved 
in an appropriate volume of Nanopure H2O to give the concentrations below.  
 
Formic Acid    100 mM 
Ammonium Formate   3 M 
 
 
